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Abstract 
 
The aim of this work was to investigate physiological, perceptive and neurological 
responses to exercise intensity in people with multiple sclerosis (PwMS). The 
thesis begins with reviews of Multiple Sclerosis (MS) and exercise followed by    
three main studies.  
The first study explores the within session and test-retest reliability of motor evoked 
potentials (MEPs) elicited by transcranial magnetic stimulation (TMS) from the 
resting tibialis anterior (TA) muscle of people with multiple sclerosis (PwMS).  
MEPs were recorded from 10 PwMS (2male, 8female) in 5 blocks of 5 trials using 
stimulators configured to fire a single pulse. MEP peak amplitudes (mV) and MEP 
areas (mV.mS) were measured at 2 durations MEPshort (30ms) and MEPlong 
(mean 50ms). The size of the first MEP (T1) from each block (mean 5.1) was 
significantly different to subsequent trials (T2 -T5) for MEPlong (mean 4.5 p <0.05). 
After T1 was discarded, repeated measures ANOVAs of blocks (averages of 4 
trials) revealed no significant differences within-subjects for amplitudes (MEPpeak) 
and areas (MEParea) for both MEPshort and MEPlong. A repeat session 7-14 
days later revealed no significant differences between sessions (p>0.05). The test-
retest intraclass coefficients of correlation (ICC) and their 95% confidence intervals 
indicated high (>0.80) reliability for both MEParea and MEPpeak. The results 
showed that consistent, repeatable TMS measures were obtained from the resting 
TA of PwMS. 
 
 3 
The second study compared physiological and perceptive measures of PwMS to a 
group of healthy individuals while performing a symptom-limited graded exercise 
test (GXT), and through the post-exercise time-course to recovery. 54 PwMS 
(MSG, mean age 52.8years ± 9.0) and 17 healthy, age-matched controls 
(CG,mean age 48.9 years ± 5.7) performed a symptom-limited graded exercise 
test (GXT). Expired air (VO2), heart rate (HR), and differential ratings of perceived 
exertion (RPE breathing and RPE legs) were recorded during exercise, and HR 
and RPE (breathing and legs) during the recovery period. There were no significant 
differences in any baseline measure except RPEleg (MSG mean1.1±1.2; CG 0.2 
±0.4 p <0.05). During the GXT MS group means (±SD) failed to reach any criterion 
measure considered to represent peak performance. The control group mean 
exercise measures reached recognised criteria for peak testing on two measures; 
mean heart rate of within ± 10 beats of age predicted HRmax, mean RER value 
greater than 1.10. Significant differences existed between groups in all peak 
measures (mean MSG VO2 peak 20.1±6.4, mean CG VO2 peak 27.8 ±6.8; mean 
MSG HRpeak 140.1±24.8, mean CG HRpeak 167.7± 9.4; mean MSG RPE 
breathing 5.1±1.7, mean CG RPE breathing 6.8± 2.3; mean MS watts 97.4±35.2, 
mean CG watts 161.8 ± 43.4 p <0.05) except for RPEleg (mean MSG 6.2 ±1.7, 
mean CG 7.0±1.8p>0.05). There were no significant effects on the peak measures 
of variables when weighted by MS classification (RR-MS, SP-MS and PP- MS).  
There were differences between group recovery values for RPEleg at 10 mins 
(mean MSG 1.8 ±1.2, mean CG 1.0±1.1 p<0.05) and Temp°C at 3mins (mean 
MSG 36.5± 0.5, mean CG 36.9± 0.6 p<0.05) and 10mins (mean MSG 36.4±0.4, 
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mean CG 37.0±0.3p<0.05) post-exercise. MS HR remained marginally above pre-
exercise HR values at 10 minutes post-exercise. Differential measures of RPE for 
both groups recovered to pre-exercise values at 5 mins (±SD). During maximal 
exertion, it was observed that PwMS irrespective of disease classification, or years 
from onset were neither limited by their heart rate, nor their breathing, but that leg 
fatigue or lack of central drive to the lower limb was the reason for their inability to 
continue.  
 
In the third study, the physiological perceptive and central responses of PwMS 
were explored during exercise at low and high intensity, and through the time-
course to recovery. Participants performed 2 exercise training (ET) sessions where 
they performed 20 minutes of exercise on a cycle ergometer at 45% (ET45) and 
60% (ET60) relative to peak watts determined during a GXT. 12 MSG and 9 CG 
completed the 2 exercise sessions. Repeated measures ANOVA revealed no 
significant differences in groups’ baseline measures of HR, Temp°C, RPEbr, 
RPEleg or TMS measures between-groups or between-sessions. When comparing 
groups during ET45, measures of all variables were similar, except for RPE leg at 
14mins,(mean MSG 3.3 ±1.1, CG 2.1±1.2 p<0.05).  During ET60 MSG HR was 
higher from 14mins (mean 107.8bpm ±12.6 bpm, CG 136.8 bpm ±13.8 p<0.05). 
When comparing the results of MSG ET45 and ET60, during the 35 minute post-
exercise phase MSG HR recovered to pre-exercise values at 10 mins (mean HR 
71.4bpm ±12.7, baseline 63.8 bpm ±9.8 p>0.05) after ET45,  while post-ET60 HR 
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failed to recover before session-end (mean HR 83 bpm ±11.3, baseline 64.6 bpm 
±8.2, p<0.05).  
TMS measures were significantly depressed after both training sessions. Mean 
MEP size were 71% ±38% of pre-exercise levels at 30 secs post-ET45 (p<0.05) 
and 52% ±17.8% post ET60 at 2 minutes (p<0.05). Post-ET45 MEPs recovered to 
pre-exercise values at 10mins while post-ET-60 MEPs recovered at 20 mins. MEP 
latency and MEPρeriph were unchanged. Following ET60 we observed a strong 
negative relationship between Temp°C and MEPs (r=-.65, p=0.023).  
The investigation revealed significant, intensity-dependent, physiological and 
perceptive differences, during exercise and through the time-course to recovery.  
Analysis of responses to post-exercise TMS revealed a significant depression in 
corticospinal excitability, with a clear intensity-dependent difference in the depth 
and duration of MEP depression. In addition, an inverse relationship was found 
between internal body temperature and corticospinal excitability. The results may 
offer further guidance to clinicians for the provision of safe, appropriate and 
effective exercise prescription to PwMS 
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Chapter 1 Multiple Sclerosis 
__________________________________________________________________ 
This Chapter is a general introduction to the clinical aspects of Multiple Sclerosis, 
including its prevalence, pathology and symptoms, and the central mechanisms 
and functional deficits that can affect exercise performance and recovery. 
__________________________________________________________________ 
1.1 Introduction 
Multiple sclerosis (MS) is a chronic, degenerative, immune-mediated disease of the 
central nervous system (CNS) affecting both white and grey matter (Dutta and 
Trapp, 2011). Inflammatory processes cause demyelination, scar formation and 
variable neuronal destruction in the brain and spinal cord leading to irreversible 
neurological disability, autonomic dysfunction, cognitive deterioration and physical 
impairment (Noseworthy et al., 2000). The clinical course follows a variable pattern 
characterised by relapses and/or progressive deterioration of physical and 
cognitive function.  At present there is no known cure.   
Although in recent years the effects of physical exercise on PwMS have received 
increasing attention, the specific relationship between exercise intensity and health 
benefit remains unresolved. There is mounting evidence that physical exercise not 
only improves fitness levels, but can also enhance lost or diminished function in 
people with MS (Rietberg et al., 2005, Dalgas et al., 2008), offering individuals the 
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opportunity to minimise the effects of the disease and maximise their quality of life. 
However few neurological conditions present such a range and complexity of 
problems (Thompson, 2008) and few pose such a challenge for determining an 
effective and appropriate programme of physical activity. Adaptive changes are 
fundamental to the rehabilitation process (Kesselring and Beer, 2005). Thus an 
understanding of the highly unpredictable and changeable nature of MS, the 
variability of its aetiology and pathology, and the heterogeneity of functional and 
physical deficits is critical for the formulation of effective, appropriate exercise 
strategies (Schapiro, 2007). The following sections review the research relating to 
this complex disease. 
1.2 Historical context 
Although many people had observed and described the pathological changes and 
symptoms of MS previously, Jean-Martin Charcot (1825-1893) is generally 
accredited as the first to comprehensively characterise MS as a distinct disease. 
During a series of lectures entitled ‘les sclérose en plaques disseminée’ presented 
in the Salpetriere Hospital, Paris, Charcot described a condition occurring in 
younger adults who at autopsy were noted to have greyish and reddish plaques of 
variable contours and size scattered through the CNS (Lehmann et al., 2007). 
Charcot gave an account of their clinical features delineating the cerebral, spinal 
and mixed cerebrospinal structures with vivid descriptions of the clinical 
pathogenesis and pathophysiology. He identified the discrepancy between lesions 
and symptoms, and established the link between axonal loss and clinical disability 
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(Compston, 2005, Clanet, 2008). However, during the ensuing 150 years the 
complexity of MS pathology, its changeable nature and the significant 
heterogeneity of symptoms contributed to the wide diversity of perspectives 
regarding its pathology and treatment. Indeed until comparatively recently, MS was 
known by many different names suggesting that each of them described a 
separate clinical condition. Throughout the first part of the 20th Century 
‘disseminated sclerosis’ was the commonly used term in England while ‘multiple 
sclerosis’ was widely used in the United States. The World Health Organisation 
continued to use the term ‘cerebral sclerosis’ until the mid-1950’s (Jock- Murray, 
2005). It was only after the rapid development of the newly formed MS Societies in 
New York and the publication of McAlpine, Compston and Lumsden’s classic book 
in 1955 that the term ‘Multiple Sclerosis’ finally became universally accepted (Jock- 
Murray, 2005). 
 1.3 Prevalence and incidence 
MS affects between 1 million and 2.5 million people worldwide. Prevalence and 
incidence rates vary considerably across the globe, with a strong north to south 
gradient defined by an increasing disease frequency with distance from the equator 
(Sellner et al., 2011). Northern Europe, in particular the British Isles and 
Scandinavia, countries of the former Soviet Union, Australia, and regions in north 
America defined as those above the 37th parallel (Kurtzke, 1993) have prevalence 
rates higher than 100 per 100,000 population (Pugliatti et al., 2002, Pugliatti and 
Rosati, 2008). The lowest rates (<5 per 100,000 population) are found in equatorial 
 
 23 
regions of Asia, South America and Africa (Pugliatti et al., 2002). Paradoxically, 
some of the lowest rates of incidence are also found among isolated communities 
of Scandinavia  in areas where national prevalence rates are among the highest in 
the world. Interestingly, dietary differences between communities living in close 
proximity have been proposed to explain the clear exception to MS risk in certain 
parts of Scandinavia (Ebers, 2008), to some extent supporting the view that 
genetic and environmental factors in association with the condition of age 
(Compston and Coles, 2008) can play distinct and inter-active roles in the 
geographical distribution of MS (Eliasdottir et al., 2011).  
 
In England and Wales epidemiological studies have provided a range of MS 
prevalence rates varying from 74 to 112 per 100,000 population (Richards et al., 
2002, Pugliatti et al., 2006), equivalent to about 58,000-66,000 people, with a clear 
association between northerliness and hospital admission rates (Ramagopalan et 
al., 2011). Scotland and its islands, in particular Orkney and the Shetland Isles 
have the highest prevalence rates of MS in the world, ranging from 145 to 196 per 
100,000 (Pugliatti et al., 2006). Scotland also reported the highest incidence rate 
ever recorded at 12 per 100,000 (Pugliatti et al., 2002).  
 
The highest incidence rates of MS occur in the 35-64 age range with typical onset 
early in the third decade (Schwendimann and Alekseeva, 2007). As a 
consequence MS is customarily depicted as a neurological disease of young adults 
(Noseworthy, 1999, Dutta et al., 2006). The female to male ratio is generally 
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reported at 2:1 to 3.1 (Pugliatti et al., 2006, Ahlgren et al., 2011). Although clinical 
presentation of MS before adulthood is rare, hospital and population studies show 
that 1.7% to 5% of people with MS (PwMS) experience their first clinical symptoms 
before the age of 16 (Deryck et al., 2006, Ness et al., 2007). A review of over 1000 
MS patients in the London (Ontario) Natural History Cohort found that 10 to 15% of 
patients were diagnosed with MS before the age of 20 (Deshpande et al., 2006).  
 
Late-onset MS (diagnosis after the age of 50 years) is uncommon (Noseworthy et 
al., 1983), and incidences of MS after 60 years of age occur very rarely (Hooge 
and Redekop, 1992). The effects of ageing on the clinical course of MS are not 
well understood and the detection of MS may be made more difficult by the 
existence of co-pathologies. There is strong evidence that incidence of MS at an 
advanced age indicate a shorter interval to higher rates of motor disability (Trojano 
et al., 2002, Confavreux and Vukusic, 2006, Kis et al., 2008). 
 
MS mortality rates are difficult to estimate as the cause of death can be attributed 
to a primary co-pathology such as chronic heart disease, or to a secondary 
complication such as pneumonia or renal failure (Sadovnick et al., 1991). 
Nevertheless death is attributed to MS in two-thirds of cases (Compston and 
Coles, 2008). Death by suicide is significantly elevated when compared to the 
healthy population, accounting for up to 15% of deaths (Stenager et al., 1996) with  
men who contract MS before the age of 30 at highest risk (Stenager et al., 1996). 
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In general the median time to death (about 30 years from disease onset) 
represents a 5-10 year reduction in life expectancy (Bronnum-Hansen et al., 2004).  
 
The high national prevalence rate and the long-term nature of the disease place a 
significant financial burden on the UK economy. In 2002 the direct yearly cost of 
MS to the National Health Service was estimated to be between £1.2 and £1.4 
billion (Richards et al., 2002). A more recent report which included non-medical 
costs, informal care and other indirect financial outgoings estimated that the total 
annual MS related expenditure in the UK exceeded £2.9 billion (MS International 
Federation, 2010).  
 
Although MS prevalence has remained stable in some geographical areas, the 
world-wide incidence of MS is continuing to grow, the latitude gradient is 
disappearing and the female-to-male ratio among patients with MS is on the 
increase (Orton et al., 2006, Alonso and Hernan, 2008, Benito-Leon, 2011); 
(Elhami et al., 2011, Hirst et al., 2009). The precise reason for the rise in MS 
incidence is unclear. Genetic influences take relatively long periods to affect 
prevalence rates, hence the increase is more likely a reflection of changing 
environmental factors, though these remain unidentified. The transcontinental 
migration of large numbers of people may have contributed to the global 
distribution of MS (Compston and Coles, 2008). Additionally, factors such as 
improvements in epidemiological study methods, improved detection of MS 
resulting from the international adoption of standard diagnostic criteria and/or 
 
 26 
greater access to diagnostic technology may also in part explain the increase in 
world-wide incidence rates (Pugliatti and Rosati, 2008).  
 
1.4 Diagnosis 
For most people, the clinical course of MS begins with episodes of neurological 
dysfunction followed by complete recovery (Confavreux et al., 2000). As the 
disease progresses, clinical disability increases with each attack but the frequency 
of attacks decreases. Transition between the clinical stages of MS is usually 
gradual and indistinct, making for many intermediate forms of the disease 
(Compston, 2004b) and complicating both its diagnosis and treatment.   
Magnetic resonance imaging (MRI) is the ‘gold standard’ for diagnosing MS and 
monitoring the disease course (Frohman et al., 2003). However, although MRI 
scans can reveal multiple lesions distributed through the white and grey matter of 
the CNS (Filippi et al., 2010b, Filippi et al., 2010a), diagnosis of MS with MRI is 
frequently confounded by the differential-diagnosis of other diseases characterised 
by demyelination of the optic nerves (neuritis), severe myelinopathy with extensive 
spinal cord lesions, or even a normal MRI with abnormalities typical to MS (Polman 
et al., 2011). Therefore, cerebrospinal fluid (CSF) analysis is often employed to 
confirm the diagnosis.  A persistent and consistent presence of oligoclonal banding 
(OCB) exists in the CSF of MS patients, thus a positive CRF analysis requires only 
2 lesions identified by MRI to confirm the diagnosis of MS (Giovannoni and 
Thompson, 2008).   
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85% of adult MS patients, 80% of pediatric MS cases and nearly all adolescent MS 
cases initially present with clinically isolated syndrome (CIS), or encephalomyelitis 
(Mikaeloff et al, 2004). CIS is an acute episode of demyelination affecting one or 
several sites in the CNS lasting for at least 24 hours. It typically involves a lesion 
affecting the optic nerve, brainstem/cerebellum, spinal cord or cerebral 
hemispheres (Polman et al., 2011). Not everyone who experiences CIS is 
diagnosed with MS. Indeed many patients with mild CIS recover without treatment. 
However, if  white-matter abnormalities are detected by MRI at clinically unaffected 
sites, the chance of a future positive diagnosis increases from 50% within 2 years 
to 82% within 20 years (Fisniku et al., 2008).  Although the probability of CIS 
converting to clinically defined MS (CDMS) increases over time, MS disease 
evolution is impossible to predict and not all patients with CIS progress to CDMS 
(Miller et al., 2005).  
 
In practice, the initial diagnosis of MS continues to be based solely on clinical 
observation of both signs and symptoms (Tremlett et al., 2008), but the higher 
availability and reliability of advanced technology such as MRI has led it to become 
critical to the diagnostic process. Thus the standard definitions of clinical course 
patterns and outcomes in people with MS were revised in 2011 to take into account 
improvements in imaging techniques, thereby allowing a confirmed diagnosis of 
MS from a single MRI scan (Polman et al., 2011).  
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1.5 Classification of MS 
A confirmed diagnosis of MS requires evidence of characteristic, neurological 
lesions in the CNS that have occurred in both time and space, and to exclude 
alternative diagnoses (Polman et al., 2011). PwMS are classified from clinical 
presentation in the following manner (Lublin and Reingold, 1996): 
 
 relapsing-remitting (RR-MS): clearly defined disease relapses with full 
recovery or with sequelae and residual deficit upon recovery; periods 
between relapses characterised by a lack of disease progression  
 secondary progressive (SP-MS): initial relapsing-remitting course followed 
by progression with or without occasional relapses, minor remissions and 
plateaux  
 primary progressive (PP-MS): disease progression from onset with 
occasional plateaus and temporary minor improvements allowed  
 benign: disease in which the patient remains fully functional in all 
neurological systems 15 years after onset 
 malignant: disease with a rapid progressive course, leading to significant 
disability in multiple neurological systems or death in a relatively short time 
after disease onset 
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1.6 Aetiology 
Epidemiological studies of MS indicate a complex aetiology in which unidentified 
environmental factors trigger the disease in genetically susceptible individuals 
(Compston, 1997). MS is linked to alleles of the major histocompatibility complex 
(MHC). Although the exact mechanisms are unknown, the human leukocyte 
antigen  HLA-DRB1*1501  gene is  the strongest genetic factor identified so far 
influencing susceptibility to MS (Lang et al., 2002), and it may also determine the 
balance between disease susceptibility and resistance (Hauser and Oksenberg, 
2006, De Jager et al., 2008). However, while some studies have reported 
associations between HLA-DRB1*1501 and spinal cord abnormalities (Sombekke 
et al., 2009) and a possible relationship to a more severe disease course (DeLuca 
et al., 2007), others have reported no significant influence on disease severity, 
brain atrophy, or cognition (Van der Walt et al, 2010). 
 Using a dataset obtained from 98 multiple case families, Haines et al (1998) 
estimated that the HLA locus accounted for up to 62% of the inheritability of MS 
(Haines et al., 1998). MS has a familial recurrence rate of about 20% (Compston 
and Coles, 2008). When both parents have MS, the risk increases to about 30% 
(Schwendimann, 2007) but to date, investigations into the recurrence of familial MS 
and studies relating to monozygotic and dizygotic twins have provided no 
conclusive evidence of the presence of hereditary genetic traits (Oksenberg and 
Hauser, 2008, Ebers, 2008).   
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A current hot topic is the interaction of HLA-DRB1*1501 with vitamin D binding 
proteins (vDBP), the major plasma carrier of vitamin D metabolites. Genetic 
differences in the vDBP gene have been found to influence vitamin D levels 
(Ramagopalan and Ebers, 2008, Agliardi et al., 2011). Vitamin D has long been 
implicated with MS.  It is known to regulate neurotrophic growth factors (Taniura et 
al., 2006), halt the progression of experimental autoimmune encephalomyelitis 
(EAE), the animal model of MS (Cantorna et al., 1996), and may influence the anti-
inflammatory immune response in PwMS (Ramagopalan et al., 2009).  
Vitamin D can be synthesised either through exposure to sunlight or through the 
diet. The consumption of oily fish, rich in vitamin D, has been proposed as the 
major factor mediating the environmental effect of MS in some parts of Norway 
(Ebers, 2008). However, other north Atlantic populations (eg, those from Iceland, 
coastal Scotland, Orkney and Denmark) also follow diets that traditionally contain a 
relatively high consumption of oily fish, yet still present very high MS prevalence 
rates. Furthermore, although vDBP has been implicated in disease progression 
(Disanto et al., 2011),  large-scale studies in Canada (Orton et al., 2011) and the 
United States of America (Simon et al., 2010) have failed to directly connect 
vitamin D metabolism to MS susceptibility. Moreover, recent studies examining the 
effects of high level vitamin D supplementation have found no significant effect on 
lesion load, nor have they been shown to produce a significant therapeutic 
advantage for PwMS (Stein et al., 2011).   
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Several studies have suggested a strong association between the Epstein-Barr 
virus (EBV) and HLA-DRB1*1501 (Ascherio et al., 2001),(Lang et al., 2002, Lucas 
et al., 2011) The evidence shows that while people without EBV antibodies have 
an extremely low risk of developing MS (Levin et al., 2010), high-blood serum 
levels of EBV antibodies can signal an 8-fold stronger marker of MS risk in younger 
people (Munger et al., 2011) and those people infected by EBV in later life increase 
the risk of developing MS by up to 30-fold (Ascherio, 2008). However, while EBV 
may play a role in MS pathology in some individuals, there is no evidence to 
support the theory that EBV predisposes an individual to MS (Pender et al., 2011). 
Other viruses such as herpes (Martin, 1981, Sellner et al., 2010), measles 
(Fewster et al., 1979)  and rubella (Horikawa et al., 1973), and various vaccines, in 
particular hepatitis B (Hernan et al., 2004) and influenza vaccines (Yahr and Lobo-
Antunes, 1972) have been postulated but dismissed as possible causative agents 
that can increase the risk of disease acquisition. While It seems likely that 
vulnerability to environmental agents occurring at a crucial moment in an at-risk 
individual’s maturation of the immune system can predispose development of the 
disease (Compston, 2004a, Bennett et al., 2008), and that those risks increase 
dramatically towards later life (Ascherio and Munger, 2007a, Ascherio and Munger, 
2007b), a conclusive link between genetic predisposition and inheritability, 
geographical region and environment, or exposure to a specific causative trigger 
has yet to be demonstrated. In summary, unravelling the genomics of MS is at an 
early stage, the roles of environment and familial susceptibility are not fully 
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understood, and the contribution of genetics to disease risk, disease outcome and 
potential treatments for MS remains to be elucidated.  
1.7 Demyelination 
Myelin is formed from the extending plasma membrane of oligodendrocytes 
creating spiral segments of sheathing that wrap around axons and envelop bundles 
of axonal segments. The insulating and protective properties of the myelin sheath 
are largely due to its structure, thickness, low water content, and its richness in 
lipids.  Myelin sheath thicknesses and internodal lengths vary according to axonal 
calibre (Baumann and Pham-Dinh, 2001). Axons in the CNS trigger myelination 
when they reach a diameter of about 0.2µm (Waxman, 2006). The number of 
wrappings around an axon can vary between 10 and 160 (Arbuthnott et al., 1980). 
Depending on the subtype of oligodendrocyte, 10 axons or more can be 
myelinated (Verkhratsky and Butt, 2007). As a consequence, inflammatory damage 
to a single oligodendrocyte has the potential to affect multiple axons.  
 
Axonal geometry in association with the biophysiological properties of voltage 
gated channels determines the propogation and transport of action potentials. 
Conduction velocity is dependent on the diameter of the axon and the action of the 
oligodendrocyte.  Each 1µM of outer diameter of the axon adds 6m/s to conduction 
velocity at 37°C.  A single oligodendrocyte increases the conduction velocity of the 
axon it sheaths by ~10%. Sodium gated ion channels (Nav) play a critical role in 
conducting action potentials (AP) along axons in the brain and spinal cord 
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(Waxman, 2006). Myelination concomitantly provokes a redistribution of Nav 
channels into clusters at the exposed (unmyelinated) segments of the axon called  
the nodes of Ranvier (Debanne et al., 2011). As myelination progresses, Nav 
expression switches from Nav1.2 to Nav 1.6 within the confines of the 
unmyelinated nodes, and axonal membrane concentrations of Nav change from 
less than 25 channels μm² under the myelin sheath, to ~1,000 μm² at the nodes of 
Ranvier (Waxman, 2006).  
 
Multiple, voltage-insensitive potassium channels (Kv) determine the resting 
potential of the axon membrane, and play an indispensable role in repolarisation of 
the membrane after an AP. The Kv channels are expressed in relatively high 
density under the myelin, falling to about one-sixth of the density at the node of 
Ranvier  (Debanne et al., 2011). The high level of Kv channels at the 
juxtaparanodal region may prevent axonal hyper-excitability and help maintain the 
fidelity of AP propagation at the node of Ranvier (Kress and Mennerick, 2009). 
When activated, Kv channels produce varied waveforms, and have a significant 
impact on subsequent AP propagation characteristics (Kole et al., 2007). Voltage 
gated calcium channels (Cav) are expressed at a lower density than Nav and K+ 
channels and require relatively high depolarisations for activation (>-30mV) 
(Debanne et al., 2011).  Although their role in AP propagation is less well 
understood  than that of Nav and KV, Cav are known to regulate firing properties 
such as spike firing, burst firing and action potential threshold (Bender and 
Trussell, 2009).  
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In summary, the myelin sheath both increases membrane resistance, and reduces 
membrane capacitance by several orders of magnitude thus restricting current flow 
along the axon to the nodes of Ranvier.  In the healthy neuron, an action potential 
(AP) initiates in the axonal initial segment (AIS) close to the soma, and propagates 
towards the terminal, jumping from node to node, thereby providing a saltatory 
pathway for the high-speed conduction of action potentials through the CNS. This 
method of conduction both increases conduction velocity, and significantly reduces 
the energy required to transport signals down an axon. 
 
Demyelination is the hallmark of MS (Dutta and Trapp, 2011). Damage to the 
myelin sheath is driven by macrophages, and auto-reactive, myelin specific CD-4+ 
and CD-8+ T-cells (Bitsch et al., 2000, Beeton and Chandy, 2005). Functionally, 
CD-4+ cells are involved in delay-type hypersensitivity and are termed T helper 
(Th) cells. In contrast CD-8+ cells are involved in the destruction of antigen-specific 
targets and are termed cytotoxic cells (Friese and Fugger, 2005). CD-4+ cells are 
shown to predominate in acute lesions while CD-8+ cells are found to predominate 
almost tenfold in chronic MS lesions (Neumann et al., 2002).  
During an inflammatory event, lymphocytes become attached to potassium (K+) 
receptors (Beeton and Chandy, 2005) in endothelial cells and pass through the 
blood-brain barrier (BBB) (Hauser and Oksenberg, 2006).  Certain components of 
myelin have been found to share, or contain the same proteins found in viruses 
such as EBV, measles, herpes or influenza.  These myelin proteins are thought to 
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provoke a misguided response in myelin-specific T-cells(Davidson and Diamond, 
2001) setting up an inflammatory process that resembles a delayed-type 
hypersensitivity (Compston, 2004b). The consequential activation of pathogenic T-
cells may result in the further opening of the BBB, and trigger the release of 
additional pro-inflammatory cytokines which then proceed to attack the myelin in 
the CNS (Lang et al., 2002). The inflammation is driven by a T-lymphocyte sub-unit 
that secretes interleukin (IL)-17 under IL-23 control (Jadidi-Niaragh and Mirshafiey, 
2011) Th-17 cytokines generate intense inflammation and tissue injury by  
recruiting neutrophils to a site of inflammation in the CNS (Hussell et al., 2010). IL-
17 and IL-22 disrupt the BBB allowing the efficient penetration of Th-17 into the 
brain where they can kill human neurons (Kebir et al., 2007). The inhibition of Th17 
has been seen to substantially ameliorate MS disease severity in the EAE model 
(Du et al., 2009).   
The different levels of demyelinating activity in lesions are characterised by the 
amount of cytotoxic T-cell (Traugott et al., 1983) and macrophage activation, and 
the phagocytosis of myelin proteins (Lucchinetti et al., 2004).  In addition, the 
deficiency of regulatory T-cells in conjunction with the proliferation of B-cells, 
(Owens et al., 2003) and matrix metalloproteinase (MMP), an instigator of cell 
death (Rosenberg, 2009), is a strong indicator of on-going demyelinating activity. 
All three are markers commonly found in the CSF of people with MS (Leppert et 
al., 1996).  
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The general consensus is that pathogenesis of the lesions in PwMS is 
heterogeneous. The pattern of the lesions appears to be totally unpredictable 
(Frohman et al., 2006), indeed different types of lesions can be found in the same 
patient (Barnett and Prineas, 2004). Whilst MS symptoms are assumed to be 
directly caused by lesion damage to the white and grey matter in the CNS, the 
relationship between the location of lesions and the extent of clinical disability is 
weak (Bashir and Whitaker, 2002), making disability levels hard to predict. In 
contrast, the quantity of lesions, especially their development at an early stage of 
MS is associated with greater disability occurring in later years (Noseworthy et al., 
2000). Brain atrophy appears to be widespread in MS, affecting both grey and 
white matter in all regions of the brain, the brainstem and the spinal cord. MRI 
studies have shown that brain atrophy commences at the very earliest stages of 
MS and accelerates rapidly as the disease develops (Bermel and Bakshi, 2006), 
with one study observing  a volume loss of up to 7% over a two year period during 
the relapsing-remitting stage (Zivadinov et al., 2001). Brain volume continues to 
decrease during the progressive forms of the disease, but at a less aggressive rate 
(Bermel and Bakshi, 2006). Grey and white matter atrophy have been found 
correlate significantly with  cognitive dysfunction (working memory and memory 
processing speed), and psychiatric symptoms (depression, anxiety, apathy) to a 
greater extent than whole-brain volume or lesion load in MS (Sanfilipo et al., 2006). 
The association between a decrease in whole-brain volume with an increase in 
physical disability is less clear, however spinal cord atrophy appears to have a 
particularly strong relationship with physical impairment (Lin et al., 2004).  
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1.8 Re-myelination 
Remyelination is associated with functional recovery in MS (Miron et al., 2011) 
although some individuals have demonstrated extensive remyelination without any 
sign of functional improvement (Patrikios et al., 2006). The rapid recruitment  of 
oligodendrocyte-precursor cells (OPCs) to areas of tissue injury appears to be 
normal in PwMS (Frohman et al., 2006). Indeed, remyelination occurs during the 
early stage of lesion development (Stadelmann and Bruck, 2008) and the initial 
stage of myelin destruction (Lassmann et al., 1997). However, the extent of 
remyelination between individuals, or even within specific MS lesions, is highly 
variable (Patrikios et al., 2006). Animal studies have shown the efficiency of 
remyelination to decline with age, more rapidly in males than females (Franklin and 
Kotter, 2008, Stadelmann et al., 2008). Complete remyelination can occur in both 
white, and grey matter lesions (Stadelmann and Bruck, 2008), however a number 
of growth-inhibiting substances have been identified within the scar of plaques that 
can arrest the development of the OPCs and prevent lesion repair (Frohman et al., 
2006).  
 
A strong indication of ongoing or past remyelination is the presence of shadow 
plaques, so-called because they are sharply demarcated plaques, clearly 
distinguishable from the surrounding white matter. The cause of this shadowy 
appearance is possibly the result of reduced myelin density, or to the loss of axonal 
fibres under the newly reformed sheath (Miron et al., 2011). During a systematic 
analysis of the incidence and distribution of shadow plaques in the autopsies of 51 
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PwMS of different clinical classifications and disease durations, Patrikios and co-
workers (2006) observed that 20% of the patients showed extensive remyelination 
across 60% to 96% of the global lesion area. The remyelination appeared, in part, 
to be dependent upon the location of the lesion (remyelination appearing more 
commonly in the deep white matter or in subcortical locations). There was 
extensive remyelination in a considerable portion of MS patients, with the number 
of shadow plaques significantly associated both with older age at death, and longer 
disease duration (Patrikios et al., 2006). Hence the CNS displays a remarkable 
capability to trigger and maintain remyelinating mechanisms for a considerable 
period after disease commencement.  Cycles of demyelination and remyelination 
may eventually exhaust the body’s capacity to continue repairing the tissue 
(Kuhlmann et al., 2008). The reasons as to why the repair mechanisms ultimately 
fail in PwMS remains unresolved. 
 
In animal models, glial cell transplantation in the CNS have been shown to 
enhance action potential conduction in myelin-deficient axons (Utzschneider et al., 
1994), and the introduction of Schwann cells into the spinal cord of rats restored 
the conduction of trains of impulses through the lesion (Felts and Smith, 1992). 
More recently a cat model has provided compelling evidence that global 
remyelination of the CNS can provide complete restoration of clinical function in 
axons that  have remained essentially intact (Duncan et al., 2009). However,  
studies exploring the stimulation, manipulation or implantation of OPCs in humans 
have found that OPCs are non-migratory, that engrafted OPCs rarely extended into 
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normal white matter and that the white matter tracts stay localised to the site of 
injection (Windrem et al., 2002).  
 
In summary, even in the progressive forms of MS, compensatory mechanisms 
have been observed to respond  to inflammatory injury to neural circuits which in 
some cases allow the partial of complete restoration of neural function (Sjostrom et 
al., 2008). However there are many disturbances to which the CNS cannot respond 
and where the insult and injury may be at such intensity that any natural response 
is inadequate (Kuhlmann et al., 2008). 
1.9 Cellular abnormalities 
Traditionally, axonal degeneration has been regarded as the major cause of 
neurological deficits and irreversible disability in PwMS (Dutta and Trapp, 2011), 
however, while it is acknowledged that the symptoms of MS are generally 
attributable to the interruption of myelinated tracts in the CNS (Hauser and 
Oksenberg, 2006), recent studies have shown that a certain proportion of 
neurodegeneration is independent of demyelination (Dutta et al., 2006, Waxman, 
2008, Mahad et al., 2008, Dutta and Trapp, 2011). Indeed, the current view is that  
the whole CNS appears to be involved in the disease (Siffrin et al., 2010). 
Inflammatory processes within the CNS can trigger a cascade of events that 
profoundly affect synaptic density (Dutta et al., 2011), neurotransmitter 
concentrations (Werner et al., 2001), signal transmission mechanisms (Waxman, 
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2005), mitochondrial density (Mahad et al., 2008) and disrupt the microtubule 
transport systems critical to  the normal functioning and survival of neurons (Dutta 
et al., 2011). The extent of MS related symptoms and disability is determined by 
the intrinsic ability of the CNS to retain the integrity and compliance of the central 
mechanisms and neural pathways (Waxman, 2006, Dutta and Trapp, 2011)  
The ability of the CNS to adapt its circuitry in response to changing conditions is 
termed neuroplasticity (Konorski, 1948). It forms the structural and functional 
correlates for learning and memory, and is the mechanism by which adaptive 
changes are modulated by appropriate therapies (Kesselring et al., 2010a) 
Neuronal electrical properties can change in milliseconds, and the changes may 
endure for hours or days (Sjostrom et al., 2008). Short term adaptations occur 
continuously (Beck and Yaari, 2008), hence alterations to the intrinsic properties of 
synapses, dendrites or axons as the result of MS, have a profound effect on the 
ability of the CNS to make continual short term adaptations to such changing 
circumstances. 
1.10 Glutamate 
Glutamate is the principal fast excitatory neurotransmitter in the CNS. Glutamate 
dependant signalling is required for all sensory and motor processing, and 
glutamatergic receptors contribute significantly to synaptic plasticity, learning and 
memory formation (Bauer and Robinson, 2012). During inflammatory episodes, 
microglia and leukocytes release substantial amounts of glutamate into the 
extracellular space (Barger et al., 2007). In PwMS, glutamate concentrations have 
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been found to be significantly elevated, both in acute lesions and normal appearing 
white matter (Srinivasan et al., 2005), and doubled in cerebrospinal fluid  (Stover et 
al., 1997).   
Ionotropic glutamate receptor sub-types are classified into two groups; NMDA (N-
methyl-D-aspartate), and non-NMDA (alpha-amino3-hydroxy-5methyl-4-isoxazole 
propionic acid (AMPA) and kainite). NMDA receptors consist of a complex 
pharmacology with multiple modulatory sites. They are key components in long-
term potentiation (LTP) of neuronal pathways, memory formation and synaptic 
plasticity (Prybylowski and Wenthold, 2004), and cell survival (Sheng and Kim, 
2002). AMPA receptors desensitize quickly, strongly influencing neuronal output, 
and are responsible for the majority of fast excitatory transmission in the human 
brain and enhanced synaptic plasticity (Lu et al., 2001). Metabotropic glutamate 
(MGLU) receptors do not conduct ionic flow, instead they activate intracellular 
enzymes through G-proteins, modulating ionic channel activity (Hassel and 
Dingledine, 2006). Recently, confocal microscopy has revealed that MS causes a 
significant decrease in excitatory synapses and mRNA proteins encoding AMPA, 
NMDA and MGLU receptors. Moreover, a significant reduction in their respective 
synaptic binding proteins within the hippocampi of post-mortem MS brains has 
been reported (Dutta et al., 2011).  
Once released, glutamate needs to be cleared quickly from the extracellular space 
in order to terminate synaptic transmission (Kalloniatis and Tomisich, 1999). 95% 
of the extracellular glutamate is rapidly taken up by astrocytes via the excitatory 
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amino-acid transporters (EAAT) (Rothstein et al., 1996) where it is synthesized into 
glutamine, then shuttled back to neuronal vesicles where it re-synthesises into 
glutamate (Lehmann et al., 2009). Protein levels of the glutamate transporters 
EAAT-1 and EAAT-2 have been found to be significantly decreased in MS brains, 
suggesting a reduction in the ability to clear glutatmate (Dutta et al., 2011).  
The increase in extracellular glutamate is capable of precipitating excitotoxic cell 
death by over-stimulation of glutamate receptors (McDonald et al., 1998, Rothman 
and Olney, 1995). Indeed, in one EAE model, more than 60% of oligodendrocyte 
loss was attributed to glutamate excitotoxicity (Pitt et al., 2000). Moreover, 
excitotoxicity causes dysregulation of calcium homeostasis triggering calcium influx 
into surrounding cells, overloading the mitochondria and resulting in the significant 
dysfunction of the electron transport chain and inhibition of ATP production(Dutta 
et al., 2006).  
1.11 GABA 
Gama-aminobutyric acid (GABA) receptors and glycine are the principal inhibitory 
transmitters in the CNS that, when activated, can generate a membrane 
hyperpolarisation and a reduction in dendritic excitatory activity that strongly 
inhibits action potential firing (Ben-Ari et al., 2007). GABA and GABA-ergic 
receptors have been found to be significantly elevated in MS demyelinated 
hippocampi (Dutta et al., 2011) suggesting that GABA exerts a powerful inhibitory 
influence in MS. 
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1.12 Nitric oxide 
When nitric oxide (NO) is released in excessive amounts it becomes neurotoxic 
and has been linked to to the neurodegenerative process in MS (Svenningsson et 
al., 1999). Under normal conditions NO acts as a signalling molecule that regulates 
vasodilation, immune responses and neuronal function. Axons within the healthy 
CNS generally experience very low concentrations of NO, reportedly in the low 
nanomolar range. (Griffiths et al., 2003).  During inflammatory episodes, activated 
microglia produce substantial amounts of NO to kill invading organisms or 
transformed cells (Merrill et al., 1993). Other cells in the CNS, such as astrocytes, 
can also be induced to express NO during an inflammatory attack.(Murphy et al., 
1993).  NO synthesis is significantly increased in acute MS lesions (Bo et al, 1994; 
Liu et al,  2001) and   high concentrations of NO markers have been observed in 
the blood, urine and CSF of PwMS (Svenningsson et al., 1999, Giovannoni et al., 
1999).  In MS, NO released from activated microglia is known to have a deleterious 
effect on mitochondria, resulting in a reduction in  ATP and an increase in 
glutamate release (Brown and Bal-Price, 2003). NO inhibits the axonal transport of 
synaptic vesicle precursors and may cause synaptic dysfunction (Stagi et al., 
2005). Moreover, NO has been implicated in the disruption of the BBB (Boveri et 
al., 2006), demyelination and axonal injury (Hill et al., 2004), and is believed to 
contribute to physical impairment and loss of function through reversible and 
irreversible conduction block in demyelinated axons (Redford et al., 1997).  
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1.13 Mitochondria 
Mitochondria have recently been shown play a role in the pathogenesis of MS 
(Dutta et al., 2006, Kalman et al., 2007, Mahad et al., 2008). The CNS accounts for 
20% of oxygen inspired at rest, yet represents only 2% of body weight (Kann and 
Kovacs, 2007). Mitochondria produce high levels of metabolic energy for neurons 
in the form of ATP. Profound alterations to mitochondrial DNA have been found to 
be significant contributors to progressive neuronal degeneration in MS (Campbell 
et al., 2010) and brain atrophy. Post-mortem brain-weight in people with diverse 
mitochondrial diseases has been shown to be reduced by almost 20% (Lax and 
Jaros, 2012). Mitochondrial abnormalities have been found to occur in synapses 
and distal regions of axons long before the first signs of inflammatory swelling 
(Dutta et al., 2006) leading to axonal disruption and  degeneration(Su et al., 2009) . 
The high level of mitochondrial dysfunction in MS lesions may be the result of nitric 
oxide (NO) blocking the electron transport chain, thus disrupting mitochondrial 
respiration and reducing ATP synthesis(Su et al., 2009). Mitochondrial stress leads 
to persistent opening of the permeability transition pore of the inner membrane of 
the mitochondria, allowing larger solutes to enter, and further adding to the 
disruption of the electron transport chain and ATP synthesis. The resulting ATP 
deficiency results in the gradual loss of the NA+/K+ATPase, which  has a critical 
role in maintaining  Na+ and K+ transmembrane gradients, membrane excitability 
and the conduction of APs (Benarroch, 2011).  
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1.14 Axonal transport 
 
Axonal transport is critical for the rapid distribution and positioning of diverse 
cellular cargoes along the microtubules of neurons and are implicated in long term 
,learning-related brain plasticity (Puthanveettil et al., 2008).  Motor proteins are 
nanoscale transport vehicles which move molecular cargoes in cells (Gilbert, 
2001). Kinesins are the principle carriers of organelles, mitochondria and vesicles 
along neurons in an anterograde direction. Each nanoscale step is coupled to 
hydrolysis of one molecule of ATP (Endow et al., 2010). Kinesins carry 
mitochondria for long distances to areas of high metabolic demand, such as the 
synapses, the axonal initial segment, nodes of Ranvier and to sites of neural 
inflammatory activity.  Axonal transport is significantly impaired by inflammatory 
cytokines (Stagi et al., 2006) and blocked by NO (Stagi et al., 2005). In addition 
KIF1A, the major micro-tubule kinesin transporter and dynein, the retrograde 
axonal transporter have been found to be significantly decreased at both mRNA 
and protein levels in demyelinated MS hippocampi (Dutta et al., 2011).  
  
1.15 MS disability, symptoms and management  
The definition and concept of MS disability is complex. There are many historical, 
social, legal and philosophical influences in its interpretation. The experience of 
disability and its impact on quality of life is unique to each person. Hence the 
overall aim of the International Classification of Functioning, Disability and Health 
(ICF) is to provide a standard language and unified framework for the description of 
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health and health-related states described  from the perspective of the 1) the body 
and its structures, and 2) activities and participation (World Health Organisation, 
2001).  According to the World Health Organisation, a physical impairment is a 
problem in body function or structure, such as a significant deviation or loss.  
Disability represents the restriction (resulting from an impairment), or an inability to 
perform certain tasks within the physical and social environment.  Within the 
definitions of the Disability Discrimination Act (DDA) at least one of the following 
areas must be badly affected; mobility, manual dexterity, physical coordination, 
continence, ability to lift or carry everyday objects, memory or ability to 
concentrate, learn or understand; understanding the risk of physical danger.   
Approximately 80% of people with MS initially present with relapsing and remitting 
MS (Noseworthy et al., 2000) . The remission of symptoms is possibly the result of 
remyelination. The early symptoms may appear trivial, occurring only once or twice 
a year. Typically patients will report sensory disturbances, optic neuritis, limb 
weakness and gait instability, clumsiness or facial weakness. As the disease 
progresses they may develop parathesias, spasticity, pain, heat intolerance, 
bladder/ bowel infections, incontinence and sexual dysfunction. 50% of MS 
patients remain ambulatory at 15.5 years from onset, however, almost 60% require 
assistance when walking and 70% are restricted in their ability to perform activities 
of daily living. Many are dependent on multiple mobility aids (Iezzoni et al., 2009). 
At any point in time approximately 30% of people with MS are restricted to a 
wheelchair (Richards et al., 2002).  
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Pain can occur as neuralgia, severe deforming spasticity or migraine, and may  
herald a relapse in MS (Kenner et al., 2007). Additional symptoms include sleep 
disorders (Tachibana et al., 1994, Stanton et al., 2006), depression (Voss et al., 
2002), reduced activity levels (Ng and Kent-Braun, 1997), and reduced quality of 
life (Pittion-Vouyovitch et al., 2006). The prevalence of depression is estimated to 
range between 23 - 54% (Brown et al., 2009). Suicidal intent is higher than in the 
general population, with a Canadian study of 140 PwMS reporting that 6.4% had 
actually attempted suicide (Feinstein et al., 2002). Although anxiety disorders are 
less well reported, there is considerable overlap in the symptomology of anxiety, 
depression and fatigue reflecting a significant comorbidity in MS patients (Brown et 
al., 2009).  
Fatigue affects almost 90% of MS patients (Krupp et al., 1988, Murray, 1985) with 
over 40% reporting it as their most serious complaint (Murray, 1985, Schwid et al., 
2002). The symptoms of fatigue can be severely debilitating and significantly affect 
mood-state, cognitive performance and executive control (Holtzer and Foley, 
2009).  Chronic fatigue is critically linked to patients’ perceptions of their general 
well-being (Egner et al., 2003).  It has a significant impact on the ability to work and 
participation in social activities (Forbes et al., 2006). However, despite its 
ubiquitous presence, fatigue as the direct result of MS remains difficult to quantify 
and very hard to measure. Indeed, the exact aetiology of fatigue is unknown. It 
seems to be triggered by multiple factors, is influenced by central, peripheral and 
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autonomic mechanisms, and  presents multidimensional challenges to PwMS 
(Rietberg et al., 2011). 
Previous studies have reported conflicting results when relating levels of fatigue to 
physical disability (Mills and Young, 2011, Iriarte et al., 2000, Kroencke et al., 
2000) but clear relationships exist between fatigue and disease impact (Mills and 
Young, 2011) and disease progress (Bakshi, 2003, Kos et al., 2007). Lassitude is 
perhaps the most common and hardest type of fatigue to understand. It occurs 
spontaneously, disables significantly (Schapiro, 2007) and is typified by an 
overwhelming sense of exhaustion or tiredness lasting from just a few hours to 
several days. 
Surprisingly there is no universally accepted definition for MS related fatigue. In 
1998 the MS Council for Clinical Practice proposed a description of fatigue as “ a 
subjective lack of physical and/ or mental energy that is perceived by the individual 
or caregiver to interfere with usual and desired activities”. However, this definition 
fails to convey the sense of overwhelming tiredness, lack of energy and the 
constant feeling of exhaustion characteristic of the malaise reported by PwMS . 
Non-activity related fatigue may be caused either by multiple factors relating to the 
disease process, or by the pathological consequence of the disease. The reasons 
why PwMS experience severe fatigue while at rest are as yet unknown.   
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1.16 Activity-related fatigue 
Exertional fatigue, muscle fatiguability and exercise intolerance are shared 
symptoms of many neurological and non-neurological pathologies that may 
originate in the CNS, the peripheral nervous system (PNS), or both (Chaudhuri and 
Behan, 2004). Activity related fatigue can be categorised into a further three 
different entities, fatigue at rest, fatiguability (due to physiological, neurological, or 
psychological stress), and the impact of fatigue on other symptoms (Iriarte et al., 
2000).  
Fatigue has been shown to respond well to physical exercise (Mostert and 
Kesselring, 2002), however the desire to participate in activities may be 
compromised by an inability to tolerate sensations of effort, and post-exercise 
fatigue. Indeed, anxieties associated with ability to recover may lead PwMS to 
compensate, or even overcompensate their daily routines rather than yield to the 
feelings of fatigue (Rietberg et al., 2011).   
There is a high correlation between dysfunction of the pyramidal tract and fatigue 
in MS (Iriarte et al., 2000, Samii et al., 1996a). Other abnormalities in the CNS may 
play an important role (Andreasen et al., 2009). A physiological explanation may 
involve the dysfunction of the motor system or its neural activation that arises due 
to altered properties within the muscle, or because the central nervous system fails 
to drive the motor neurons sufficiently (Gandevia, 2001). Central activation of 
skeletal muscle has been shown to be impaired in PwMS suffering from fatigue 
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(Andreasen et al., 2009). Some MS patients presenting with chronic fatigue exhibit 
dysfunction of the Hypothalamic-Pituitary-Adrenal (HPA) axis (Siegert and 
Abernethy, 2005). Studies have demonstrated that a hyperactive HPA axis is 
associated with neurological disability, cognitive impairment and brain atrophy, and 
may be used as a marker to predict future neuro-degeneration in MS (Heesen et 
al., 2007). 
1.17 Physical management 
Whilst there is general agreement that physical therapy plays an important role in 
maintaining and improving function, there is no evidence that physical therapy halts 
the primary symptoms of MS, and no consensus on the most effective approach of 
delivering therapeutic rehabilitation. Management factors relating to physical 
exercise PwMS are covered in greater depth in Chapter 2. 
1.18 Medication 
Disease modifying therapies for MS are still at a relatively early stage of 
development. Drugs have been shown to be effective for reducing relapse rates in 
the early forms of the disease with a 30% reduction in frequency of new episodes 
over 2 to 3 years, and to a certain extent slowing clinical progression during 
relapsing-remitting episodes (Noseworthy, 2008). However, studies have shown no 
useful effects of drug therapies on the secondary-progressive phase except in rare 
cases of progressive forms of the disease with continuing high relapse rates (El-
Moslimany and Miller, 2008). Long-term observational studies assessing the 
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validity of drug interventions have suffered through the lack of patients’ willingness 
to participate, or in some cases loss to follow-up, or death (Ebers et al., 2009). 
Initially, there appears to be a high level of compliance and adherence to 
medications, but discontinuation rates have been reported as high as 50%  within 2 
years of drug initiation (Wong et al., 2011). Classes of medication taken by 
participants in the experimental stages of the thesis can be found in Appendix 8.6 
Overall, ß-interferon has been shown to decrease clinical relapses and possibly 
slow-down the progression of disability, however the effects are inconsistent, and a 
high number of PwMS are non-responders (Oksenberg and Hauser, 2008). A 
Cochrane review examining the protective effects of interferon reported only a 20% 
reduction in the relative risk of an exacerbation of symptoms (Rice et al., 2001). 
Large clinical trials of interferons in progressive forms of MS have reported modest 
or no effect  on disability outcomes (Group, 1998). A  Cochrane review of the 
evidence relating to glatiramer acetate (Capaxone) found that disease progression 
was unaffected by its use. Indeed, there was no evidence to support a  beneficial 
role of glatimere acetate for RR-MS patients over time, and its benefit on clinical 
relapses for RR-MS was also questionable (Munari et al., 2004). Nevertheless, 
early use of immuno-modulatory drugs suggest markedly better responses (Bates, 
2011) within a narrow window of opportunity (Smith and Waxman, 2005), however, 
symptoms and functional deficits are not reversed. As the disease progresses, 
benefits from drugs appear to become minimal (Noseworthy, 2008), while deficits 
and disabilities continue to accumulate. Moreover, neither existing symptoms nor 
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functional disability are reversed. In general MS progression can be delayed but 
not completely stopped by available drug therapies (Goodin and Kappos, 2008). 
1.19 Summary 
MS presents a complex, unpredictable, changeable and heterogeneous disease 
that affects the CNS causing moderate to severe disability in the majority of those 
affected by it. Symptoms can change without warning leading to an unpredictable 
level of dysfunction and recovery (Thompson, 2008). The fluctuating, progressive 
nature of the disease can present confusing pictures to clinicians, complicating its 
management. An incomplete understanding of its pathophysiology and the 
ineffectiveness of available therapeutic and immune-modulatory treatments means 
that in general, PwMS experience a gradual decline in physical and cognitive 
function, well-being and quality of life.  
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Chapter 2 Exercise 
 
__________________________________________________________________ 
This Chapter introduces the aims of the thesis describing the principles of exercise 
and the general health benefits to be gained from participation in it, the limiting 
factors affecting PwMS, and sets out the definitions and concepts on which the 
experimental parts of the thesis are based. 
__________________________________________________________________ 
2.1 Introduction 
The aim of this thesis is to examine acute physiological, central and perceptive 
responses of PwMS to exercise intensity during both the active phase, and 
immediately afterwards, through the post-exercise time-course to recovery. The 
short-term effects of exercise intensity in PwMS are unknown. As detailed in 
Chapter 1, PwMS are constantly required to adapt to an unpredictable and 
changeable disease that imposes considerable limitations on their daily activities 
(Stuifbergen et al., 2006, Soundy et al., 2011). Spasticity, weakness pain and 
fatigue are ubiquitous characteristics requiring constant management. Hence the 
intensity of any physical activity and the ability to recover from it are critical 
considerations.  Increased levels of physical activity are proposed to limit the 
degree of disability experienced by an individual with MS while improving health, 
function, well-being and quality of life. However, despite its importance as a key 
component of an exercise prescription, little or no evidence exists relating to the 
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effects of exercise intensity on PwMS, either during the active phase or during the 
post-exercise time-course to recovery. 
 
2.2 Exercise for health and rehabilitation  
 
For the general population, evidence linking higher levels of physical activity to 
increased health benefits is unequivocal (Warburton et al., 2006, Lee et al., 2010). 
A higher level of physical fitness significantly delays all-cause mortality and 
reduces morbidity from the four main causes of death in developed countries; 
cardiovascular disease, cancer, diabetes and stroke (Haskell et al., 2007). 
Moreover, for people disabled by disease or injury, exercise is recommended  as 
part of an active process that aims to improve their health, maximise participation, 
increase functional independence and enhance their quality of life (Beer, 2010). 
One of the primary aims of exercise for PwMS is to reduce disability and 
impairment, and increase levels of activity, participation and independence 
(Langdon and Thompson, 1999, Kesselring and Beer, 2005). Health-promoting 
behaviours such as regular physical exercise present an opportunity for PwMS to 
participate in the disease management process (Turner et al., 2009). Hence, 
interventions for PwMS need to be adaptable to the unpredictable changes in 
clinical status and appropriate to an individual’s functional capacity (Kesselring and 
Beer, 2005, Beer, 2010).  
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The International Classification of Functioning, Disability and Health model (ICF) 
developed by the World Health Organisation as a framework for disability and 
health, acknowledges the complex interaction between an individual’s health 
condition, and personal and environmental factors (Ustun et al., 2003). According 
to the model, outcomes should be measured at the following levels: body function 
and structure (impairment), activities and participation.  Implicit to the success of a 
therapeutic programme is the understanding that treatment is fundamentally 
influenced by an individual’s choice (Noseworthy, 2008). In the context of exercise 
prescription, the clear inference is that exercise programmes should deliver an 
effective physical, mental or social benefit that encourages participation and 
adherence.  The setting of specific, measurable, realistic and attainable goals is an 
important issue in this respect (Kesselring and Beer, 2005). 
There is a growing body of evidence that exercise is well tolerated by PwMS. 
Health benefits have been shown to be gained through cycling (Mostert and 
Kesselring, 2002), aquatic exercises (Gehlsen et al., 1984), aerobic and strength 
training (Romberg et al., 2004b) and walking (Newman et al., 2007). Exercise 
training has been shown to significantly improve aerobic fitness, (Petajan et al., 
1996), mobility (Snook and Motl, 2009), muscle strength (Broekmans et al., 2011, 
Dalgas et al., 2009), mood-state and anxiety (Petruzzello et al., 2009). On the 
other hand, lower levels of physical activity have been associated with the 
worsening of MS symptoms (Motl et al., 2008). 
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2.3 Attitudes and barriers to exercise 
 
For PwMS, participating in exercise remains somewhat controversial (Schapiro, 
2010). It is not uncommon for PwMS to be advised to avoid participation in 
strenuous activities in case they provoke a worsening of existing symptoms (Smith 
et al., 2006), stimulate the onset of new symptoms such as fatigue (Sacco et al., 
2011) or facilitate an exacerbation of the disease itself (Sutherland and Andersen, 
2001, van Diemen et al., 1992, Rasova et al., 2006). This view remains prevalent 
in a high number of MS communities (Bjarnadottir et al., 2007), particularly within 
older age-groups where a high percentage advocate no exercise at all (Turner et 
al., 2009). As a consequence PwMS engage less in physical activity than non-
diseased populations, to such an extent that their sedentary lifestyle has been 
described as “alarming” even in the context of the general prevalence of physical 
inactivity and sedentary lifestyle of adults in the USA (Motl et al., 2005).  Sedentary 
behaviour refers to activities that fail to increase energy expenditure substantially 
above the resting level, such as sleeping, sitting, lying down, and watching 
television (Pate et al., 2008).  
 
Chronic diseases can have a significant effect on patterns of sedentary behaviour 
(Chastin and Granat, 2010). A general lack of activity can precipitate a downward 
spiral leading to a further reduction in fitness and health affecting their function and 
mobility, independence, well-being and quality of life (QOL). PwMS who are 
detrained and unused to exercise face increased challenges and health risks when 
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starting an exercise prescription, especially if they also present with co-morbidities 
such as cardiovascular-pulmonary disorders or life-style related neuromuscular 
impairments. Moreover, unpredictable changes to components of fitness either due 
to the primary disease, or as secondary consequences of enforced physical 
inactivity can present confusing pictures to clinicians which further complicates the 
prescription of an appropriate exercise dose (Dawes, 2008b). The special 
considerations for this group includes spasticity, incoordination, ataxia, muscle 
weakness, foot drop and visual disturbances (Jackson and Mulcare, 2009a). 
Further barriers to exercise for PwMS include lack of provision of appropriate 
fitness facilities, and lack of exercise professionals with expertise in training people 
with specific neurological conditions (Rimmer et al., 2004). 
2.4 General definitions and principles of exercise 
 
Physical activity is traditionally defined as any bodily movement requiring energy 
metabolism above resting levels (Caspersen et al., 1985). Exercise is a subset of 
physical activity that is planned, structured and repetitive with the intention of 
improving or maintaining one or more of the components of health and  fitness 
(Garber et al., 2011). The terms physical activity and exercise are often used 
interchangeably, although the characteristics of the tasks and resultant health 
benefits can differ widely.  
 
Physical fitness describes a set of attributes relating to an individual’s ability to 
perform physical activity (Holly and Shaffrath, 2001). It reflects the body’s ability to 
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cope with the demands of activities of daily living, work or during leisure pursuits 
without experiencing undue fatigue (Caspersen et al., 1985). Each component of 
physical fitness, whether cardiorespiratory, muscle strength, endurance, flexibility 
body-composition or neuro-motor fitness (balance, coordination and 
proprioception) has an influence on components of health and well-being (Garber 
et al., 2011). Increased volumes of physical activity are associated with higher 
levels of physical fitness (Garber et al., 2011), and small improvements in physical 
fitness are associated with significant reductions in health risks (Erikssen et al., 
1998, Myers et al., 2002). 
 
Physical fitness is based on the principle of adaptation, which states that if a 
specific physiological capacity is taxed by a physical training stimulus within a 
certain range and on a regular basis, this capacity usually expands (Holly and 
Shaffrath, 2001). Thus in order to elicit a training response, the body has to be 
challenged beyond a certain point, the training threshold. The gains and benefits of 
improved physical fitness are quickly reversed when the overload is withdrawn or 
training is reduced (Taivassalo and Haller, 2004). Training responses are generally 
specific to the tasks performed. Both central and physiological systems are 
involved.  Hence, a training programme designed to improve aerobic power must 
overload the cardiovascular-pulmonary systems(Powers and Howley, 2004a). 
Anaerobic training normally involves working against resistive loads leading to an 
increase in muscle contractile proteins, neuromuscular efficiency, and ultimately, 
gains in strength and power (Kraemer et al., 1988). 
 
 60 
Based on the specificity concept, the magnitude of adaptation can vary 
considerably depending on the mode of training. When considering the health and 
fitness benefits of exercise for PwMS, the training should provide a sufficient 
cardiovascular overload that stimulates improvements to optimal cardiac output, by 
using muscle groups that enhance local circulation and the metabolic machinery. 
Given that strength deficits may limit the ability of PwMS to exercise at sufficient 
intensity and duration to produce health benefits (Dalgas et al., 2009), endurance 
training produces adaptive changes to active muscle and greater improvements to 
cardiovascular-pulmonary systems. Cardiorespiratory fitness and endurance is 
essential to maintaining function and independence in most activities of daily living 
for PwMS. Therefore, this thesis will focus on the acute neurological, physiological 
and perceptive responses to cardio-respiratory, endurance training. 
 
2.5 Exercise Prescription 
To achieve health and fitness benefits, individuals are required to increase their 
physical activity by changing from a sedentary life-style to one that achieves 
recommended physical activity levels (Haskell et al., 2007). Health and fitness 
benefits from exercise are associated with the volume of activity performed (the 
sum of the frequency, intensity, duration and type of exercise), above the training 
threshold (Haskell et al., 2007). The relationship between an exercise dose 
(volume of exercise performed) and the response (health benefit) is generally 
linear (Powers and Howley, 2004a), suggesting that those PwMS who can tolerate 
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exercise at higher intensities for longer periods will achieve greater health benefits 
(Erikssen et al., 1998).  
 
For clinical groups, optimal adaptations to exercise training require the 
development of, and adherence to a specific programme of activity, an exercise 
prescription. The prescription will define the potency of an exercise dose, and the 
frequency required to elicit and maintain a health benefit. However, an individual’s 
response to an exercise dose is difficult to predict. Numerous factors such as age, 
clinical status, and environmental conditions will influence the response. For 
example, PwMS often require modifications to exercise intensity due to factors 
such as spasticity, weakness, pain or optical neuritis.  
ACSM’s Guidelines for Exercise Testing and Prescription (ACSM, 2010) lists 
several reasons for altering prescriptions: 
 Variance in objective and subjective responses to an exercise session. 
 Variance in the amount and rate of exercise training responses 
 Differences in goals between individuals 
 Variance in behavioural changes relative to the exercise prescription 
With respect to PwMS, exercise professionals need to be aware of the various 
symptoms, and be aware of the effects that such symptoms may have on exercise 
performance (Jackson and Mulcare, 2009b). 
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2.6 Exercise intensity 
 
Exercise intensity can be described objectively as the physiological response to 
physical activity, for example heart rate (Wasserman et al., 2005), or measured as 
the amount of work being produced, or described subjectively as an individual’s 
perception of the magnitude of the work being performed. Measures of intensity 
can provide markers that reflect the integrity and compliance of neurological, 
physiological and perceptive mechanisms to produce and maintain physical 
exercise. 
Intensity can be manipulated either by altering the time to produce a specific 
volume of exercise, or by altering the amount of exercise performed within a 
specific time. Regardless of the activity or mode of delivery, exercise intensity and 
duration are inversely related; the higher the exercise intensity, the shorter the 
duration that exercise can be sustained (Heyward, 2010). However, whilst intensity 
is a key component of an exercise prescription, the relationship between exercise 
intensity and health benefit for PwMS remain unknown. 
2.7 Exercise in MS  
The ability to work at intensities high enough to induce an adaptation is dependent 
on the functional state of the cardiovascular and respiratory processes to efficiently 
deliver oxygen, nutrients and cells via the blood stream, and the ability of skeletal 
muscle to utilise the oxygen and produce energy (Buckley and Hughes, 2008). An 
impairment or dysfunction in any of these processes reduces an individual’s ability 
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to function normally. Respiratory dysfunction is a common problem in MS, mainly 
caused by respiratory muscle weakness (Buyse et al., 1997). In one study of 71 
MS patients, respiratory impairment was observed in over 60% of the participants 
(Grasso et al., 2000), and pulmonary dysfunction in MS has been found present 
even in the absence of reduced respiratory muscle function (Altintas et al., 2007). 
Abnormal cardiovascular responses have been detected in a high proportion of 
PwMS (Anema et al., 1991, Acevedo et al., 2000) with clinical signs, such as atrial 
fibrillation, linked to the appearance of brain stem lesions (Chagnac et al., 1986, 
Schroth et al., 1992). Cardiovascular reflex testing of PwMS has revealed 
abnormalities of both sympathetic and parasympathetic mechanisms of the 
autonomic nervous system (ANS) (Nasseri et al., 1999). An abnormal 
disassociation between heart rate and blood pressure, with a profound attenuation 
of the pressor response, has been reported after a maximum voluntary contraction 
(Pepin et al., 1996), however differences in muscle strength and muscle mass 
between MS and healthy controls may explain the blunted pressor response (Ng et 
al., 2000). For an individual exercise prescription, an exercise dose relative to an 
individual’s maximal exercise capacity is recommended, especially for clinical 
populations and deconditioned persons (Garber et al., 2011). In the Health and 
Fitness setting, the most commonly used method to set exercise intensity is to 
calculate the percentage of predicted maximal heart rate calculated from the 
formula ‘220 - age years’ (Londeree and Moeschberger, 1984). The accuracy of 
age predicted maximal heart rate is not supported by all studies (Tanaka et al., 
2001). Indeed, the ability to tolerate exercise intensity differs considerably between 
 
 64 
individuals, and is dependent on multiple factors, such as resting heart rate, age, 
mode of exercise, fitness levels and clinical health status (ACSM, 2010).  
 
The extent to which any level of exercise intensity contributes to fatigue or failure in 
the exercise task  is thought to depend on the relative demand placed on each of 
the mechanisms and processes contributing to the force exerted by the muscle 
(Maluf et al., 2005). Gender and age are major contributing factors to muscle 
fatigue onset. For instance, when performing sustained voluntary contractions at 
low to moderate intensity, women have up to a 50% longer time to task failure, 
however at higher intensity, muscle fatiguability between the genders is less 
evident (Hunter and Enoka, 2001) and  the difference in time to task failure 
between genders is reduced with age (Hunter et al., 2004). In PwMS, 
measurement of muscle function can be complicated by factors such as disease 
related weakness and spasticity. The precise central components and processes 
contributing to central drive deficits and muscle weakness in PwMS remain 
unknown, however the loss of ability to generate force, particularly in the lower limb 
is consistent with muscle impairment observed in other neurological conditions and 
spinal cord injury (Ng and Kent-Braun, 1997). In PwMS, long-term disuse has been 
found to result in lower bone density, atrophy of type I and type II fibres, and 
decreased enzyme content per fibre in lower-leg muscles similar to that found in 
hemiplegia (Kent-Braun et al., 1997). Muscle myosin heavy chain (MHC) and fibre-
type characteristics in some upper- leg muscles of PwMS have been found to be 
more similar to those of age-matched sedentary controls with a significant 
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reduction in average muscle area  (Carroll et al., 2005). The lower limb frequently 
tends to be affected before, and more than the upper limb (de Ruiter et al., 2001) 
with weakness in muscle groups directly relating to problems performing the 
activities they control (Iriarte, 1998) and in particular, difficulty generating fast 
powerful movements due to impaired central activation(Thoumie et al., 2005, Ng et 
al., 2004).  
Two specific problems that may affect the ability of PwMS to generate and 
maintain a higher work-rate are fatigue and thermosensitivity (Beer, 2010). 
Exertional fatigue, muscle fatigue and exercise intolerance are shared symptoms 
of many neurological and non-neurological pathologies that originate in the CNS, 
the peripheral nervous system (PNS), or both (Chaudhuri and Behan, 2004). 
Activity related fatigue in MS can be categorised into three entities, fatigue at rest, 
fatiguability (due to physiological, neurological, or psychological stress), and the 
impact of fatigue on MS symptoms (Iriarte et al., 2000).  
There is a high correlation between dysfunction of the pyramidal tract and fatigue 
in MS (Iriarte et al., 2000, Samii et al., 1996a), although other abnormalities in the 
CNS may also play an important role (Andreasen et al., 2009). CNS deficits may 
cause a failure to sufficiently activate motor neurons sufficiently (Gandevia, 2001). 
Central activation of skeletal muscle has been shown to be impaired in PwMS 
suffering from fatigue (Andreasen et al., 2009). Some MS patients presenting with 
chronic fatigue exhibit dysfunction of the Hypothalamic-Pituitary-Adrenal (HPA) 
axis (Siegert and Abernethy, 2005). Studies have demonstrated that a hyperactive 
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HPA axis is associated with neurological disability, cognitive impairment and brain 
atrophy, and may be used as a marker to predict future neuro-degeneration in MS 
(Heesen et al., 2007). 
Many PwMS exhibit a worsening of MS related symptoms with a rise in body heat. 
The effect is named after Wilhelm Uhthoff (1853-1927) who first identified and 
reported the phenomenon. In thermo-sensitive PwMS, exacerbations of symptoms 
can occur rapidly in response to any form of heat exposure, whether it be small 
changes in core body temperature or full body immersion in hot baths or showers 
(Guthrie and Nelson, 1995). In fact, the symptoms are so distinct that until 1983 the 
‘hot bath’ test was accepted as a reliable clinical method to diagnose MS (Guthrie, 
1951).  
 
It has been postulated that an increase in core body temperature may negatively 
affect conduction properties of either partly-myelinated, or demyelinated axons in 
the CNS (Humm et al., 2004). Paradoxically, central conduction of evoked motor 
potentials in PwMS has been observed to be more affected by cold than by heat 
(Humm et al., 2004). However, when compared to non-cooled participants during a 
maximal exercise test, pre-exercise cooling produced both a lower heart rate, and 
reduced ratings of perceived exertion (White et al., 2000). Clearly, the process of 
thermoregulation in MS is not well understood.  Although heat accumulation does 
not appear excessive, the inability to thermo-regulate may cause overheating, and 
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exacerbate deficits in central drive and symptoms of fatigue (Humm et al., 2004, 
Davis et al., 2005). 
 
Dehydration in MS appears to be associated to disability levels, perhaps reflecting 
a strategy to manage bladder incontinence (Collett et al., 2011a), yet hydration 
status, and the effects of dehydration in exercising PwMS are rarely considered. 
Collett and colleagues (2011), recently reported that 42% of a MS test group 
(n=26) were inadequately hydrated. Hydration status profoundly affects blood 
pressure in people with autonomic failure, and substantially affects older people 
from the general population (Jordan et al., 2000). Even in healthy groups, mild 
dehydration provokes changes in cardiovascular, metabolic and central nervous 
system function (Murray, 2007). Higher core temperatures during exercise have 
been reported in dehydrated individuals (Greenleaf et al., 1971). Dehydration is 
also associated with higher ratings of fatigue and lower levels of cognitive function 
(Maughan, 2003). More importantly, during aerobic exercise even of short duration, 
cardiac output, blood pressure, sweating responsiveness and exercise 
performance are significantly impaired (Sawka and Coyle, 1999, Maughan, 2003, 
Montain et al., 1995), hence hydration status remains an important consideration 
for PwMS 
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2.8 Benefits of exercise 
Cardiorespiratory fitness (CF) describes the ability to perform dynamic, moderate 
to high intensity activities for prolonged periods and is a strong, independent 
predictor of all-cause mortality (Blair et al., 1995). CF training in PwMS has been 
shown to  lead to increased oxygen uptake (Petajan et al., 1996, Mostert and 
Kesselring, 2002), increased functional capacity (Schulz et al., 2004), greater 
mobility (Kileff and Ashburn, 2005, Romberg et al., 2004b), improved lung function 
(Mostert and Kesselring, 2002),and improved task performance and 
cerebrovascular function (Prakash et al., 2007). In addition, higher fitness levels 
have been linked to lower levels of emotional distress and depression, perhaps 
due to improved mobility and functionality offering a higher level of behavioural 
activation and social inclusion (Turner et al., 2009). 
 Exercise has been shown to induce considerable physiological change in the 
immune system (Pedersen and Hoffman-Goetz, 2000). CD4+ cells decline after 
intensive cycling (Pedersen et al., 1988), perhaps due to the increase in natural 
killer cells which are significant mediators of cytotoxic cells in the innate immune 
system (Mackinnon, 1989), and potentially raise resistance to viral infections 
(Pedersen and Hoffman-Goetz, 2000).  In animal models, angiogenesis (the 
growth of new blood vessels) is the primary effect of endurance training in the 
motor cortex (Swain et al., 2003) and the hippocampus (Ding et al., 2006), perhaps 
in order to meet the increased metabolic demands of cortical neurons (Adkins et 
al., 2006). Voluntary wheel running increases concentrations of micro-glia and 
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astrocytes in mice, and  may improve brain function (Ehninger and Kempermann, 
2003). Animal models have also shown that exercise increases both brain derived 
neurotrophic factor (BDNF), and insulin like growth factor (IGF-1) in the CNS 
(Cotman et al., 2007), both mechanisms which may enhance learning and cortical 
plasticity (Berchtold et al., 2002). Rodent brains have shown enhanced 
neurogenesis in response to increased neural progenitor cells (van Praag et al., 
1999). Furthermore, exercise accelerates both the growth, and enhances the 
density, of dendritic spines which support changes in synaptic strength (van Praag, 
2009, van Praag et al., 1999), hence facilitating neuroplasticity and adaptation.  
 
2.9 Exercise recommendations for PwMS 
 
For many years, exercise recommendations for PwMS have followed  the 
American College of Sports Medicine(ACSM) guidelines for exercise testing  and 
prescription,  sometimes with modifications based on the authors’ experience, or 
others (White and Dressendorfer, 2004). However, when considering the 
heterogeneous and changeable nature of MS, exercise recommendations can 
serve only as basic guidelines. Table 2.1 shows the published exercise 
recommendations for PwMS, outlining the frequency, duration and intensity, and 
preferred mode. 
Perhaps the most cited paper is that by Petajan and colleagues who randomly 
assigned 54 PwMS to an exercise programme consisting of 40 minute sessions of  
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Table 2.1 Recommendations for exercise programmes for people with MS  
 
Author 
 
Frequency 
 (sessions   
per week) 
 
 
Duration 
(minutes) 
 
Exercise         
intensity 
 
Mode 
 
RPE 
 
Wichmann, R; 
Hulme, J.B. 
(2008) 
 
 
3 
 
30-60 
 
60-70% HRpeak 
 
Treadmill,  
Exercise bike 
Rowing 
 
N/A 
Kraft, G.H. 
Catanzaro, M 
(2000) 
 
3 20 N/A Treadmill,  
Exercise bike 
Swimming 
N/A 
Mulcare, J. 
Jackson, K. 
(2004) 
 
3 30 50-75% 
HRpredmax 
Exercise bike 11-13  
(6-20 scale) 
Plow, M. 
Motl, R. 
(2013) 
 
3 30 60-85% HRmax Aerobic exercise NA 
Hutchinson, B. 
Hicks, R. 
(2005) 
 
3-5 15-60 55-90% HRmax Walking,  
Cycling 
Swimming 
N/A 
White, L. 
Dressendorfer, R. 
(2004) 
 
2-3 20-30 
(or 2x15) 
65-75% HRpeak Walking,  
Cycling 
Swimming 
11-14  
(6-20 scale) 
Dalgas et al  
(2008) 
2-3 10-40 60-80% HRmax Walking,  
Cycling 
Swimming 
 
N/A 
Carroll, C. 
Lambert, C. 
(2009) 
 
At least 3 30 60-75% HRpeak Walking,  
Cycling 
Swimming 
N/A 
 
Note; N/A = not available 
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combined arm and leg ergometry, 2-3 times a week for 15 weeks. Participants 
performed five minutes of exercise at 30% of 2OV
 max followed by 30 minutes at 
60% of 2OV
 max. When compared against base-line measures, the exercise group 
displayed a significant improvement in maximal aerobic capacity, upper and lower 
body strength together with improvements in bladder and bowel function, fatigue, 
mood-state and factors relating to QOL (Petajan et al., 1996). Importantly, over the 
course of the intervention, 7 of the 54 participants experienced a ‘noteworthy’ 
exacerbation of MS symptoms requiring clinical treatment, and 2 participants’ 
exacerbations were severe enough to preclude further participation (Petajan et al., 
1996). Nevertheless, based on the results of the study, the authors recommended 
that PwMS should be encouraged to engage in regular aerobic activity. 
Rietberg et al (2004) reviewed 2593 titles on behalf of the Cochrane Collaboration 
to formally assess exercise based rehabilitation programmes. Interestingly, 
although the Petajan paper was one of only 9 that fulfilled their inclusion criteria, 
only the study of Mostert and Kesselring (2002), was cited as describing evidence 
of deleterious effects after exercise testing, and no evidence of deleterious effects 
of exercise was found in the included studies. In the Mostert study, 13 PwMS 
trained for 3-4 weeks, for up to 5 sessions per week lasting 30 minutes performing 
aerobic exercise on a cycle ergometer at an unspecified intensity. Interestingly, 
although only 2 participants withdrew from the study, they reported a low 
adherence rate by the remaining subjects to the exercise programme. In contrast 
to Petajan et al, they found no measurable improvement in aerobic capacity. 
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However they concluded that an increased level of physical activity lead to an 
improved perception of health status, and recommended that regular aerobic 
exercise should be part of future inpatient rehabilitation programmes (Mostert and 
Kesselring, 2002).  
In 2007, Rampello et al followed the same exercise protocol proposed by Petajan 
et al. 19 PwMS performed  three supervised 60 minute training sessions per week 
for 8 weeks on a cycle ergometer at 60% maximal work rate (watts) calculated 
from a GXT. Intensity was progressively increased every week up to 80% of 
maximum work rate. There were significant increases in VO2peak and maximal 
work rate. However, eight participants (26%) failed to finish the study. The exercise 
programme induced a perception of breathlessness and fatigue in 2 PwMS, which 
persisted up to the beginning of the next exercise session, and they subsequently 
withdrew from the study. Two more participants withdrew because they felt the 
exercise programme was too stressful. Four subjects had a relapse of MS and 
could not complete the study, though whether this was also the result of the 
exercise programme is not discussed.  Whilst the authors conceded that the high 
rate of participant loss implied a limited exercise tolerance in their MS group, and 
accepted that the exercise programme may have harmed some of their 
participants, they concluded that their results supported exercise training may be 
beneficial to those patients who do not experience an exacerbation of symptoms. 
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More recently, a systematic review by Asano et al, (2009) examined the role of 
exercise in MS. Specifically, the objective was to estimate the effect of prescribed 
exercise and to assess the methodological quality of interventions specifically 
prescribed exercise, exercise therapy and physical activity. Over two hundred 
publications were screened with eleven studies meeting the criteria (DeBolt and 
McCubbin, 2004, Oken et al., 2004, Romberg et al., 2004b, Schulz et al., 2004, 
Petajan et al., 1996, van den Berg et al., 2006, Surakka et al., 2004, Storr et al., 
2006, Mostert and Kesselring, 2002, Harvey et al., 1999, Rampello et al., 2007). 
The methodological quality of the studies, assessed using the Physiotherapy 
Evidence Database (PEDro), scored from fair to good. The most common type of 
exercise intervention was aerobic (walking or cycling). The duration of the exercise 
interventions ranged from 30-90 minutes a session, with a frequency of 1-5 
sessions a week for 3 weeks to six months. While there was some evidence to 
support the positive effects of exercise, the reviewers concluded there was 
insufficient evidence to guide a comprehensive exercise intervention or to provide 
an exercise recommendation for an individual with MS (Asano et al., 2009).  
The Asano et al (2009) review was in broad agreement with the reviews of 
Rietberg et al (2004) and Dalgas et al, (2008). There was general consensus 
amonst the reviewers that future exercise interventions for PwMS needed to 
provide better evidence for the optimal dose of exercise prescriptions, in particular, 
exercise intensity (Rietberg et al., 2005, Dalgas et al., 2008, Asano et al., 2009).   
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Only recently has a study controlled for intensity as an independent component of 
exercise volume. Collett and colleagues (2011) conducted a clinical trial to 
evaluate the effect of exercise intensity over a three month period. They randomly 
allocated 54 PwMS to 3 different exercise groups. Individuals cycled for 20minutes 
at either 45% or 90% (30s cycling interspersed with 30s rest) of their peak work 
rate determined by a symptom-limited graded exercise test (GXT). A third group 
performed 10 minutes of the 90% protocol followed by 10 minutes at 45%.  The 
cadence was set at 50 rpm for all interventions. Thus, although individuals 
performed exercise at different intensities, the total relative volume of exercise 
performed was the same across the 3 groups. Of note is that only 53% of 
participants in the combined exercise group completed the 12 week programme 
(against 95 % of the continual lighter work-rate). The investigators observed that 
when taking into account the number of adverse events, frequency of attendance 
and the number of withdrawals during the 12 week training programme, individuals 
tolerated the low-intensity exercise programme best, but remained cautionary 
about making recommendations on exercise intensity (Collett et al., 2011b).  
In summary, PwMS live with uncertainty regarding their functional ability to perform 
basic activities of daily living. Exercise is an attractive, low-cost intervention that 
improves cardio-respiratory fitness levels, mobility, self-esteem and confidence, 
reduces depression and anxiety(Dawes, 2008a), and may lead to a reduction of 
symptoms that contribute to the functional deficits in PwMS (Motl and Goldman, 
2011). However, compliance and adherence to exercise programmes at 
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recommended exercise intensities (Table 2.) are low (Mostert and Kesselring, 
2002, Collett et al., 2011b) which imply that the recommended exercise intensity 
for PwMS may be set too high.  There is a paucity of literature relating to exercise 
intensity for PwMS and the acute physiological, neurological and perceptive 
responses to intensity remain unreported. The implications are that little or no 
information exists to steer safe, effective and appropriate exercise strategies, to 
optimise training outcome, and engender participation.  
2.10 Aim of the thesis 
The aim of the thesis is to examine the acute physiological, central and perceptive 
responses of PwMS to exercise intensity, through both the exercise phase and the 
post-exercise time-course to recovery. 
Specifically this work will 
1. Compare maximal exercise capacity in PwMS and controls 
2. Examine and compare the physiological and differential perceptive 
responses to exercise   
3. Examine the central, physiological and perceptive responses during the 
post-exercise recovery period in PwMS 
4. Compare 2 different exercise intensities 
This thesis starts by detailing the methods used to measure exercise intensity and 
reviews the techniques used to assess physiological and perceptive responses. It 
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is important that the measures are reliable, responsive, and appropriate for PwMS. 
Chapter 4 explores responses to maximal exercise intensity during a graded 
exercise test. Chapter 5 describes the methodology of transcranial magnetic 
stimulation to explore central motor pathways. Chapter 6 explores the reliability of 
motor evoked potentials (MEPs) recorded from the lower limb of PwMS. Chapter 7 
examines physiological, perceptive and corticospinal responses to intensity during 
20 minutes of exercise, and for 35 minutes during the post-exercise time course to 
recovery. 
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Chapter 3 Methods and materials 
 
_______________________________________________________________ 
 
The aim of this chapter is to describe and determine the suitability of the methods 
and materials used for the experimental chapters of this thesis. 
_______________________________________________________________ 
3.1 Introduction 
 
Evaluating the outcome of exercise interventions at any stage of MS is not only 
extremely challenging, but also of the greatest importance to improve the process 
and impact of exercise prescription and rehabilitation (Thompson, 2008). In view of 
the complex, unpredictable and heterogeneous nature of the disease, clinically and 
scientifically robust measurement tools are essential for assessing responses to 
exercise intensity in PwMS. The need to measure the outcome and effectiveness 
of therapeutic treatments and interventions is accepted as being essential to good 
practise in research. Reliability, validity and administrative burden are properties of 
measurement instruments that affect the credibility of the measurement process 
and the reporting of such research findings (Salter, 2005).Specifically, the methods 
used should be reliable, reproducible, responsive and appropriate.   
 
Reliability refers to the quality of reproducibility and relates to the consistency and 
repeatability of a measure (Weir, 2005, Batterham and George, 2000). 
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Measurement error, whether random (eg noise or physiological adaptation), or 
systemic (eg bias resulting from learning through prior exposure to the 
measurement task) is present in all tests and measurements. The reliability of a 
measure is the degree to which it is free from random error. If no random error is 
present, the reliability is 1.0. The closer the number is to zero, the more random 
error increases (Cano and Thompson, 2010). A reliable measure provides 
confidence that changes in measurement parameters are due to natural changes 
within the subjects and not due to error in the test, the instrumentation or indeed 
error in the measures themselves (Weir, 2005).   
 
Responsiveness reflects the ability to discriminate between values, and is a 
particularly important measure when evaluating change over time (Cano and 
Thompson, 2010). The two major components of responsiveness are 1) internal 
responsiveness; the ability of the method to detect change over time, and 2) 
external responsiveness, the extent to which a change in a measure relates to a 
reference measure that is regarded as an accepted indication of change (Cano and 
Thompson, 2010).   
 
Determining the consistency and reproducibility of methods remains an essential 
part of methodological validation. Validity refers to the appropriateness and 
accuracy of the method to measure the desired parameter. Concurrent validity 
infers that a test correlates well to a previously validated measure. Conclusion 
validity relates to the utilisation of appropriate statistical tests, adequate sampling 
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and reliable measurement procedures. Standing procedures for each test must be 
rigorously adhered to in order to minimise inconsistencies and to ensure accuracy 
and reproducibility.  
3.2 Research setting 
 
The research was carried out at the Clinical Exercise and Rehabilitation (CLEAR) 
Unit, The Human Performance Centre, Oxford Brookes University, Oxford UK, and 
the Nuffield Centre of Enablement, Oxford.  
3.3 Performance measures:  Intensity 
 
During exercise, work rate (or power) is the function of force and velocity (Enoka, 
2002) describing the amount of work accomplished per unit of time. Exercise 
intensity can be described in absolute terms;` such as power output (watts), 
oxygen consumption per minute ( 2OV
 max L.min-1), heart rate (HR), blood lactate 
(Bla), or energy expenditure such as calories or metabolic equivalents (METs). It 
can also be described as a subjective measure that reflects a participant’s rating of 
their perception of exertion (RPE). The following sections describe and determine 
the suitability of the methods and materials used for the experimental chapters of 
this thesis. 
3.3.1 Measuring intensity; The mode of exercise  
 
The treadmill and the cycle ergometer are the most commonly used devices in 
clinical exercise testing (ACSM, 2002). The principal difference between the two 
 
 80 
test modes is that for most individuals, peak oxygen consumption ( 2OV
 ) is 
approximately 5% to 20% lower on the cycle ergometer (Visich and Ehrman, 2009) 
even though maximum  heart rate and blood lactate have been shown to be similar 
after tests on both (Wasserman et al., 2005).  
 
The main disadvantage of using a treadmill for exercise testing is quantifying the 
work rate (watts). Moreover, a poor tolerance to treadmill exercise has been 
related to increased energy cost in PwMS (Olgiati et al., 1986). Ambulatory deficits 
in MS, such as foot- drop and other signs of paresis, can develop during walking. 
However, holding on to any part of the treadmill for support during a test, either due 
to impaired balance or gait problems, eliminates use of the arms causing a 
consequential reduction in work rate and interfering with the accurate 
determination of 2OV
 .  
 
The advantage of a cycle ergometer for PwMS includes the precise estimation of 
work rate, and greater safety (Wasserman, 2005), especially for those with 
orthopaedic, or neurological limitations that restrict weight bearing activity (Pina et 
al., 1995). On the cycle- ergometer, balance is not a factor since participants are 
seated in a fixed position on a stable construct and the upper body remains 
relatively quiet. The pedalling movement is complex enough to provide a 
functionally relevant test as the combined mechanical work of the legs has to be 
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sufficient to overcome the resistive load, therefore work production can be easily 
controlled and calculated. 
 
Resistance is applied to the flywheel by a belt or cord. Adding weight to the weight-
plate increases the friction on the flywheel.  The work rate is calculated from the 
formula;  
Power = weight (kg) x distance travelled by the flywheel (6m) x rpm =kgm.minˉ¹ 
(ACSM, 2000) 
 
Arm ergometry offers an alternative mode for assessing maximal exercise capacity 
in people with gait deficits. However, a study of 24 MS patients, Foglio et al (1994) 
reported that one-third of the subjects were unable to participate in the arm 
ergometer exercise, either due to the lack of upper-limb coordination, or because 
of inadequate upper-body strength (Foglio et al., 1994). Moreover, peak 2OV
  
achieved from an arm ergometer test has been reported to be about 70% that of 
cycle ergometer test, and 89% to 95% of the maximal values achieved during a 
treadmill walking test (Wasserman et al., 2005) . 
 
A cycle ergometer can be calibrated by various methods. The standard method of 
calibrating a mechanically braked cycle ergometer is to attach a calibrated weight 
to the balance spring, and to check that the weight corresponds to the pendulum 
weight scale (Howley and Don-Franks, 2007). In the absence of calibration 
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devices, human ‘biological’ calibration can be performed (Cooper and Storer, 
2001). When performed on a regular basis, dynamic ‘human’ calibration can 
indicate the reproducibility of physiological variables at standardised work rates, 
thus confirming a degree of ergometer calibration and reproducibility (Cooper and 
Storer, 2001). A limitation is that ‘biological’ calibration will not detect small 
changes in ergometer calibration, however it does indicate larger errors that can be 
dealt with subsequently.  
Cycle ergometry has been used extensively to investigate the exercise capacity of 
PwMS (Petajan et al., 1996, Romberg et al., 2004a, Prakash et al., 2010). There is 
no specific test that can be considered to be a valid measure of both power and 
capacity because different protocols are required to measure different components 
of high intensity performance (Smith, 1987). In view of the broad range of physical 
and cognitive abilities of PwMS, a cycle ergometer was selected both as the most 
appropriate mode for testing maximal exercise capacity, and for conducting further 
exercise sessions at intensities relative to peak exercise values (White and 
Dressendorfer, 2004).  
3.5 Measurement of Intensity; Oxygen consumption ( 2OV
 ) 
During steady state exercise the oxygen (O2) consumed by all tissues is termed 
2OV
 (Cooper and Storer, 2001). O2 uptake changes linearly with incremental 
increases in workload. 2OV
 max describes the highest oxygen uptake that an 
individual can obtain and consume during dynamic exercise (Astrand and Rodahl, 
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1986, Bassett and Howley, 2000) and  is a criterion measure of the cardiovascular-
pulmonary system’s ability to increase heart rate and deliver oxygen to working 
muscle in both healthy and clinical groups  (Wasserman et al., 2005, Heyward, 
2010).  
The value of a graded exercise test (GXT) to evaluate cardiovascular fitness and 
functional capacity is well established both in the general population (Holly and 
Shaffrath, 2001) and in PwMS (Jackson and Mulcare, 2009b)  The results guide 
decisions relating to the delivery of medical and therapeutic treatment across a 
broad spectrum of clinical conditions. Traditionally, 2OV
 max is defined by the 
reaching of a plateau where oxygen consumption fails to increase, despite an 
increase in workload (ACSM, 2000). However, an individual’s ability to reach the 
plateau during maximal exercise testing is highly variable (Day et al., 2003).  Even 
in healthy subjects, about one-third exercising at maximal effort actually reach the 
2OV
  plateau in oxygen consumption, mainly because of the inability to endure the 
physical discomfort (Wasserman et al., 2005). Therefore, the highest measure of 
oxygen consumption achieved during an exercise test is defined as 2OV
 peak 
regardless of whether or not a plateau is reached (Heyward, 2010). In reality, 
although  2OV
 peak does not fully satisfy the definition of 2OV
 max , it is usually 
equivalent to the 2OV
 max of healthy subjects (Wasserman et al., 2005) and the 
values can be construed as the same (Mulcare and Jackson, 2004).  
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In general, 70-85% of the limitation in 2OV
 max can be attributed to maximum 
cardiac output (Cerretelli and diPamprero, 1987) and skeletal muscle blood flow 
(Saltin and Calbet, 2006). The limiting factor for 2OV
 max in PwMS and other 
neurological populations is less clear. Some MS studies have reported that 2OV

peak is reduced in PwMS with mild to moderate disability (Romberg et al., 2004a) 
while others have found that reduced 2OV
 peak is related to respiratory muscle 
function rather than to disability (Foglio et al., 1994). Most studies show that the 
expiratory muscles of PwMS suffer more weakness than inspiratory muscles 
(Buyse et al., 1997, Tantucci et al., 1994). Indeed, pulmonary dysfunction can be  
present in MS even in the absence of any respiratory symptoms (Altintas et al., 
2007). Peripheral factors that limit 2OV
 max include reduced central drive, and 
decreased muscle diffusion capacity, mitochondrial enzyme levels and capillary 
density (Bassett & Howley 2000). Furthermore, clinical perturbations or 
complications as a result of co-pathologies may prevent PwMS from attaining the 
criteria for attaining 2OV
 max during a graded exercise test.  Mono-paresis, leg or 
chest pain, dyspnea (shortage of breath) or  lack of motivation may also cause 
PwMS to stop exercising (White and Dressendorfer, 2005). 2OV
  can also be prone 
to inherent variation due to anxiety and the psychological state of the 
individual(Sutherland, 2005). Anxiety may manifest as dyspnea (Gilman and 
Banzett, 2009) or panic disorder leading to hyperventilation (Sansone and 
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Sansone, 2009). These are important considerations when exercise testing PwMS 
as both anxiety and reduced cardiorespiratory fitness are frequently present. 
 
For a given individual, measured oxygen consumption at a given work rate has 
been shown to be highly reproducible (ACSM, 2000). Hence a symptom-limited 
test to the limit of tolerance facilitates the identification of specific physiological 
limitations (Cooper and Storer, 2001) and is a valid index of 2OV
 peak. As 2OV
  
depends to a large extent on body size, it is generally reported in terms relative to 
body weight (ml.kg-¹.min-¹). 
 
For the purpose of this study,  O2 and carbon dioxide (CO2) content of the expired 
air was measured using a breath-by-breath gas analyser (Metamax 3B, Cortex 
Biophysik GmbH, Leipzig, Germany) via a face mask worn by the participant (Hans 
Rudolf, Kansas City, USA). The Metamax has been shown to be a reliable tool in 
healthy young adults (Meyer et al., 2001) and has been used widely for exercise 
testing in sports and clinical research settings.  Prior to each test session the 
system was calibrated according to manufacturer’s instructions using standard 
calibration gas (~15% O2 and ~ 5% CO2, balance N2). A three litre pump syringe 
was used to calibrate the flow sensor to determine the volume of expired air. 
Calculation of VO2 consumed and carbon dioxide (VCO2) produced per minute was 
through Haldane equations using the volume of expired air per minute (VE) and the 
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atmospheric pressure. The data was recorded and analysed via online telemetry to 
a personal computer. 
 
3.7 Measurement of intensity. Respiratory exchange ratio 
A product of 2OV
 max testing is the respiratory exchange ratio (RER). During 
exercise the amount of chemical energy released by each oxygen molecule is 
dependent on the fuel substrate used. Generally, protein plays a small role as a 
substrate during physical activity, thus the value of the respiratory quotient (RQ) 
reflects the relative amount of carbohydrate (CHO) and fat metabolised (Powers 
and Howley, 2004b). During aerobic exercise at submaximal levels an RQ of 0.7 
indicates a reliance on fat metabolism, RQ  ~ 0.85 represents a condition where fat 
and CHO are contributing to energy production in equal amounts and RQ of 1.0 
indicates the metabolism of primarily CHO. The RER reflects the respiratory 
exchange of CO2 and O2 and commonly exceeds 1.0 during exercise (Ross, 
2003). 
 
Notwithstanding the altered muscle characteristics of PwMS, it has been been 
identified that the high individual variability of muscle composition and their unique 
firing patterns during dynamic exercise affects O2 kinetics independent of RER 
(Kushmerick et al., 1992). Indeed, even dietary-induced metabolic adaptations alter 
RQ kinetics. A high-fat diet increases the contribution of fat oxidisation, while 
conversely, a predominantly CHO diet increases the range of CHO metabolism 
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(Mole and Hoffmann, 1999). Muscles are able to extract CHO even from a low-
CHO diet, suggesting that muscle may utilise stored muscle glycogen as an energy 
source even at  low intensity exercise (Sue et al., 1989). At 75% of 2OV
 max, it is 
quite possible for one individual to be reliant on entirely aerobic sources while 
another requires considerable anaerobic supplementation (Ekkekakis and 
Acevedo, 2006). 
 
In order for RER to be used as an estimate of substrate utilisation, an individual 
must have reached a steady physiological state where blood and gas transport 
systems are keeping pace with tissue metabolism. During non-steady-state 
strenuous exercise, hyperventilation and the increased buffering of blood lactate 
causes the volume of VE to rise, thus altering the ratio of VCO2 to 2OV
 . In practise, 
achieving a steady state may not be possible in impaired PwMS.  Nevertheless, 
RER is considered to be a measurement parameter of maximal effort and a value 
of 1.15 remains a criterion for achieving true 2OV
 max (O'Connor et al., 2009). 
3.6 Measurement of intensity. Metabolic equivalents 
 
Metabolic equivalents (METs) are multiples of resting metabolic levels often used 
to quantify the intensity of physical activities in the clinical rehabilitation setting 
(Holly and Shaffrath, 2001). One MET is defined as the energy cost at rest. The 
higher the intensity of work, the greater the number of METs required to perform an 
activity. A major difficulty with using METs in the research setting is that individuals 
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vary widely in their functional capacity (Ferguson et al., 2001). The relative METs 
calculated for certain activities may be above the maximal capabilities of some 
individuals (Beale et al., 2010), especially when factors relating to skill, age, 
variations in fitness, cognitive and clinical status are taken into account. A recent 
position statement on exercise intensity terminology has suggested that absolute 
MET values are appropriate only for healthy adults up to the age of about 30 years 
(Norton et al., 2010) . Based on current evidence METs are not suitable measures 
for this study. 
3.7 Measurement of intensity. Heart rate (HR) 
The most frequently used method to measure exercise intensity in both clinical and 
exercise settings is heart rate (HR). It is well established that HR increases linearly 
with increases in oxygen uptake and exercise intensity, regardless of age and 
gender (Astrand et al, 2003). Because of the linear relationship between exercise 
intensity and HR, training intensities can be set by using HR values equivalent to a 
percentage of 2OV
 peak (ACSM, 2010). As with 2OV
 peak measurements the HR 
response is dependent to some extent on the mode of testing. Nevertheless, heart 
rate is widely used as a criterion for achieving peak exertion in the determination of 
maximal aerobic capacity (Wasserman et al., 2005)  
 
Tachycardia is essential to maintain increased cardiac output. HR and stroke 
volume are responsible for the increase in cardiac output during exercise, however 
stoke volume does not increase beyond a work intensity equivalent to 40% of 2OV

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peak in untrained individuals and thereafter, the rise in cardiac output is achieved 
by increases in HR alone. As with VO2max measures, HR may fail to increase 
despite an increase in work-load, in which case HRpeak values are recorded. 
Additionally, maximal cardiac output is not reached during sub-maximal exercise or 
during peak leg exercise on a recumbent cycle-ergometer (Stenberg et al., 1967). 
Submaximal exercise tests are often based on the assumption that age predicted 
HRmax values for individuals of a given age are accurate (Londeree and 
Moeschberger, 1984, Tanaka et al., 2001). However,  Ponichtera-Mulcare et al, 
tested 20 ambulatory PwMS (MS1) and 8 semi-ambulatory (MS2) to volitional 
fatigue on a cycle ergometer and found mean maximal heart rates reflecting 87% 
(MS1) and 81% (MS2) of age predicted HRmax respectively for the two groups 
(Ponichtera-Mulcare et al., 1994). Even in the general population, up to 7% of men 
and women have an HRmax  of 15bpm below age predicted HRmax, and up to 
13% have HRmax that exceed age predicted max by 15bpm (Whaley et al., 1992). 
 
In the absence of a maximal exercise test, exercise intensities are generally based 
on the Karvonen equation, or percentage of heart rate reserve (HRR) method, 
which takes into account an individual’s resting HR (Karvonen and Vuorimaa, 
1988). HRR is often recommended as a more appropriate method of setting 
exercise intensity for PwMS (ACSM) however, large errors may occur in age-
predicted HRR. For that reason, intensities based solely on a percentage of HRmax 
or HRR are also likely to impose variable cardiovascular and metabolic demands in 
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PwMS, especially those with chronotropic incompetence and co-pathologies 
(Dwyer et al., 1994, Beale et al., 2010).   
 
3.8 The Consistency of Resting HR in people with multiple sclerosis 
One of the themes of this thesis is to assess the effects of exercise intensity on 
heart rate in PwMS. Resting HR reflects both the status of the cardiovascular 
system and acts as an indicator of autonomic tone (Thayer and Lane, 2007).   
Heart rate may increase in individuals who decrease their activity levels due to 
illness. Indeed, recent large scale epidemiological studies have shown that resting 
HR is an independent predictor of cardiovascular and all-cause mortality (Diaz et 
al., 2005)   Due to the well documented inter-individual variability of HR in people 
with MS, the effects of their cognitive and  emotional state on chronotropic 
competence, and taking into account environmental factors,  there was a need to 
establish the validity and reliability of utilising measures of resting HR in this 
population. 
3.8.1 Test Procedure 
Testing was carried out in the Oxford Centre for Enablement, Oxford, UK. 
Participants were asked to refrain from the consumption of tea, caffeine, alcohol, 
cigarettes, for a period of at least 2 hours prior to testing, and not to take part in 
strenuous physical exercise for 24 hours prior to testing. The test session 
procedures were carried out by the same investigators, between 1200 and 
1500hrs, in a quiet room at standard temperature (~21°C). They were required to 
lie semi-supine on a two-section medical examination plinth set so that their upper 
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bodies were angled to 30º of an up-right position. Resting HR was recorded with 
using HR monitor technology (Polar Electro, Finland) at 5 minute intervals for 20 
minutes. The test was repeated 3 times within 21 days. 
3.8.2 Analysis 
Data was imported into SPSS V 17.0 (SPSS inc, Chicago USA) software for 
statistical analysis. Repeated measures analysis of variance (ANOVA) was used to 
determine differences in resting HR within, and between sessions  
 
3.8.3 Results 
Mean HR (±SD) for each session is shown in Table 3.1. Repeated measures 
ANOVAs revealed no differences in the resting HR in PwMS, either within or 
between sessions (p>0.05). 
 
Table 3.1 Mean resting heart rates during 3 sessions (7-21 day apart) 
 
n=12 Session 1 Session 2 Session 3 
Heart rate (beats.minˉ1)  64.3   ±9.3 64.7   ±8.0 64.3   ±9.0 
Range 50.8 - 85.8 56.0 – 82.8 50.8 – 82.0 
 
3.8.4 Conclusion 
 
Resting HR is a stable and reliable measure in PwMS. 
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3.9 Measures of Intensity, Blood lactate 
 
Although measures of blood lactate are commonly used as a means of calculating 
metabolic responses to exercise intensity, there is a paucity of literature relating to 
blood lactate in PwMS.  The physiological basis for the use of blood lactate is 
based on muscle biochemistry and its part in blood lactate accumulation. Lactate 
concentrations increase as exercise intensity increases. The rise in blood lactate 
concentrations may occur either due to an increase in lactic acid production, or a 
decrease in lactic acid removal (Powers and Howley, 2004b) however considerable 
controversy exists over the precise mechanisms that lead to the rise in blood 
lactate levels.   
 
Measurement of blood lactate is a useful aid for assessing exercise performance 
although the accumulation of lactate is not held to be a causative factor in fatigue. 
Measures between  groups of PwMS and age and gender matched controls during 
maximal testing have shown little difference between the two groups (Morrison et 
al., 2008). Although a plateau in lactate values signifies the attainment of a true 
2OV
 max, 8mmol. Lˉ¹ is accepted as a reasonable criterion value (O'Connor et al., 
2009). The Lactate Pro is a portable blood lactate analyser that uses the 
electrochemical method of measuring enzymatic reactions on a small electrode by 
capillary action directly from a fingertip. It has been shown to be a reliable method 
of measuring blood lactate concentrations (Shimojo et al., 1993). Only a small 
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sample (5 µL) of blood is required, which is an advantage when multiple specimens 
are required from a single individual, but contains a greater risk of contamination 
from sweat in such a small sample. Therefore an alcohol-saturated tissue prior is 
used to remove oil, dirt and sweat from the skin before each sample. The skin 
should be allowed to dry prior to each specimen of blood being collected. The 
Lactate pro is supplied with calibration strips to ensure accurate function. 
3.10 Rating of Perceived Exertion (RPE) scale 
 
3.10.1 Introduction 
 
In PwMS, the measurement of perceptual responses to exercise intensity provides 
a valuable and reliable indicator of exercise tolerance (Morrison et al., 2008) and 
physical functional (Fry and Pfalzer, 2008). Subjective measures are characterized 
by the fact that conscious awareness is indexed by a subject’s self-reports of their 
perceptual experiences (Merikle, 1992). The conscious signal of exertion is neither 
purely muscular nor purely central but a combination of both that can reliably adapt 
behaviour to physiological capacity (Cabanac, 2006).  Responses to exercise 
intensity are generally held to represent the complex interaction of multiple 
feedback signals from heart, lungs, muscle, joints and skin in response to effort, 
stress or discomfort interpreted from the body during physical exercise (Williamson 
et al., 2006). There is strong empirical evidence that perception of exertion grows 
exponentially with regard to increases in force, workload, O2 consumption, HR and 
blood lactate levels across a variety of exercise modalities and conditions (Noble 
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and Robertson, 1996). More recently it has been proposed that corollary discharge 
pathways act  at all levels of sensory processing (Poulet and Hedwig, 2007) and 
that all motor signals are  generated in circuits engaged in sensory processing, 
whether or not they are directly engaged in generating a motor action or involved in 
coordinating different components of the motor pathways (Poulet and Hedwig, 
2007).  
Neurophysiological evidence for the role of corollary discharge in humans is 
lacking, however it is generally agreed that the central integration of sensory 
feedback is designed to support different types of physical activity, at different 
levels of intensity over a variety of time courses. It is plausible that both the central 
response to exercise and perceptions of exertion may share common motor 
pathways, but act independently in coordinating responses (Sommer and Wurtz, 
2002, Williamson, 2010). For instance it has been shown that perception of effort 
can affect the cardiovascular response independent of exercise (Gandevia et al., 
1993).  It has been proposed that the CNS may anticipate the generated 
perception of effort involved, and displays a forward model of sensory- motor 
processing that predicts sensory feed-back (Wolpert and Flanagan, 2001). The 
issue of corollary discharge is a current ‘hot topic’ generating considerable debate, 
possibly indicating that perception of effort and sensory feedback is a highly 
complex process that is not fully understood. 
 
Scales of perception are based on Steven’s law of psychophysics which holds that 
the magnitude of sensation grows as a power function of the stimulus magnitude. 
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The general rule is that a constant percentage change, or a just noticeable 
difference in a stimulus produces a constant percentage change in a sensed effect 
(Stevens, 1986) . Magnitude estimation requires participants to assign numbers to 
stimuli of different intensities in such a way that the numbers match the perceived 
intensities and vary directly in proportion to them. Stevens proposed that the 
intensity of the sensation related to the physical magnitude of the stimulus 
proportional to the neural activity in the sensory pathway. 
Gunnar Borg, recognising the importance of relating numbers to verbal descriptors 
and ‘landmarks’ (Fuhr et al., 2001), developed an interval (or ratio) scale that 
reflected individualised ratings of the magnitude of subjective intensity during 
physical exertion (Borg, 1982). The visual analogue scale uses verbal anchors 
corresponding to numerical values.  Perceptions of exertion are separated into 
categories according to descriptors of intensity and a number assigned to each. 
The verbal anchors therefore determine the relationship between physical intensity 
and perception of exertion.  
3.10.2 Borg’s Rating of Perceived Exertion Scale (RPE) 
 
The RPE scale was initially constructed as a 15 point scale from 6-20 to reflect the 
range of heart rate (HR) in a healthy group of young subjects (60 beats/min at rest 
to 200 beats/min) during maximal exercise on a cycle ergometer.  The ratio scaling 
method showed that the perception of exertion grew with the physical work load 
(Borg, 1990). When it became clear that the CR-16 scale was not  appropriate for 
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all participants, exercise modes or environmental conditions, the scale was revised 
to the CR-10 scale, making it applicable to  a variety of physical functions and 
physiological responses(Borg, 1990). Differential ratings are distinct measures of 
perceived exertion relating to specific functions or parts of the body. For example, 
during a cycle test, RPE measures relating to the sensation of breathing and 
sensations relating to muscular in the legs can be recorded. The RPE CR10 scale 
has shown reasonable validity, sensitivity and reliability as a subjective measure in 
the healthy population, independent of the mode of exercise and fitness of 
participants. 
 
3.10.3 RPE in MS 
 
In PwMS, Morrison et al (2008) compared perceptive responses from a group of 
PwMS (n=12) to a group of age matched sedentary adults during an incremental 
cycle-ergometer maximal exercise test. RPE was recorded every 30 seconds using 
the modified 10-point Borg scale. There were no significant differences between 
the two groups in the means of RPE measured at during each stage or at 100% of 
VO2max.  Enjoyment of a physical activity has been shown to be  determinant of 
physical behaviour, and greater adherence to an exercise prescription in PwMS 
(McAuley et al., 2007).  RPE levels during 30 minutes of exercise at moderate 
intensity (60% V02max)  have been shown to be significantly lower in PwMS if 
participants are pre-cooled, either in a cold bath (Wilson et al., 2002), or through 
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wearing cooling vests(Meyer-Heim et al., 2007) however, uncertainty remains 
whether the reduced RPE was due to lower heart-rates during the exercise, or the 
pre-exercise cooling having a placebo effect (White et al., 2000). A 20 minute cold 
bath prior to two 10-minute walks interspersed with a 30-minute rest did not reduce 
RPE during ambulation (Chiara et al., 1998).  
 
RPE has been shown to be reliable measure for the 6 Minute Walk Test, 
Functional Stair Test, Static Standing Balance Test and Sit to Stand Test in PwMS 
(Fry and Pfalzer, 2008). However, subjects rated RPE consistently each visit, RPE 
did not always correlate well with performance (Fry and Pfalzer, 2008). The RPE 
scale been used to investigated central motor drive, as measured by transcranial 
magnetic stimulation (TMS) and perception of effort during sub-maximal finger 
abduction (Thickbroom et al., 2006).  
 
The CR10’s simplicity makes it appropriate for use by individuals with cognitive 
impairments such as brain injury. It enables determination of both relative and 
absolute subjective levels (Noble,1983). The CR10 has demonstrated reasonable 
inter-individual reliability and good correlation co-efficients (r=0.91) with HR Blood 
lactate and percentages of peak power. The scale has been shown to be sensitive 
in discriminating between different sensory descriptors in relation to percentages of 
peak power during cycling (Hamilton 1996). However, great care needs to be taken 
when recording RPE from neurological groups. People with cognitive impairment 
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find it difficult to ‘dual task’. Thus, giving additional cognitive tasks to people with 
cognitive impairment while performing exercises, especially at higher intensity, may 
detrimentally affect their performance (Dawes et al, 2003). 
To standardise the procedure and improve the accuracy of the RPE scale it is 
important that participants understand both the verbal anchors and the numerical 
value. The instructions given to each participant can be found in Appendix 8.1 
3.11 Symptom-limited exercise testing 
 
In view of the heterogeneous nature of MS related symptoms, physiological 
deconditioning, cognitive impairment and lower limb deficits, no single factor can 
be considered to be responsible for maximal exercise limitations. When an end-
point set on physiological maximal criteria is deemed to unsuitable, a symptom 
limited peak exercise test can be performed. Individuals are instructed to pedal 
until discomfort, pain or fatigue prevents them from maintaining the required 
cadence. When the participant performs a test at maximal effort, the test is 
normally terminated due to volitional fatigue (Visich and Ehrman, 2009) or until 
discomfort, pain or fatigue prevents them from maintaining the required cadence 
(Wasserman et al., 2005). Explicit instructions given to a participant prior to 
exercise testing increases test validity and data accuracy (ACSM, 2010). The 
preliminary instructions given to each participant to standardise the procedure can 
be found in Appendix 8.2  
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3.12 Measuring disability  
There are a wide range of measures tools for assessing impairment and disability, 
however care is required in selecting the appropriate test for PwMS. Functional 
outcome assessments can be confounded because much of the disability during 
the early phases of MS may be sub-clinical, and during the latter stages may be 
undetectable. Moreover, values of a specific measure or scale can fluctuate widely 
within the same patient as the disease progresses (Cofield and Cutter, 2008). The 
following sections review the functional tests used in the thesis. 
3.12.1 MS Functional tests 
 
Functional walk tests provide objective measures of functional status, capacity and 
mobility.  The Barthel Index (BI) was developed by Mahoney and Barthel in 1965 
as a 10 point scale that assesses functional status and independence in personal 
care and mobility. The BI has shown evidence of satisfactory psychometric 
properties, and predictive validity acceptable for outcome use (Christiansen, 2005). 
It is a reliable and valid instrument of activities of daily living and mobility (Collin et 
al., 1988), and is well suited to PwMS with moderate to severe disability 
(Coulthard-Morris, 2000). The BI relates significantly with other measures of a MS 
patients status, and has been shown to be better able at discriminating between 
individual PwMS on the basis of their disability than the Expanded Disability Status 
Scale (EDSS) (Polman et al., 2006). While, the BI has been found to be sensitive 
to change in the functional status of MS patients with moderate to severe disability, 
it may be less sensitive to improvements made my mildly impaired PwMS 
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(Coulthard-Morris, 2000). However, its psychometric validity and reliability make it 
an appropriate measure for this study. 
3.12.2 Walking mobility tests. 
Timed walking tests are simple to administer but limited in their ability to assess 
important aspects of gait, such as quality of movement, balance, the use of walking 
aids (walking sticks or crutches), and the amount of physical assistance required to 
complete the timed duration. Nevertheless, they are commonly used to assess 
both function and fitness. Traditionally, the 6 minute walk test (6MWT) has 
provided a reliable and responsive measure, however the burden it places on 
PwMS, especially those with ambulatory difficulties, remains a source of concern. 
The 2 minute walk test (2MWT) has been described as the fastest and most 
efficient measure among the timed tests (Brooks et al., 2001, Brooks et al., 2002). 
It has been found to be a good predictor of community mobility in PwMS and has 
been shown to be a reliable and valid measure of  mobility in patients presenting 
with neurological impairment (Rossier and Wade, 2001). When compared with 
timed walks of longer duration (6 and 12 minutes) in stroke patients the 2MWT not 
only minimises the effects of fatigue, but correlates well to the longer distances 
(Kosak and Smith, 2005).  More recently Connelly and colleagues (2009) reported 
high reliability of the 2MWT performed by a group of elderly subjects (mean age 
87years) who averaged 77 metres and 80 metres during two test sessions 
(Connelly et al., 2009). Gijbels et al, (2011) compared the results of the 2MWT test 
to the more commonly used 6MWT in a group of people with MS reported that 
although they found a higher margin of error in the 2MWT in PwMS with mild 
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ambulatory dysfunction, the two timed walks captured the same aspects of 
mobility. Based on the 2MWT scores, the authors concluded that the last 4 minutes 
of the 6MWT test were unnecessary (Gijbels et al., 2011). 
3.12.3 The ‘timed up and go’ test (TUG) 
 
A  timed ‘up and go’ (TUG) test performed once has been shown to be a clinically 
relevant and reliable measure for measuring walking mobility in PwMS (Nilsgard, 
2007, Wade 1992) and correlates well with the Barthel Index (Podsiadlo and 
Richardson, 1991). The test requires the participant to stand up from a standard 
chair, to walk to a point 3 metres away, turn around a cone placed on the floor, 
walk back to the chair and sit down again as fast as possible (Podsiadlo and 
Richardson,1991; Nilsagard, 2007). A time of more than 17 seconds is predictive of 
a decline in basic activities of daily living (Pandyan et al 1999, 2003). Participants 
received instructions regarding walking aids (sticks or wheeled walkers) and 
advised on how to manoeuvre around the cone in a safe manner. 
 
3.13 Pilot Study: The appropriateness of maximal exercise testing 
on people with multiple sclerosis 
 
3.16.1 Introduction 
 
The purpose of this pilot study was to examine the appropriateness of a symptom-
limited GXT for people with clinically confirmed MS. Responses to intensity were 
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recorded during the active phase and the post-exercise recovery period. In addition 
participants were contacted at home, 24 hours after completing the GXT. 
 
3.16.2 Participants 
 
.Six people with confirmed MS (5 women and 1 man, age mean 59 ±0.01 years) 
agreed to participate.  Prior to the GXT, baseline measures of tympanic 
temperature (Temp°C), heart rate (HR) and differential measures of RPE (CR10) 
for both breathing (RPEbr) and legs (RPEleg) (CR10) were recorded.  
3.16.3 Methods 
 
Participants performed the symptom limited GXT on a cycle ergometer. Feet were 
firmly supported by toe clips reinforced with straps and the handlebars adjusted for 
comfort. Following 2 minutes of unloaded pedalling RPE, HR, Temp°C, were 
recorded immediately prior to 500 grams being loaded onto the weight pan, 
increasing the resistance on the flywheel by 25 watts. Thereafter, the process was 
repeated at 2 minute intervals. As the test proceeded, participants were given 
verbal encouragement to achieve their best performance. The end-point was 
defined by the participants’ inability to maintain the pre-determined cadence, for 
whatever reason. 
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Respiratory gas exchange variables were determined, breath-by-breath, on a 
Metamax mobile gas analyser. Peak measures of HR and VO2 (L/min) were the 
average values recorded during the final 20 seconds of the last completed stage.  
 
 
3.16.4 Results 
 
The mean maximum work rate achieved during the exercise test was 133 ±13 
Watts, 2OV

peak mean 20.6 ±1.1ml.kg
-1.min-1 , respiratory exchange rate (RER) 
mean 1.19 ±0.05,  HR mean 143 ±14 b.min-1; CR10breath mean 5 ± 2; CR10legs 
mean 6 ± 1; lactate mean 7.1 ±1.6 mmol.L-1. Temperature increased by mean 0.1 
±0.1 oC. The difference between baseline and end rest period temperature was 
mean 0.0 ± 0.4 oC and HR was mean 19 ± 10 b.min-1. The difference in next day 
vitality from baseline was mean 0.1 ±2.1.  
3.16.5 Discussion 
The incremental cycle ergometer test was well tolerated by the participants. 
However, it should be noted that not all physiological and perceptual markers 
indicated that participants were achieving maximal work rate. RPE and HR values 
were below what would be expected as maximal. In addition, no participant 
achieved a plateau in 2OV
  consumption during the final stage. The RER and 
lactate values indicated a pronounced anaerobic contribution to the exercise 
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performed. Perceptions of exertion in the legs were consistently higher than those 
for breathing. Post-exercise values of HR, BP and RPE were monitored for a 
further 25 minutes. Some parameters did not return to baseline levels during that 
period. No adverse events were reported, either during the exercise test or the post 
–exercise recovery period. All the participants were followed up the next day and 
answered the vitality questionnaire.  
3.16.6 Conclusion 
This study suggests that a symptom limited graded exercise test is an appropriate 
protocol for determining the absolute and relative exercise capacities of people 
with MS. No adverse events were reported, nor did it have a detrimental effect on 
feelings of vitality the day following maximal fitness testing.  
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3.17 Neurophysiological Measures 
 
3.18 Transcranial Magnetic Stimulation 
Transcranial magnetic stimulation (TMS) is a well-established, non-invasive 
technique used to examine the integrity and excitability of the corticospinal -
neuromuscular pathway in healthy and neurologically impaired populations (Barker 
et al, 1986; Hess et al, 1986; 1997; Kobayashi and Pascual Leone, 2003; Hallett, 
2007).  The following sections describe the technical principles underlying TMS, 
the methodological considerations and safety issues that influence the design of 
the TMS experiments 
3.19 Principles of TMS 
 TMS was developed in 1985 by Barker and co-workers in Sheffied (Barker et al., 
1985), and was first used to test the integrity of the neural pathways during spinal 
cord, brainstem and cerebral cortical surgery.  More recently TMS has been used 
to study central motor conduction disruption caused by neurological disease and 
disorders, rehabilitative stimulation and brain/ function mapping. TMS has also 
been used extensively, both in the general population and PwMS to monitor 
changes in cortico-spinal excitability after exercise,. 
The technical principle of TMS is based on Faraday’s law of induction. An electrical 
current flowing through a coil of wire generates a time varying magnetic field. The 
rate of change in the magnetic field determines the induction of a secondary 
current in a nearby conductor (Kobayashi and Pascual-Leone, 2003). In TMS the 
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stimulating coil acts as an electro-magnet and neural tissue acts as the nearby 
conductor. When triggered, a brief surge of current lasting ~100µs  passes through 
the coil inducing a rapidly changing magnetic field of up to 2.2 Tesla (Hallett, 
2007).  Although the stimulator capacitor releases a  charge of up to 5000 amps, 
only a small fraction (100,000th) of the coil’s magnetic energy is actually transferred 
into the brain (Ruohonen and Risto, 2005). The pulse volume, estimated to be ~10 
mm radius, ~15 -20mm depth (Wagner et al., 2008), is able to penetrate  soft 
tissue and bone virtually unattenuated. The induced electrical field stimulates 
underlying nerve cells in a focused volume. The mechanism that drives active 
stimulation in cortical cells remains unclear and there remains considerable debate 
over the depth of the pulse, the neuronal populations it affects, and the pathways it 
takes. The characteristics of the response are suspected to be initiated at axonal 
initial segments, bends in neural fibres, or from synaptic boutons  where the 
descending volleys have their maximal effect (Wagner et al., 2009).  
The immediate measurable response to a pulse of TMS administered at the motor 
cortex is the direct activation of descending axons (D-wave) (Terao and Ugawa, 
2002) closely followed by a series of indirect wave (I-waves) of about 1.5 - 2.0ms 
duration (Hanajima et al., 2002) that continue to fire for several milliseconds after 
the stimulus. The mechanisms that produce I- wave periodicity are unknown, but 
they are possibly due to the natural recurrent synaptic activation of the 
corticospinal neurons in response to the induced electrical field (Hallett, 2007, 
Gandevia, 1998), or  to the intrinsic properties of the neuronal membranes in 
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response to the large synchronous excitatory input of the magnetic pulse (Priori et 
al., 1993).  
A single stimulus evokes multiple descending volleys in corticospinal motor 
neurons producing a contralateral, synchronous muscle response, a motor evoked 
potential (MEP). Surface EMG electrodes are placed on the target muscles that are 
to be stimulated and once positioned, the magnetic coil is fired and MEPs recorded 
by surface EMG electodes. The repetitive discharge of spinal motor neurons is 
considered to represent the natural excitability of the corticospinal-neuromuscular 
muscular pathway in response to the magnetic pulse (Todd et al., 2007, Petersen 
et al., 2003, Taylor and Gandevia, 2004, Reis et al., 2008).   
3.20 Magnetic Stimulators 
TMS can be applied as a single pulse, in paired-pulses or as trains of pulses 
(rTMS). Repetitive (rTMS) stimulation of the motor cortex and other regions in the 
brain may induce effects that outlast the stimulation period. As well as being used 
as an investigational tool to explore cognitive processes and cortical physiology, 
rTMS has become an important method for the treatment of a variety of 
neurological and psychiatric disorders (Daskalakis and Chen, 2005) (Rothwell, 
2007). Paired-pulse techniques involve the delivery of a conditioning stimulus to an 
area of the brain in order to assess the changes produced by the following test 
stimulus. Paired-pulse experiments are generally designed to explore the nature of 
cortical circuitry, and to examine connections within the motor cortex to other parts 
of the CNS (Rothwell, 2005).  Paired-pulse systems consist of twin stimulators 
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connected by a module that controls pulse delivery. The timing of pulses can range 
from 1-999ms. Alternatively the stimulators can be fired simultaneously to generate 
a single pulse. The electrical field of a single pulse fired from two stimulators 
increases by ~113% when compared to a single stimulator. However, the length of 
the pulse increases by ~140% (Rothkegel et al., 2010). Recent research has 
shown that the longer pulses reduce resting motor thresholds by about 20%, and 
reduce MEP variability when muscle is under tonic contraction (Rothkegel et al., 
2010) making the method an attractive proposition for exploring the central 
pathways in clinical groups with central conduction abnormalities. 
3.21 Stimulating coil 
The strength of the magnetic field is at its highest close to the coil surface however, 
the spatial distribution of the pulse is dependent on coil geometry and the anatomy 
of the region of the induced current. Circular coils deliver a diffuse field over the 
brain while figure of eight coils allow focal stimulation at a more limited and clearly 
defined location (Epstein, 2008), however, small movements of a focal  coil 
substantially influences the size of the MEP. The cortical area or volume of brain 
stimulated depends on the location of the coil, the stimulator intensity needed to 
produce an effect, and direction of the induced electrical field.  The depolarisation 
of the underlying neuronal cells is not due to the magnetic field but rather to the 
induced electrical field within the brain (Wagner et al., 2009) 
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3.22 Safety 
Single pulse TMS is a safe procedure for examining corticospinal excitability if 
used with basic precautions (Rossi et al., 2009, Sandbrink, 2008). In general, 
contraindications to TMS are related to exposure to the magnetic field, and 
therefore similar to those for magnetic resonance imaging, applying to both the 
participant and the examiner (Sandbrink, 2008). Side effects are generally 
transient, but may include short term discomfort due to contracting scalp muscles 
near the site of stimulation, or a mild headache during or following TMS that is 
treatable with over-the-counter analgesics. There is no evidence of significant 
adverse effects to TMS in either the short or long term, on cognition, memory, 
sensory perception, hormone release or the cardiovascular system (Sandbrink, 
2008, Chokroverty et al., 1995). While some participants have experienced 
transient hearing difficulties after TMS of deep brain regions (Zangen et al., 2005), 
others have reported no hearing-loss even after years of exposure to common 
TMS procedures (Pascual-Leone et al., 1992).   
Seizures caused by single-pulse TMS are rare but possible in those people who 
are susceptible to intractable seizures (Rossi et al., 2009, Classen et al., 1995) 
(Anand and Hotson, 2002). The single report of a seizure during TMS of a person 
with MS was published as a single-case study. The investigators hypothesised that 
the  seizure may have been the result of focal brain lesions detected by fMRI,  or 
due to the use of olanzapine (Haupts et al., 2004), an anti-psychotic  used for the 
treatment of schizophrenia and bi-polar disorder.  
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While the risk of TMS related adverse effects are rare, they cannot be completely 
excluded. The TMS experiments in this thesis conformed to the published safety 
guidelines (Wassermann, 1998), and the ethical and regulatory requirements  
pertaining to research and clinical applications of TMS (Rossi et al., 2009).  The 
consent form included a safety questionnaire (Keel et al., 2001) commonly used by 
TMS investigators to screen subjects for various conditions that may increase risk. 
 
3.23 MEP variability 
The MEP is influenced by intrinsic factors relating to the excitability of the 
corticospinal pathway (Hess et al., 1987, Rothwell, 2008), such as  the number of 
motor neurons recruited by the magnetic pulse, the number of motor neurons 
discharging more than once in response to the stimulus and the synchronisation of 
the motor neuronal discharges (Rosler and Magistris, 2008).The stimulus response 
relationship varies considerably between subjects, between muscles in the same 
individual, even those closely anatomically located, such as hand muscles or upper 
leg muscles (Ellaway et al., 1998). Corticospinal excitability can be affected by 
tonic muscle contractions, de-synchronisation of the discharges, phase 
cancellation and impedance mismatch. Changes in the repetitive discharges in 
response to the magnetic pulse are purported to cause much of the  trial to trial 
variability  (Magistris et al., 1998), but appear to be independent of age, gender, 
and height, or indeed the strength of the stimulus. Repetitive discharges, the 
indirect consequence of the magnetic pulse, occur with cortical stimulation but not 
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with stimulation at the level of the brainstem, suggesting a substantial contribution 
to variability from sub-cortical processes (Taylor et al., 2006). However, it remains 
unclear which neurophysiological mechanisms are involved in the varying levels of 
desynchronisation, and repetitive discharge of neurons. Moreover, whether the 
initial part of the stimulus or the repeat waves activates the motor neuron not only 
depends on the strength and number of the descending volleys, but also on the 
excitability of the cortico-spinal pathway (Taylor and Gandevia, 2008). Extrinsic 
factors that are implicated in MEP variability are the role of the coil, and its position 
on the scalp. Furthermore, MS related conduction block, conduction impedance 
and slowing of signal velocity may modify the MEP (Rosler and Hess, 2010). 
3.24 TMS measures; Motor threshold 
The measures most commonly used in the analysis of motor data are resting motor 
threshold (the minimal TMS intensity required to evoke an MEP), latency (the time 
from triggering the pulse to the start of the MEP), amplitude (base-line to peak or 
peak to peak value) and area (measured as root mean squared, or as the area 
under the line of the rectified signal). The absolute amplitude reflects both upper 
and lower motor neuron activity and is affected by peripheral nerve disorders 
(Sandbrink, 2008). 
Motor threshold (MT) is the lowest stimulus intensity of TMS that gives a 
recordable MEP in the target muscle (Sandbrink, 2008). Obtaining accurate resting 
motor thresholds requires a systematic search for the optimal coil position (hotspot) 
above the motor area corresponding to the target limb or muscle (Conforto et al., 
 
 112 
2004, McDonnell et al., 2004). When the coil is directly over the hotspot it is 
general practise  to obtain 5-10 MEPs of 50 цV in at least 50% of successive trials 
(McDonnell et al., 2004). Extensive mapping of the motor cortex has shown that 
there are considerable differences between individuals and that the hotspot for 
stimulating a specific muscle may be several millimetres from any given point.  
Additional factors such as skull thickness, brain morphology, age or neuronal 
properties can also affect the MTs, and there are significant inter-hemispheric 
differences in ‘hotspots’ related to dominant handedness (Marchand-Pauvert et al., 
1999)  
Motor thresholds (MTs) are generally recognised as a measure of the integrity and 
excitability of the neural pathway at both the cortical and spinal level (Taylor and 
Gandevia, 2004). Studies investigating MTs have reported conflicting results. 
Wasserman (2002) found a wide variation in MTs over time (Wassermann, 2002).  
Other studies have reported consistent MTs over two sessions (Wheaton et al., 
2009, Cacchio et al., 2009). Due to their variability, both within and across 
subjects, MTs cannot be recognised as suitable measurements in tests for 
individual subjects, or between groups, even with minor differences (Wassermann, 
2002). Nevertheless, precise recordings of MTs are critical for determining the 
optimal experimental stimulator intensity as a % of maximal output.  
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3.25 Central motor conduction time (CMCT) 
The latency of the evoked potential is the time taken from triggering the stimulus at 
the motor cortex to the start of the MEP. The time taken for a volley generated in 
the motor cortex to travel through the spinal cord, the ‘central motor conduction 
time’ (Olivier et al., 2002, Mesin et al., 2008, Sheean et al., 1997), can be 
determined by comparing the difference between the latency of a cortically 
stimulated MEP, and the latency of a TMS pulse at the spinal roots, or the latency 
of the response of electrical /magnetic stimulation at a point on the motor nerve. 
The physiological conduction velocity in the corticospinal tract has been measured 
between 65m/sec (Eisen and Shtybel, 1990) and 68.5m/sec (Ugawa et al., 1995). 
The CMCT of leg muscles is height dependent. Normative values for the tibialis 
anterior (TA) are 28.5 ± 2.5 milliseconds (ms) for people 150-174 cms tall, and 
30.7± 1.8ms for 175 -191 cms tall (Dvorak et al., 1991) with little change between 
men and women (Furby et al., 1992). People with MS generally have a prolonged 
CMCT represented by prolonged MEP latency (Sheean et al., 1997).  
3.26 The cortical silent period 
The ‘silent period’ (CSP) is characterised by an interruption of the EMG signal after 
TMS is delivered at the motor cortex during a tonic contraction (Orth and Rothwell, 
2004). It is defined as the time between the end of the MEP and return of the EMG 
signal (Damron et al., 2008). CSP requires an individual to contract the target 
muscle at ~20-30% of MVC. The duration of the CSP is dependent on the % of 
stimulator output, yet appears to be unaffected by the intensity of MVC (Damron et 
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al., 2008). The resulting CSP lasts for only ~100ms with considerable variability of 
duration between subjects (Orth and Rothwell, 2004). The initial portion (40-50ms) 
of the CSP is generally believed to be a response to spinal inhibitory mechanisms 
that follow motorneuron excitation, namely hyperpolarization and recurrent 
inhibition. Inhibitory mechanisms at the spinal level are known to mediate the CSP 
during the latter stages (Orth and Rothwell, 2004).  
The CSP is distributed unevenly between muscles and needs to be measured 
under the precise control of stimulus intensities relative to individual motor 
threshold values (Noordhoot, 2002), making it a difficult measure to control. 
Furthermore, the need to generate and maintain a tonic contraction within the 
specific parameters that precipitate a CSP may be difficult after lengthy physical 
exercise of moderate or vigorous intensity, especially in PwMS. Therefore, for the 
purpose of this thesis, we will not use CSPs as a measure of corticospinal 
excitability. 
3.27 TMS and exercise induced fatigue 
In the general population MEPs measured during, or within a few seconds of an 
isometric contraction, are reported to be increased in size relative to pre-exercise 
MEPs. This phenomenon is termed post-exercise MEP facilitation(PEF). 
Conversely, MEPs recorded from resting muscle after exercise display post-
exercise depression relative to pre-exercise values (Samii et al., 1996b). Post 
exercise facilitation is short lived after a fatiguing contraction (~30seconds), but 
can increase the amplitudes of MEPs to higher than those measured from direct 
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electrical stimulation of the muscle. The associations between PEF and muscle 
fatigue remains unclear.  
Previous studies examining corticospinal excitability after physical activity have 
reported a significant post-exercise depression in MEP amplitudes lasting several 
minutes, thought to be a marker of central fatigue (Petersen et al., 2003, Gandevia, 
2001, Gandevia et al., 1996). Brasil-Neto et al (1994) first used TMS and EMG 
recordings to investigate fatigue and neuromuscular changes in the upper arm 
muscles after exhaustive exercise, reported a post-exercise depression of MEPs 
lasting several minutes (Brasil-Neto et al., 1994). Since then, TMS has been used 
to central responses to a broad range of anaerobic and aerobic activities in both 
trained and untrained subjects (Verin et al., 2004, Meaney et al., 2007). The 
longest duration of MEP depression was reported by Ross and colleagues, who 
observed a 67% depression in the tibialis anterior after 42.2 km treadmill running. 
At 4 hours post-exercise, MEPs were still depressed by 43% suggesting that the 
duration of exercise had a profound effect on corticospinal excitability (Ross et al., 
2007) 
Post-exercise depression was  generally thought  not to occur after exercise lasting 
less than 2 minutes (Samii et al., 1996b). In 2007, our group examined 
corticospinal responses to supramaximal exercise following a 30 second Wingate 
test (WAT) (Meaney et al., 2007). MEPs were recorded from the rectus femoris 
(RF) of 10 healthy participants. Immediately following the WAT, mean MEP 
amplitudes were depressed by 22.09% (p >0.05) and proceeded to decrease to 
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31.9% (p< 0.05) at 8 minutes compared to pre-exercise values.  MEP amplitudes 
remained depressed for 20 minutes post-exercise (p<0.05). In view of the short 
duration (30 seconds) of the test, it was concluded that the post-exercise MEP 
depression was an effect of the intensity of exercise (Meaney et al., 2007). 
3.28 TMS and multiple sclerosis 
MS was the first neurological disease studied using TMS. Early trials on people 
with MS found that central motor conduction time (CMCT) was prolonged, motor 
thresholds were increased and MEP amplitudes were reduced (Hess et al., 1986). 
Since then, TMS has been used extensively in MS to study the lower limbs and 
functional motor disability (Ingram et al., 1988, Facchetti et al., 1997), disease 
classification (Humm et al., 2003, Rico et al., 2009), fatigue (Sandroni et al., 1992), 
drug treatment (Humm et al., 2006) and functional electrical stimulation (Everaert 
et al., 2010). There is a relationship between motor impairment and MEP 
threshold, latencies and MEP duration in people with MS (Thickbroom et al., 2005). 
Indeed,  conduction deficits in the corticospinal-neuromuscular pathways can 
manifest as delayed, smaller MEPs making it difficult to both elicit and analyse 
responses to TMS (Rosler and Magistris, 2008).  
There is a paucity of TMS literature relating to exercise induced fatigue in PwMS. 
Although MEP depression has been observed previously in PwMS (Petajan and 
White, 2000, Liepert et al., 2005) reports are rare. Indeed, many investigators have  
concluded that post-exercise MEP depression fails to occur in PwMS (Perretti et 
al., 2004, Jorgensen et al., 2005, Thickbroom et al., 2006) due to disease related 
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disinhibition in higher brain centres (Thickbroom et al., 2008, Teo et al., 2011). 
However, we postulated that perhaps the intensity at which the exercise had been 
performed in previous studies, rather than MS, may have limited the occurrence of 
post-exercise MEP depression 
3.29 TMS Pilot Study  
3.29.1 Introduction  
We undertook a pilot study to investigate the corticospinal excitability of an 
individual with confirmed MS in response to dynamic exercise. We hypothesised 
that after exercise, the size of MEPs elicited by TMS would be depressed. We 
further hypothesised that if exercise intensity caused MEP depression, then 
exercise at higher intensity would have a greater effect on corticospinal excitability 
and would be reflected in the size of MEP. 
3.29.2 Methods 
Following institutional ethical approval a 59 year old male with confirmed MS 
agreed to participate. The investigation was conducted within the published safety 
guidelines for the application of TMS in clinical practice and research (Rossi et al, 
2009). The participant was required to complete a TMS safety screening 
questionnaire (Keel et al, 2001) and a pre-exercise health questionnaire. Exclusion 
criteria were in accordance with published suggested safety guidelines 
(Wasserman 1998).  A graded exercise tolerance test (GXT) performed to volitional 
fatigue was performed on a friction-braked cycle ergometer.  
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3.29.3 TMS 
The participant attended 2 further sessions. On arrival, surface electrodes were 
placed over the rectus femoris of the dominant leg determined by dynamometer..  
He lay on a medical examination plinth for 20mins while 5 pulses of TMS were 
administered at 5minute intervals.  At each session he performed 20mins cycling 
exercise at either 45% (ET45) or 60% (ET60) of the peak watts achieved during 
the GXT before returning to the lying position. TMS was administered within 30 
seconds of completion and repeated at 2, 4, 6, and 8 minutes.  The experiment 
was conducted at 120% of pre-determined threshold. 
3.29.4 Analysis 
MEP amplitudes were visually examined for general trends. T-tests were used to 
determine differences between pre- and post- ET45 and ET60 data.  Significance 
was accepted at p < 0.05.  
3.29.5 Results 
There was no difference in the pre-ET45 and pre-ET60 MEP amplitudes (p>0.05), 
or between the pre-exercise and post-exercise data for ET45 (p>0.05). However, 
post-ET60 MEP amplitudes were significantly depressed (p<0.01) and a significant 
difference existed between post-exercise ET60 and ET45 (p<0.01). 
3.29.6 Conclusion   
The pilot study found that MEP amplitudes were significantly depressed after 20 
minutes of exercise at 60%, but not at 45% of the maximum GXT workload. The 
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results suggest that corticospinal responses to exercise at different intensities can 
be measured using TMS. In addition it found that exercising at 45%  may be better 
tolerated in pwMS, however further tests incorporating more physiological markers 
are required before benefits established.  
 
Figure 3.1 Participant exercising during the single-case pilot study 
 
Note; The Bistim² and figure-of eight coil are at the forefront of the photograph. The 
cycle ergometer was used during all exercise test sessions. 
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Figure 3.2 Transcranial magnetic stimulation (TMS) of the participant 
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Chapter 4 TMS Reliability 
 
__________________________________________________________________ 
This chapter examines the reliability of responses to transcranial magnetic 
stimulation in the resting tibialis anterior of people with multiple sclerosis 
_________________________________________________________________ 
4.1 Introduction 
Multiple sclerosis (MS) was the first neurological disease to be explored using 
transcranial magnetic stimulation (Hess et al., 1986, Hess et al., 1987). MS is a 
progressive, degenerative disease of the central nervous system (CNS) 
characterised by demyelination and neuro degeneration (Waxman, 2006, Siffrin et 
al., 2010, Dutta and Trapp, 2011). Progressive axonal loss is the major cause of 
permanent neurological disability (Frischer et al., 2009, Dutta and Trapp, 2011) 
with physical impairments particularly distinct in the lower body where incomplete 
motor unit activation and altered muscle characteristics are similar to those 
reported in hemiplegia and spinal cord injury  (Kent-Braun et al., 1997, Carroll et 
al., 2005). Lower limb weakness and locomotor dysfunction are distinctive 
characteristics of MS (Kesselring and Beer, 2005) with the evaluation of lower limb 
function an important current focus (Everaert et al., 2010, Kesselring, 2010)  
During the last 25 years transcranial magnetic stimulation (TMS) has become a 
well-established, non-invasive technique to examine the integrity and excitability of 
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the corticospinal-neuromuscular pathway in both healthy and neurologically 
impaired populations (Barker et al., 1986, Hess et al., 1986, Hess et al., 1987, 
Kobayashi and Pascual-Leone, 2003, Thickbroom et al., 2005, Thickbroom et al., 
2006, Moosavi et al., 1999).  The repetitive discharge of motor neurons and 
subsequent size of the motor evoked potential (MEP) in response to TMS is 
considered to represent the net inhibitory and excitatory influences on corticospinal 
cells, and the natural excitability of the corticospinal neuromuscular pathway 
(Taylor and Gandevia, 2004, Todd et al., 2007, Reis et al., 2008).  
TMS studies have consistently reported prolonged central motor conduction times 
(CMCT) (Schmierer et al., 2002, Conte et al., 2009) higher motor thresholds (MT) 
(Caramia et al., 1991, Sheean et al., 1997) and reduced MEP size (Jorgensen et 
al., 2005, Thickbroom et al., 2005) when comparing MS patients to healthy 
controls. Abnormal MEPs may be the product of demyelination causing decreased 
central conduction velocities, frequency dependent conduction block (the inability 
to conduct trains of action potentials at high frequency), or complete conduction 
block (Kesselring et al., 2010a); Rosler and Hess, 2010). Temporal dispersion 
resulting from the desynchronisation of descending action potentials and phase 
cancellation further affects the MEP area in an unpredictable manner (Rosler et al., 
2002, Wasserman et al., 2008). Nevertheless, TMS studies show that MEPs are 
sensitive to motor impairment and neurological dysfunction from the earliest stages 
of MS (Gagliardo et al., 2007, Rico et al., 2009), provide markers  of motor function 
and post-exercise fatigue (Thickbroom et al., 2005, Thickbroom et al., 2006, 
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Thickbroom et al., 2008, Perretti et al., 2004), can be used for monitoring 
responses to treatment (Everaert et al., 2010) and may predict MS disease 
progression (Conte et al., 2009). However, the stability and repeatability of the 
TMS measure from resting muscle of the lower limb of people with MS (PwMS) 
remains unreported.  
 
Evoking consistent responses in the lower limb with TMS, particularly in people 
with myelopathies or spinal cord injury can be difficult (Roy et al, 2010). The higher 
stimulus intensities required to stimulate skeletal muscle in the lower body 
generates repetitive corticospinal discharges leading to prolonged, complex 
polyphasic MEP forms (Rosler and Magistris, 2008) thus MEPs are generally 
delimited in order to reduce artefact and variability (Ellaway et al, 1998) however, 
the effect of MEP reduction on reliability has not been reported. In addition, 
subjects are commonly required to maintain a tonic contraction in order to both 
facilitate the MEP and reduce its variability, but this can prove problematic for 
patients with central motor conduction abnormalities (Everaert, 2010). 
Furthermore, active muscle contractions for PwMS may hide very small 
depressions in MEP size following exercise or therapeutic interventions. We 
therefore investigated the internal stability, consistency and reproducibility of 
blocks of trials from resting muscle over a 20 minute period and at a repeat session 
several days later. 
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4.2 Methods 
Candidates for the study were referred by neurologists in Oxford or self-referred 
from regional MS societies. Participants were people with clinically definite MS 
(Poser 1983) as confirmed by a consultant neurologist however recently revised 
diagnostic criteria (Polman et al, 2011) were unavailable. The experiment was 
carried out at the Nuffield Orthopaedic Centre, Oxford. Ethical approval was 
obtained from Oxfordshire Research and Ethical Committee (07/H0604/84).  
The investigation was conducted within the published safety guidelines for the 
application of TMS in clinical practice and research (Rossi et al, 2009).  
Participants were required to complete a TMS safety screening questionnaire (Keel 
et al, 2001). Exclusion criteria were in accordance with published suggested safety 
guidelines (Wasserman 1998). Participants were excluded if they had history of 
migraine or epilepsy, were fitted with cardiac pacemakers or cranial ferromagnetic 
implants, showed evidence of uncontrolled hypertension, pregnancy, or reported 
any occurrence of relapse or new neurological symptoms within 4 weeks of the 
investigation.  Having been informed of the nature of the testing procedures, and 
advised that they could withdraw from the study at any time without giving reason, 
each participant signed an informed consent document in accordance with the 
Declaration of Helsinki. Details of medication were recorded. The 3 metre ‘timed up 
and go’, was used to assess mobility ( Podsiadlo and Richardson, 1991), and the 
Barthel Index  measured functional status, including mobility and independence in 
activities of daily living (Wade and Collin, 1988). Subjects were asked to refrain 
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from smoking or taking drinks containing caffeine or alcohol for at least 3hrs, and 
not to participate in strenuous exercise for 48 hours prior to the experiment. 
4.3 TMS data acquisition 
TMS was administered on two separate occasions (7-14 day interval). Participants 
attended test sessions at the same time of day performed under standard 
conditions at room temperature ~21°C. They were required to lie semi-supine on a 
two-section medical examination plinth set so that their upper bodies were angled 
to 30º of an up-right position. Baseline body temperature was recorded with a 
tympanic thermometer and repeated every 5 minutes throughout the experiment. 
The target muscle from which MEPs were to be recorded was the tibialis anterior 
(TA) on the less affected, or previously dominant side of the body. The skin lying 
under the electrodes was cleaned with an alcohol swab. Paired silver-chloride 
surface electrodes (T3404, Thought Technology Ltd, Montreal, Canada) were 
positioned with the inter-electrode distance set at 20mm over the middle of the 
belly of the muscle in line with its longitudinal contour. The locations of electrodes 
were carefully noted for precise replacement during the next visit. The reference 
electrode was attached at the olecranon prominence of the ulna at the elbow. 
Twisted-paired electrode cables connected the electrodes to a four channel pre-
amplifier (Neurolog 844, Digitimer Ltd, Letchwort, UK).  
Single pulse TMS to the motor cortex was applied using two magnetic stimulators 
connected to a Bistim² module (Magstim Company, Dyfed, UK). The stimulators 
were set to fire simultaneously producing a single pulse from a double, cone 
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shaped coil with a diameter of 110mm, (Magstim Company, Dyfed, UK) specifically 
designed to elicit responses from relaxed muscles of the lower pelvic floor and 
lower limbs. Initial exploration determined the optimal stimulation point (hotspot) for 
the TA.  The hand-held coil was placed on the head parallel to, and ~ 0.5-1.5 cm 
lateral to the mid-line (nasion to innion), with its mid-point aligned antero-posteriorly 
(auricular point to auricular point) against the vertex (Devanne, et al. 1997; Cacchio 
et al, 2009). The stimulators were set at 60% of the maximum combined output 
and the coil moved systematically around the location until the hotspot was 
identified. The exact coil position was carefully maintained throughout the 
experiment by aligning it to marks on the scalp made with an indelible ink pen. 
The motor threshold (MT) of each subject (the lowest TMS intensity necessary to 
evoke MEPs in the target muscle) was determined by starting stimulation at 60% of 
maximal Bistim² output and reducing power in 5% increments until the stimulus 
artefact disappeared. The stimulator output was then increased in 1% increments 
+until threshold was reached. MT was defined as the intensity that elicited 5 or 
more MEPs with amplitudes of > 50µV in at least 5 of 10 successive stimuli from 
the relaxed target muscles (Rossini and Dal Forno, 2004). For the comfort of the 
participants we set an upper limit of 80% of maximal Bistim² output to elicit motor 
threshold. The experiment was conducted with the stimulator output set at 120-
130% of the motor threshold value.  
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During the test procedure, the participants received a total of 25 TMS trials 
delivered in 5 blocks of 5 trials (T1-T5) with a delay of 7-10 s between each trial 
and a period of 5 minutes between each block.  EMG signals were recorded 
through a NL844 (Neurolog 820) and relayed to a CED Micro1401 (Cambridge 
Electronic Design, Cambridge UK), amplified(x 1000) and filtered with a band-pass 
filter of 1000Hz to 10Hz. A 55Hz notch filter was applied. The data was digitised at 
2000 Hz and stored for further analysis on a computer. 
4.4 Data Analysis 
The EMG signals were analysed using Signal v.3.11 (Cambridge Electronic 
Design, Cambridge UK). MEPs were full wave- rectified (Halliday and Farmer, 
2010), and calculated as the product of the mean amplitude (Mv) multiplied by the 
duration (mS), taken as the area under the line delimited by vertical cursors (see 
Fig 1) (Ellaway et al, 1998). Two MEP durations, MEPshort and MEPlong were 
considered for analysis. The onset of rectified MEPs was defined as the deflection 
point of the leading edge of stimulus artefact above the background EMG and 
marked by a vertical cursor (C2). MEPshort was delimited at C2 with the second 
vertical cursor (C3) set at precisely 30ms from C2. MEPlong was delimited at C2, 
with the second vertical cursor (C4) set at the inflection point on the trailing edge of 
the longest waveform above background EMG of each participant (See Fig.1).  
Areas were calculated for each trial (T1-T5) and then averaged into blocks of 5 
trials. The data was imported into SPSS V 17.0 (SPSS inc, Chicago USA) software 
for statistical analysis. Demographic data was explored using descriptive statistics. 
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Repeated measures analysis of variance (ANOVA) was used to compare trials (T1- 
T5) and blocks of trials at both MEP durations. 
 
Figure 4.1 Measurement of a motor evoked potential (MEP) 
 
Note: MEP recorded from the TA. The rectified EMG signal displays the 20ms pre-
stimulus window. Vertical lines denote cursor placements. Cursor (1) marks the TMS 
stimulus, (2) the onset of the MEP (3) shows the 30ms marker for MEPshort and (4) 
denotes the end point of MEPlong.  MEP latency is calculated as the elapsed time (ms) 
between cursors 1 and 2. MEPpeak is the maximum amplitude, and MEP areas are 
calculated as amplitude (Mv) multiplied by duration (ms) measured under the line between 
the limits set by the cursors.  
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Areas were calculated for each trial (T1-T5) and then averaged into blocks of 5 
trials. The data was imported into SPSS V 17.0 (SPSS inc, Chicago USA) software 
for statistical analysis. Demographic data was explored using descriptive statistics. 
Repeated measures analysis of variance (ANOVA) was used to compare trials (T1- 
T5) and blocks of trials at both MEP durations. If ANOVA revealed a significant 
main effect, tests of within-subjects, contrasts were used to determine different 
trials or blocks. To compare measures between sessions, paired two-tailed t-tests 
were used supported by ICC’s and their 95% confidence intervals (CI). 
4.5 Results 
 
Fourteen subjects (11 female, 3 male, age 51.07 yrs ± 9.76, 169cms ±9) with MS 
agreed to participate in the study. Participants’ characteristics are detailed in Table 
4.1. Mean tympanic temperatures were 36.6 ºC ±0.4º and 36.5 ºC ±0.3º for 
sessions 1 and 2 respectively. Responses to TMS were obtained from the TA of 10 
participants (3 female participants failed to produce 50% MT before the pre-
determined threshold limit was reached; 1 male participant was excluded due to 
excessive signal interference). MEPs contaminated by artefact or showing 
evidence of voluntary activation during the 20ms pre-stimulus ‘window’ and post-
stimulus ‘latency’ period were excluded (<2% of trials per session). None of the 
participants reported adverse events in response to TMS. Table 4.2 displays the 
stability of motor threshold, MEP latency and MEPshort. MEPlong reflects high 
individual variability of amplitudes between sessions. 
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Table 4.1 Descriptive details of participants 
 
Participants 
  
Age (yrs) mean 51.07 ±9.8 range 31 - 67 
Gender (m/f) 3male 11 female 
MS Categorisation RR  n=7 SP  n=7 
Disease duration (yrs) mean 12.8  ±9.6 yrs range 2 - 36 
Barthel Index (20 point) median 20 range 14 - 20 
TUG (s) mean 11.1 ±3.7 range 5.8 - 18.3 
 
Note; Clinical and self-reported characteristics; MS categorisation, RR =relapsing remitting 
SP=Secondary Progressive.  TUG= ‘timed up and go’, a test of basic mobility. The Barthel 
Index is a scale of functional status, mobility and independence in activities of daily living. 
 
Table 4.3 shows the effect from the repeated measures ANOVA of trial order from 
T1 to T5. The results of within blocks analysis revealed that trial 1 (T1) was 
significantly different to T2 -T5 for MEPlong (F=4.674; p = 0.036; partial eta² 
=.087). T1 was discarded from all further analysis. Thereafter, the repeated 
measures ANOVAs of blocks constructed from the averages of 4 trials (Table 4.4) 
revealed no significant differences within-subjects, for either MEPshort or MEPlong 
(p=<0.05). The results of the repeated experiment 7 days later (Table 4.5) revealed 
no significant differences between sessions (p<0.05) for blocks of 4 trials 
measured over both durations. The test-retest ICCs and 95% confidence intervals 
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further indicated good (<.70) to high (>.80) reliability for both MEPshort and 
MEPlong. 
 Table 4.2 MEP characteristics 
 
 
Note; Mean MEP characteristics, paired 2 tailed t-tests and intra-class correlation 
coefficients with respective 95% confidence intervals based on a two-way, mixed effect 
model with absolute values. 
 
 
TMS 
Measure 
 
Session1 
 
Session2 
 
t-test 95% CI 
Lower  upper 
ICC 95% CI 
Lower  upper 
Motor 
threshold 
 
 
48.4 ±4.8 
 
48.7 ±4.7 
 
.080 
 
-.808     .058 
 
.992 
 
.947     .948 
Latency 
(ms) 
35.1 ±6.9 35.4  ±7.2 .306 -.933     .333 .993 .972     .988 
MEP 
duration 
(ms) 
 
 
 
 
    
MEPshort  30 30 - -         - - -         - 
MEPlong  50.2  ±4.6 51.7  ±5.4 .405 -5.18     2.3 .601 -.81     .904 
 
MEPpeak 
amplitude 
(mV) 
      
MEPshort  315  ±340 380  ±437 .270 -.192     .062 .911 .658    .979 
MEPlong  398  ±347 396  ±449 .173 -.197    .042 .916 .683    .980 
MEPArea 
(mV.ms) 
      
MEPshort 3.9    ±4.1 4.9    ±4.9 .114 -2.2       .292 .919 .668      .991 
MEPlong  5.8    ±6.6 7.0    ±7.0 .058 -2.53     .560 .957 .765      .991 
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Table 4.3 Effect of trial order 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note; Repeated measures one-way analysis of variance (ANOVA) determined the effect 
of trial order. Each group consisted of 49 trials in their respective order from each block.  
Table 4.4 Within-session stability of MEP blocks (4 trials) 
 
 
Note;Repeated measures ANOVAs based on the means of the MEP amplitudes and 
areas followed by Intra-class correlation coefficients (ICC’s) and confidence intervals (CI) 
based on a two-way, mixed effect model with absolute values. 
 
MEP area (mV.ms) 
 
 
 
F 
 
Sig 
 
Partial eta² 
MEPshort     
trial 2 v trial 1  1.408 .241 .028 
trial 3 v trial 2  1.990 .165 .039 
trial 4 v trial 3  1.951 .169 .038 
trial 5 v trial 4  .010 .920 .000 
MEPlong     
trial 2 v trial 1  4.674 .036 .087 
trial 3 v trial 2  .001 .974 .000 
trial 4 v trial 3  .798 .376 .016 
trial 5 v trial 4  .002 .964 .000 
5 Blocks (4 trials)  
Peak amplitude (mV) 
F sig ICC 95% Confidence interval 
Lower limit           Upper limit 
MEPshort 
MEPlong 
.990 
1.001 
.426 
.420 
.899 
.894 
.752               .965 
.769                .986 
Area (mV.ms) 
MEPshort 
MEPlong 
 
1.773 
2.196 
 
.156 
.089 
 
.937 
.955 
 
.856             .981 
.934             .995 
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Table 4.5 Test-retest of Blocks (4 trials) 
 
Note; MEPshort = delimited to 30ms, MEPlong = full length MEP, MEParea = ms.mV, 
MEPpeak = mV (the highest point during the MEP). Blocks consisted of 4 MEPs. Paired 2 
tailed t-tests, intra-class correlation coefficients (ICC) and 95% confidence intervals 
determined test-retest reliability 
 
Block Id 
 
Test 1 
 
Test 2  
 
T test  
p 
 
95% 
confidence  
 
ICC                 
 
95% 
Confidence  
MEPshort    Lower    upper  Lower  upper 
1     Area 
     Peak 
3.36  ±3.84 
295   ±301 
4.55  ±5.38 
418   ±512 
.239 
.205 
-3.37       0.99 
-321         081 
.832 
794 
.418       .963 
.365       .949 
2     Area 
    Peak 
2.49  ±2.91 
248   ±260 
2.91  ±3.19 
253   ±223 
.491 
.930 
-2.09       1.13 
-.143      .085 
.846 
.827 
.377       .971 
.334       .963 
 3    Area 
    Peak  
3.81  ±4.13 
330   ±419 
5.28  ±5.19 
393   ±462 
.093 
.218 
-3,24       3.10 
-.172       .047 
.862 
.945 
.479       .967 
.789       .987 
4     Area 
   Peak 
4.34  ±4.57 
262   ±285 
4.89  ±5.29 
338   ±478 
.423 
.402 
-2.05       0.95 
-.273       .110 
.924 
.815 
.719       .982 
.361       .959 
5     Area 
    Peak 
3.19  ±3.82 
188   ±225 
4.24  ±3.63 
288   ±312 
.121 
.091 
-2.44       0.34 
-.197       003 
.860 
.821 
.497       .967 
.323       .962 
MEPlong        
1     Area 
    Peak 
5.12  ±6.41 
306   ±320 
6.69  ±8.57 
430   ±521 
.218 
.151 
-4.31       1.17 
-.305       .056 
.897 
.832 
.601       .978 
.441      .959 
2     Area  
    Peak 
3.14  ±3.65 
248   ±261 
4.25  ±4.25 
273   ±239 
.202 
.575 
-3.01        0.79 
- .126      . 076 
.849 
.891 
.406       .972 
.566       .977 
3     Area 
    Peak 
5.66  ±6.92 
330   ±419 
7.97  ±8.89 
413   ±482 
.055 
.085 
-4.69       0.06 
-.180       .014 
.894 
.949 
.514       .977 
.759       .989 
4     Area 
    Peak 
6.19  ±6.82 
262   ±285 
7.26  ±8.10 
339   ±481 
.198 
.400 
-2.83       0.06 
-.282       .127 
.948 
.812 
.798       .988 
.354       .949 
5     Area 
    Peak 
4.72  ±6.12 
188   ±225 
6.31  ±5.79 
296   ±325 
.067 
.073 
-3.33        0.14 
-.233        .013 
.903 
.812 
.567       .978 
.275       .960 
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4.6 Discussion 
 
In a repeated sequence of 5 trials of MEP area elicited from the resting TA of 
PwMS, we observed that for MEPlong, the first MEP (T1) was significantly larger 
than subsequent MEP trials (T2-T5), confirming previous observations in healthy 
adults (Brasil-Neto et al, 1992). Having excluded T1 from MEPlong analysis, we 
found that subsequent trials (T2-T5), and blocks of 4 trials were stable over a 20 
minute period. MEPshort remained stable throughout the experiment. Whilst there 
was a great deal of heterogeneity between individuals in MEPs collected and 
analysed from  resting muscle, motor thresholds, MEP latencies and MEP area 
markers  were stable when re-tested on a separate occasion 7-14 days later. 
When considering the effect of delimiting MEPs to 30ms, the ICCs revealed that 
blocks of MEPlong (after eliminating T1) and blocks of MEPshort produced high 
levels of reliability (Portney and Watkins, 2000). Our results suggest that with 2 
stimulators firing a single pulse, reliable baseline measures can be obtained from 
resting muscle with as few as 2 trials after excluding the first trial. In addition we 
found that MEPs can be delimited to 30ms duration in order to minimize 
contamination by signal artifact with no effect on reliability. 
 
To the authors’ knowledge this is the first study to report the reliability of MEP area 
elicited from resting muscle in the lower limb of PwMS. While our findings may 
have important implications for designing TMS test paradigms within this clinical 
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group, they need to be considered alongside previous research exploring TMS 
methodology (Rico et al, 2009; Gagliardo et al, 2010; Rothkegel et al, 2010).  The 
mechanisms underlying responses to TMS are unclear. MEPs are known to be 
sensitive to factors relating to coil placement and orientation, stimulus magnitude, 
muscle activation and mood state. Even motor imagery of a simple lower extremity 
movement can evoke increases in corticospinal excitability (Bakker et al, 2008).  
Indeed, although the true cause remains uncertain, the consistently larger size of 
T1 is thought to reflect an initial facilitation (Schmidt et al, 2009) perhaps in 
anticipation of the impending series of TMS stimuli (Moosavi et al, 1999). 
 
Interpretation of MEPs can be further confounded by the well documented trial to 
trial variability that occurs within subjects, between subjects and between tests 
(Ellaway et al, 1998; Wassermann, 2002), though the causes of the instability 
remain unexplained. The general consensus is that MEP variability in the general 
population is due to intrinsic, time-varying changes in the excitability of 
corticospinal and motorneuronal pathways (Ellaway et al; Rosler et al, 2008). 
Indeed, the higher interindividual variability, higher ICC values with respective 95% 
confidence intervals we obtained within a session rather than on separate days, 
and the lack of bias in our data recorded both within a session and on separate 
days, together suggest that the variability in TMS responses within our group of 
PwMS is also mostly due to inherent, time-varying neurophysiological processes 
rather than measurement bias per se.  
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Whilst our findings are novel, they are limited by the small number of PwMS taking 
part. However, the 10 individuals with MS that were included in the experiment 
were representative of a broad age range (30 - 67 yrs old), the elapsed time since 
first diagnosis of MS spanned from 2 to 32 years. They were characteristic of a 
relatively high functioning group of MS patients in terms of mobility and their self-
reported ability to perform independent activities of daily living (see Table 1) 
(Gijbels et al, 2010).   Individuals imaging data (MRI) was not available, therefore 
we cannot identify individuals by their current MS criteria (Polman et al, 2011) and 
other pathologies that may have affected our results. Thus our results may not 
extrapolate to all individuals with MS, and further studies are required to investigate 
whether our findings are replicated in individuals with higher levels of disability. 
MEPs have been shown to be significantly affected by the methodology (Rico et al, 
2009; Rothkegel et al, 2010).  as such, our findings using the Bistim² stimulator 
configured with a 110mm double cone shaped coil producing a pulse with a 
magnetic field rise of 176ms @ 100% (theoretically 131ms @ 75%max stimulator 
output) do not extrapolate to other stimulator configurations. With this configuration 
we recorded notably lower TA motor thresholds from PwMS than those recently 
reported from the TA of healthy subjects (Cacchio et al, 2009; Cacchio, 2011) and 
those previously reported in PwMS (Jorgensen et al, 2005)  using a single 
stimulator.   
Demyelination and axonal damage in MS can result in conduction abnormalities, 
abnormal temporal dispersion and desynchronisation of descending action 
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potentials leading to phase cancellation that can reduce the size of MEPs. In 
addition, the age of the participant, temperature intolerance, the categorisation of 
MS, certain medications and fatigue may further limit MEP size. Moreover 
rectification of the EMG signal may have obscured phasic waves specific to MS. 
Our method possibly lacks the sensitivity of the triple stimulation technique (TST) 
to quantify small to moderate deficits in conduction parameters relevant to MS 
(Humm et al, 2003; 2004; 2006) however TST of the lower limb is a relatively 
complex, technically demanding, invasive procedure (Buhler et al, 2001) which 
may limit its availability to quantify TMS responses in the lower body either during, 
or immediately following therapeutic exercise interventions.  
An important finding from this study is that MEPs can be reliably elicited from 
resting muscle in PwMS. MEPs are frequently facilitated during voluntary 
contraction of the target muscle in order to reduce variability (Darling et al, 2006). 
Maintaining a tonic contraction based on the percentage (customarily ~10-30%) of 
a maximal voluntary contraction (MVC) has a substantial effect on motor 
thresholds and MEP amplitudes (Darling et al, 2006). Maximum contractions can 
increase MEP amplitude by 50% in the general population (Di Lazzaro et al, 2008) 
and an increase in both the stimulus intensity and muscle activation has been 
shown to lead to a significant reduction in motor thresholds (Darling et al, 2006), 
however volitional effort-dependent manoeuvres to requiring maximal force depend 
to a large extent on subject motivation and understanding (Kesselring and Beer, 
2005). In a clinical group with a neurological disorder such as MS, changes to the 
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muscle and/or nerve tissue, reduced central activation, symptoms of spasticity, 
increased sensations of pain or fatigue, together with cognitive difficulties 
(Schillings et al, 2007) may prevent the production of a true MVC especially in the 
lower limb. PwMS are frequently unable to contract their muscles voluntarily, are 
prone to high levels of fatigue and have symptoms which may affect their threshold 
to discomfort (Kesselring and Beer, 2005). Moreover, maintaining consistent levels 
of submaximal voluntary contraction in the leg muscles and producing the same 
level of consistency across several sessions, particularly after a dynamic exercise 
intervention lasting several minutes, can prove problematic for PwMS (Everaert, 
2010). Thus establishing a methodology that facilitates the collection of TMS 
responses from resting muscle in this clinical group is extremely important.  
4.7 Conclusion 
This study found that dual TMS stimulators configured to fire simultaneously 
through a single coil can produce consistent, repeatable TMS measures from 
resting muscle in the lower limb of PwMS. In addition, we found that delimiting 
MEPs to 30ms is a valid method to analyse complex TMS responses induced by 
stronger pulses. While our findings suggest that with this technique, investigators 
need record just 2 trials to establish a baseline, it remains to be replicated in other 
studies. In view of the high level of inter-individual heterogeneity displayed in the 
MEPs elicited from this clinical group, collecting a low number of repeats in 
baseline testing on resting muscle may limit the sensitivity to detecting change. 
Moreover, post-intervention responses can display low levels of change with 
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increased variability, thus we recommend researchers obtain a relatively higher 
number of trials over a longer baseline period. These results point to an exciting 
opportunity to obtain important TMS data from resting muscle in the lower limbs of 
PwMS. Further studies are required to explore post-intervention MEP parameters 
in PwMS using this methodology. 
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Chapter 5 Exercise at maximal intensity 
 
________________________________________________________________ 
This chapter compares the cardiovascular and perceptive responses in people with 
multiple sclerosis (PwMS) to a group of healthy individuals during a graded 
exercise test (GXT) and through the post-exercise time-course to recovery.  
__________________________________________________________________ 
5.1 Introduction 
 
Chapters 1 and 2 presented the deficits in central motor drive, autonomic 
imbalance and cognitive impairment that can profoundly affect the ability of PwMS 
to perform exercise at high intensity. Exercise tests requiring maximal effort are 
used extensively, both in research and clinical settings to evaluate cardiovascular 
and functional capacity, to stratify potential health risks and to identify limitations 
and contra-indications to exercise. The accurate assessment of exercise capacity 
is essential for determining safe, effective exercise intensities for PwMS (ACSM, 
2000). In addition, tests to volitional fatigue facilitate the design of activity 
programmes that promote greater adherence and compliance to clinical exercise 
prescriptions (Perri et al., 2002).  
 
In healthy populations, heart rate and perceived exertion are used as accurate 
measures of exercise intensity (Noble and Robertson, 1996). At the cessation of 
intense exercise the heart rate decreases, in most cases at a significantly faster 
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rate in physically fit individuals than those from the sedentary population (Brown 
and Brown, 2007). Heart rate recovery (HRR) to pre-exercise measures is 
considered to be almost entirely regulated by vagal reactivation mediated by 
parasympathetic activity of the autonomic nervous system (ANS). Although the 
intensity and duration of exercise have a major influence on heart rate recovery 
(Coote, 2010) the precise mechanisms and relative contributions of sympathetic 
and parasympathetic activity to the cardiovascular response are still not well 
understood. Given that a significant number of PwMS show evidence of autonomic 
dysfunction involving the cardiovascular system (Senaratne et al., 1984), post-
exercise recovery may be slowed. Autonomic processes are also thought to 
mediate the sensation of effort during exercise (Williamson, 2010) and the 
perceptual experience of intensity is a major contributory factor in the participant’s 
decision to terminate a GXT (Wasserman et al., 2005). Previous investigations 
have reported that ratings of perceived exertion (RPE) in PwMS are similar to 
healthy control groups (Ng et al., 2000)  with no significant difference between men 
and women (Romberg et al., 2004a, Morrison et al., 2008), however, studies have 
been limited by small group-sizes and restricted to PwMS with mild functional 
impairment. When considering the distinct symptomatic effects of exercise on the 
cardiovascular and neuromuscular systems, we propose that differential measures 
RPE may be more appropriate for this clinical group. Differential ratings of 
perception allow for the measurement of responses relating to specific functions in 
different parts of the body (Borg, 1990) meaning that sensations relating to 
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breathing can be measured distinctly from the sensation of working muscle in the 
legs (Noble and Robertson, 1996).  
 
There remains a paucity of literature relating to physiological responses to exercise 
intensity in PwMS (Dalgas et al., 2008) and none relating to post-exercise recovery 
after maximal exertion. In addition, differential measures of RPE during a GTX and 
through the time-course to recovery remain unreported. 
 
5.2 Hypothesis 
 
We hypothesised that whilst performing exercise to a maximal intensity, individuals 
with MS would demonstrate reduced exercise capacity, but share similar 
physiological and perceptive responses with a group of healthy controls through 
both the active and recovery phases of a graded exercise test. 
5.3 Methods and materials 
5.3.1 Participants 
Sixty one individuals with clinically definite MS (Poser et al., 1983) of mixed MS 
classification and 17 healthy volunteers of similar age and gender agreed to 
participate. Exclusion criteria for participants are described in Chapter 3.2. Each 
participant was required to sign an informed consent document in accordance with 
the Declaration of Helsinki (1983). The experimental protocols were approved by 
the Oxfordshire Research and Ethical Committee (08/H0604/3). Testing was 
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carried out in the Oxford Centre for Enablement, Oxford, UK. Participants were 
asked to refrain from the consumption of tea, caffeine, alcohol, cigarettes, for a 
period of at least 2 hours prior to testing, and not to take part in strenuous physical 
exercise for 24 hours prior to testing. The test procedures were carried out 
between 1200 and 1500hrs in a quiet room at standard temperature (~21°C). 
5.3.2 Procedures 
Personal details, MS classification, duration from disease onset, co-pathologies 
and treatment history were documented on arrival. Participants of both groups 
completed the Pre-participation Physical Activity Questionnaire (PAR-Q). The MS 
group completed the Barthel Index (BI), the Subjective Vitality Scale (VS) and the 
Fatigue Severity Scale (FSS). Declared medications were screened for precautions 
and contra-indications to exercise. Height, weight, resting heart rate (BHR) and 
blood pressure (BP) were recorded.  Leg extension power (LEP) was measured in 
both legs with the Nottingham power rig (NUMAS, University of Nottingham 
Medical Faculty Workshops, Nottingham, UK) (Bassey and Short, 1990). The 
measurements were repeated until no further improvement was seen. The highest 
recorded power output was recorded in Watts (W). 
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5.3.3 Cycle ergometer 
Individuals were seated on a friction-braked Monark Ergo-medic 824E cycle 
ergometer (Monark AG, Sweden) in an upright posture with the handlebars 
adjusted for comfort. Saddle heights were adjusted to accommodate partial flexion 
of the knee between 170° to 175° with 180° denoting a straight leg position.  Feet 
were firmly supported in the pedals by toe clips and straps. Additional taping was 
used where necessary to ensure that both feet remained secure in the pedals 
during the test session and that the heel was held away from the pedal crank 
(Mulcare and Jackson, 2004). 
5.3.4 Measurement of oxygen uptake 
Peak oxygen consumption and respiratory exchange ratio were measured via the 
collection of expired air via a face mask (Hans Rudolf, Kansas City, USA) 
connected to a breath-by-breath gas analyser (Metamax 3B, Cortex Biophysik 
GmbH, Leipzig, Germany). The gas analysis system was calibrated according to 
manufacturer’s instructions with known concentrations of oxygen and carbon 
dioxide (~15% O2 and ~5% CO2, balance N). Breath by breath measures of gas 
concentrations and volumes were digitally stored on a personal computer. Heart 
rate was recorded from a chest monitor (Polar Electro, Kempele, Finland). 
5.3.5 Exercise test  
A continuous multi-stage graded exercise test was employed. The assessment 
started with 2 minutes unloaded cycling at the target cadence of 50 revolutions per 
minute (rpm). Participants who were unable to achieve the selected cadence of 50 
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rpm unloaded pedalling were asked to maintain a lower maintainable cadence (45 
or 40rpm).  At precisely two minutes into the test a weight of 0.5kg was placed in 
the weight plate equating to an increase of 25 Watts workload at 50 rpm (Carroll 
and Lambert, 2009). Resistance was then added in 25 watt increments every 2 
minutes. Measures of work-load, HR, RPE breathing and legs, and tympanic 
temperature were taken in the last 30 seconds of each incremental stage. 
Participants received verbal encouragement throughout the test to perform at 
maximal effort.  
5.3.6 Test termination 
 
In view of the broad range of physical impairment and individual fitness levels of 
PwMS, a set end-point based on meeting maximal criteria was not suitable. Hence, 
the GXT was symptom-limited. Individuals were instructed to pedal until discomfort, 
pain or fatigue prevented them from maintaining the required cadence (Jackson 
and Mulcare, 2009b).  On ceasing exercise, participants were asked their reason 
for stopping. The face mask was removed, their BP was recorded and the 
participants were then assisted to a chair positioned within 1 meter of the cycle 
ergometer. During the post-exercise recovery phase, HR, BP, Temp°C and RPE 
were recorded at 3 minutes, 5 minutes and 10 minutes. 
5.4 Statistical analysis 
Data was imported into SPSS v 17.0 (SPSS inc, Chicago, USA) software for 
statistical analysis. Normal distribution of data was determined using a 
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Kolmogorov-Smirnov test. In view of the disparity in sample sizes, differences 
between the MS and control groups were calculated as continuous variables using 
one way analysis of variance (ANOVA) with the group as the single factor variable 
presented as the mean ± standard deviation (SD) (Bewick et al., 2004). Linear 
regression was used to test the strength of association between variables (Bewick 
et al., 2003). Appropriate parametric and non-parametric correlation coefficients 
determined the strength of association between baseline, performance and 
recovery measures. Expired air measures were calculated as mean values from 
the last 15 seconds of each stage. To investigate the relationship among several 
variables, multivariate regression models were fitted with various criterion 
measures as dependent or independent variables. All regression models were 
based on the mean values of participants when all measurement parameters were 
present. Recovery profiles between groups were calculated measures using one 
way ANOVA. Linear and quadratic equations were fitted to the recovery data and 
relationships determined by the strength of correlation coefficient together with the 
significance of slope coefficients. Significance was set at alpha (p< 0.05). Cohen’s 
classification of correlation coefficients was used to determine strength of 
association, r =>0.50 is rated as strong, r= 0.30  to 0.49 is considered moderate, 
and r= 0.10 to 0.30 are considered weak when p<0.05 (Weinburg and Abramowitz, 
2008). 
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5.5 Results 
This study compared resting, energetic and recovery parameters derived from a 
maximal exercise test in healthy individuals and PwMS. Descriptive details of 
participants and resting measures are detailed in Table 5.1. There was no 
difference between groups in age, gender, height and weight. Baseline resting 
measures between the MS and control groups did not differ significantly (p >0.05) 
except for RPEleg (p< 0.05). MS group pre-GXT functional test scores as 
measured by the Barthel Index, Vitality Scale and Fatigue Severity Scale are 
presented in Table 4.2.   
 
One participant with MS who showed signs of uncontrolled hypertension during the 
recording of baseline measures was referred back to their general practitioner. Two 
participants with MS who experienced dizziness and nausea when sitting on the 
cycle- ergometer withdrew prior to the GXT commencing. Four PwMS whose 
results were asymptomatic of MS were excluded from further analysis.  The 
cardiovascular response of one control participant was affected by beta-blocker 
and consequently discarded however, measures of other variables showed no 
effect and were therefore included. Therefore the results of 54 PwMS (21 RR-MS, 
26 SP-MS, 7 PP-MS) and 17 age-matched controls were analysed. 
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Table 5.1 Descriptive details and resting measures of participants 
 
 One- way ANOVA determined differences between groups. 
 
 
Group 
 
MS 
 
 
CG 
 
P-value 
 
 
N= 
                  
                  54 
     
    17 
 
 
Gender 
 
M =18;   F = 36 
 
M =3;   F =14 
 
.410 
 
Age (years) 52.8    ±9.0 48.9    ±5.7 .109 
 
Height (cms) 166.7   ±5.9 167     ±8.0 .369 
 
Weight (Kgs) 72.3     ±14.1 75.1    ±8.8 .439 
 
 
Resting measures 
 
   
 
HR (bpm) 74.2   ±9.6 71.7     ±9.6 .385 
 
BP Systolic (mmg) 133.3   ±18.3 130.3    ±18.1 .558 
 
BP Diastolic (mmg) 78.0    ±11.1 83.8     ±8.5 .054 
 
Temp°C 36.4   ±0.4 36.6     ±0.3 .187 
 
Blood lactate mmoL 1.6     ±0.6 1.5      ±0.5 .840 
 
RPEbr (CR10) 0.8     ±0.9 0.8      ±0.7 .842 
 
RPEleg (CR10) 1.1     ±1.2 0.2      ±0.4 .009 
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Table 5.2 Multiple sclerosis disability scores and functional test results 
 
 
 
 
Results of peak performance are summarised in Table 5.3. No adverse reactions 
were reported from individuals of either group during the test. The results indicate 
that MS group means (±SD) failed to reach any criterion measure considered to 
represent peak performance. Average age predicted HRmax values (220-age) 
were calculated as 167.2bpm ±9.1 for the MSG, and 171.1bpm ± for controls. The 
MS group achieved only 82.5% of age-predicted HRmax compared to 98% for the 
control group. Conversely, the control group mean exercise measures reached 
recognised criteria for peak testing on two measures; mean heart rate of within ± 
 
Test 
N = 54 
Mean (±SD) 
 
 
min 
 
max 
 
Barthel Index 
 
18 (median) 
 
 
11 
 
20 
Fatigue severity scale 4.43  ±1.03 
 
1.5 5.9 
Subjective Vitality Scale 
 
4.62   ±1.56 1 7 
2 minute walk test (metres) 96.85    ±50.26 9.0 205.9 
 
Timed up and go Test 
(secs) 
 
18.46    ±21.44 
 
4.1 
 
117.0 
 
Average leg strength 
(l/r)watts 
 
103.81   ±56.76 
 
 
27.4 
 
254.2 
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10 beats of age predicted HRmax, mean RER value greater than 1.10 (Newton et 
al, 2008). Significant differences existed between groups in all peak measures 
except for RPEleg (p>0.05).  
 
Table 5.3 Comparison of group peak performance values  
 
 
Note: One-way ANOVA determined differences between groups for all variables. 
 
 
 
 
 
Parameter 
N 
 
MS group  
mean (±SD) 
 
N 
 
Control group  
mean (±SD) 
p 
 
Max Watts 
 
 
54 
 
97.4     ±35.2 
 
17 
 
161.8    ±43.4 
 
.000 
HRpeak (bpm) 
 
53 140.1    ±24.8 16 167.7    ±9.37 .000 
VO2max 
mL.kg¯¹ 
 
48 20.1    ±6.4 10 27.8     ±6.8 .001 
 
RER 
 
47 1.03    ±0.12 10 1.15    ±0.05 .001 
RPEbreathing  
 
54 
 
5.1     ±1.7 17 6.8    ±2.3 .001 
RPElegs 
 
54 6.2     ±1.6 17 7.0    ±1.8 .093 
BLa peak 
(mmol/L) 
49 5.4     ±3.7 14 7.7     ±2.1 .013 
Temp °C 
 
44 36.4     ±0.4 11 36.8    ±0.5 .006 
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In the MS group there was a strong correlation between functional walking capacity 
as measured by the 2MTW, and 2OV
 max ( r= .59, p <0.05), max watts (r= .56, p 
<0.05)  HRpeak (r= .55, p <0.05) and RER (r=.50, p<0.05) In addition leg strength 
was strongly correlated with maxWatts (r=.71, p<0.05) and a moderate relationship 
existed between leg-strength and HRpeak (r=.59, p<0.05).  Figure 5.1 shows the 
linear relationships between heart rate, differential measures of RPE, and oxygen 
consumption relative to percentage of watts peak work load (watts), for MS and CG 
groups. ANOVA of between group differences found no evidence of altered heart 
rates during the first 3 stages of the GXT (p <0.05).  Linear regression was 
determined by curve estimation as the best line of fit. Regression analysis revealed 
a high level of variability in MS group measures. For the purpose of this study, 
recovery will be defined as the post-exercise decline from peak to baseline values 
(±SD). The MS group displayed a significant (p<0.05) curvo-linear relationship 
between time in minutes post-exercise and HR recovery as a percentage of mean 
baseline measures (R²=0.99, y=11.12x²-80x+264.28) while the control group 
produced a non-significant (p>0.05) quadratic relationship (R²=0.97, y=20.173x²-
134.46x+349.46).  
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Figure.5.1   Changes over time to heart rate during the graded exercise test  
  
N = 51 
 
N = 17 
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Figure 5.2 Changes over time to RPE breathing during the graded exercise test 
           
N = 53 
        
N = 17 
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Figure 5.3 Changes over time to RPE legs during the graded exercise test 
 
 
N = 53 
      
         N = 17 
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Figure 5.4 Changes over time to oxygen uptake (VO2) during the graded exercise 
test        
 
                                        N = 48 
                                     
                                  N = 10 
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Figure.5.5 Scatterplot of heart rate to % peak power (watts) 
n=51
n=17 
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Figure 5.6   Scatterplots of ratings of perceived leg exertion to % 
                          peak power (watts) during a graded exercise test 
 
n=53 
n=17 
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Figure 5.7 RPE breathing to % peak power (watts) during a graded exercise 
test 
 
 n = 53
 
n = 17 
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Figure 5.8 Maximal oxygen uptake (VO2) to % peak power (watts) during a 
graded exercise test 
n = 48 
n = 10 
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There was no change in MS Temp°C from pre-exercise values, during or following 
the GXT. Multiple regression analysis found no significant effects on the peak 
measures of variables  when weighted by MS classification (RR-MS, SP-MS and 
PP- MS).  Using the enter method with age, gender, weight, MS Classification and 
the time elapsed since diagnosis (years), a significant model emerged: F = 6.813, 
p< .0005, however the regression model revealed that only age and weight were 
moderately predictive of 36% of the variance (adjusted R² = .36) in peak work-rate.  
Repeated measures ANOVA found no difference between PwMS reporting a pre-
exercise RPEleg value of  2 or higher (n=18), and the remainder of the MS group, 
in baseline or performance variables. Twenty eight of the MS group cited leg pain, 
leg weakness, or the inability to maintain the cadence as the reason for terminating 
the test.  The remainder of the MS group, and all members of the control group 
cited non-specific reasons such as ‘had enough’ or ‘unable to continue’ for 
terminating the GXT.  
 
The recovery profiles (Table 5.4) show significant differences (p>0.05) between 
group recovery values for RPEleg at 10 mins and Temp°C at 3 and 10mins post-
exercise. Although the control group exercised at a significantly higher work rate, 
HR recovered at a faster rate than the MS group, remaining marginally above pre-
exercise HR values at 10 minutes post-exercise. Differential measures of RPE for 
both groups recovered to pre-exercise values at 5 mins (±SD). 
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Table 5.4   Measures of heart rate, RPE and temperature during recovery 
 
 
Post-GXT data-points showing mean group measures and values relative to peak 
exercise measures.   
 
 
 
 
MS 
 
 
CG 
 
 
p 
 
MS 
% of Peak 
 
CG 
% of Peak 
HR 
(beats.minˉ¹) 
     
3mins 
 
102.8  ±23.8 107.3  ±10.7 .472 73.8  ±13.7 63.6 ±6.1 
5mins 
 
90.6    ±16.1 97.9    ±8.2 .087 64.5   ±12.3 58.1 ±4.4 
10mins 
 
85.7    ±14.9 93.1    ±7.3 .059 57.0   ±17.4 55.3 ±3.9 
RPE(CR-10) 
breathing 
 
 
    
3mins 
 
2.4     ±1.5 2.4     ±1.3 .957 55.4  ±26.8 36.3  ±19.2 
5mins 
 
1.6     ±1.1 1.6     ±1.0 .841 40.5  ±23.6 24.4  ±17.0 
10mins 
 
1.0     ±1.0 0.8     ±0.8 .544 22.8  ±24.4 11.4  ±9.7 
RPE(CR-10) 
legs 
     
3mins 
 
3.3    ±1.7 2.5    ±1.6 .069 53.9  ±28.6 35.4  ±18.2 
5mins 
 
2.4    ±1.4 1.7    ±1.3  .070 39.7  ±26.7 24.0  ±14.7 
10mins 
 
1.8    ±1.2 1.0    ±1.1 .020 28.8  ±23.9 13.9  ±11.8 
Temp°C      
3mins 
 
36.5   ±0.5 36.9   ±0.6 .026 - - 
5mins 
 
36.5   ±0.4 36.9    ±0.5 .105 - - 
10mins 36.4   ±0.4 
 
37.0    ±0.3 .007 - - 
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Fig 5.9 Recovery profile as a percentage of peak heart rate 
 
 
5.6 Discussion.  
This study confirmed a substantially reduced exercise capacity in PwMS when 
compared to healthy controls, but also observed that during maximal exertion, 
individuals with MS were neither limited by their heart rate, nor their breathing. 
Rather, when considering the comparable ratings of exertion experienced in their 
legs with the control group at exercise termination, the strong relationship of leg 
strength to peak exercise performance, and the reasons PwMS gave for 
terminating the GXT, it would appear that leg fatigue, or lack of drive to the lower 
limbs were the limiting factors to achieving higher peak exercise values in this 
group. Considering recovery, PwMS recovered at a slower rate than the control 
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group. More importantly it was observed that PwMS continued to experience 
sensations of exertion in the lower limbs, even during rest.  
 
Participants in the MS and control groups were similar for gender, age, height and 
weight. There were no significant differences between the two groups in these 
parameters. Likewise, with the exception of RPE leg, no significant differences 
existed between group values of the pre-GXT resting measures.  However 
significant differences existed in the average peak exercise values, with the 
exception of RPEleg. The protocols and methods used were identical for both 
groups. Consequently, the differences in the GTX peak performance values can be 
attributed to impairments and deficits caused by MS. Because the responses to 
incremental cycle ergometer tests in healthy groups have been well described, the 
discussion section of this Chapter will focus on the results relevant to the MS 
group. 
 
Several factors may have contributed to the high level of variability in the 
performance measures of the MS group. Cardiovascular fitness levels and 
muscular MS symptoms between individuals, differences caused by impaired 
central motor drive, intolerance to environmental factors or to the exercise itself 
may have affected exercise performance. Small increases in body temperature 
have been shown to affect walking velocity (Humm et al., 2004).  Bladder 
dysfunction frequently causes PwMS to limit fluid intake (Collett et al., 2011a) 
which may in turn increase the risk of symptomatic heat intolerance (Fromont et al., 
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2010), generate fatigue and limit  peak performance (Freal et al., 1984, Humm et 
al., 2004). We attempted to minimise diurnal fluctuations of MS symptoms by 
performing the tests at the same time of day, however PwMS are prone to 
unpredictable episodes of fatigue, spasticity, pain or weakness with sudden-onset, 
even at rest.  
Previous studies have been inconsistent when attempting to establish an 
association between exercise capacity and disability as measured by the expanded 
disability scale (EDSS) (Foglio et al., 1994, Motl and Goldman, 2011, Romberg et 
al., 2004a) In view of the well reported limitations of the EDSS (Goodkin et al., 
1992, Herndon, 2007), its poor psychometric properties (Hobart et al., 2000) and 
its inability to measure fatigue related to disability (Polman et al., 2006) we 
assessed levels of ambulatory impairment by comparing the results of the TUG 
and T2MW to those from previous studies. Recently, Nilsagard et al,(2009), Gijbels 
et al, (2010), and Sosnoff et al,(2011) have reported mean TUG times of 
17seconds, 15.7 seconds and 16 seconds respectively for groups of PwMS with 
moderate ambulatory impairment (Nilsagard et al., 2009, Gijbels et al., 2010, 
Sosnoff et al., 2011). In contrast, an average TUG time of 8.8 seconds has been 
reported for 35 ambulatory subjects with relapsing-remitting MS(Weikert et al., 
2011), agreeing with the results obtained from other mildly-impaired MS groups. 
The mean TUG time of 17 seconds achieved in this study strongly suggests that, 
on average, our MS group was moderately impaired, but representative of a very 
broad range of ambulatory ability (from mild to moderately severe). This 
assessment is supported by the results of the T2MW. In their recent examination of 
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walking performance in PwMS with mild or moderate ambulatory impairment, 
Gijbels and colleagues  reported an average distance of 104 metres (±41) for the 
moderately impaired group, agreeing with the 97 metres (±50) walked by our MS 
group. Again, the distance walked, ranging from 9 metres to 206 metres (showing 
normal distribution) reflects a very broad range of ambulatory ability within the 
group.  
 
When matching the 2OV
 peak results with other groups of similar age and moderate 
ambulatory impairment utilising similar exercise ergometry, values of 21.7±6.0 
ml.kg¹min¹ (Romberg et al., 2004a)  and 21.7±5.5 ml.kg¹min¹ (Petruzzello and Motl, 
2011) compare closely to the 20.1± 6.4 ml.kg¹min¹ achieved in this study. In 
summary, when compared to other MS studies, the results of the GXT covers the 
broadest range of ambulatory abilities in PwMS reported to date, with the mean 
measures of the functional mobility tests confirming the moderate ability status of 
the group. Interestingly, peak work-rates correlated strongly with the pre-exercise 
average leg strength (r= .71) suggesting that leg strength may be a predictive 
measure of exercise capacity in PwMS, and as such warrants further investigation.  
 
With regards to the concerns of PwMS performing exercise at high intensity (Collett 
et al., 2011b), the question remained whether a sub-maximal exercise test (SMXT) 
would serve as an appropriate alternative to the GXT. The SMXT differs to the 
GXT in that it is terminated at some pre-determined heart rate intensity. Moreover, 
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the SMXT assumes that the mechanical efficiency (ie the 2OV
 ) at a given work rate 
is stable (ACSM, 2000). Our results revealed that the relationship between 2OV

peak and work-rate for the MS group (as shown in Figure 2) to be highly variable 
(R² = .39), probably the result of reduced drive to the legs. Furthermore, the SMXT 
assumes that an individual’s maximal heart rate fits the HRmax equation 220-age 
(Londeree and Moeschberger, 1984). Because heart rate and 2OV
  generally show 
a linear relationship in response to an increase in work-rate, the slope of HR/ 2OV
   
regression can be extrapolated to the 220-age estimate of HRmax (ACSM, 2000) 
However, on average the MS group achieved only 82.5 % of age-predicted 
HRmax, a result consistent with that reported (Ponichtera-Mulcare et al., 1994) 
whose group of 8 semi-ambulatory MS subjects achieved 81% of age-predicted 
HRmax from a GXT on similar ergometry.  
 
When considering that 40 individuals from our MS group who failed to achieve the 
criterion measure of 2OV
 max averaged only 74% of age predicted HRmax, the 
heart rate assumptions of the SMXT are clearly not met.  This has important 
implications in the clinical and fitness settings for this clinical group. An exercise 
prescription or SMXT based on age-predicted HRmax is at risk of substantially 
over-estimating the exercise capacity of individuals with MS.  In view of their 
recovery to baseline measures within 10 minutes of test termination, and that none 
reported adverse reactions, either during the GXT or the recovery period, it seems 
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reasonable to suggest that the GXT should remain the ‘gold standard’ for 
assessing exercise capacity in the MS population. 
 
The recovery slopes in this study indicate that the HR of PwMS recovered at a 
substantially slower rate than those of the control group. At 3 minutes post-
exercise, the HR of the control group had dropped 36.6 % from HR peak. In 
comparison the HR of the MS group had only fallen 26.2%. Quantifying HRR after 
intensive exercise is difficult because rates of recovery can be affected by multiple 
factors such as an individual’s age, gender and level of cardiovascular fitness (Darr 
et al., 1988), or the duration and intensity of exercise performed (Buchheit et al., 
2007). Nevertheless, in the MS group we observed a statistically significant 
moderate correlation between HRR at 3 minutes, 5 minutes and 10 minutes and 
the peak exercise values of watts (p<0.05) and 2OV
  (p<0.05).  
 
An attenuated HRR measured within 2minutes of exercise has been demonstrated 
by numerous studies to be prognostic of all-cause mortality in both clinical and 
healthy populations (Ellestad, 1996, Cole et al., 1999, Georgoulias et al., 2009), 
although there is conflicting evidence as to whether a delay in HRR provides a 
reliable prognostic marker when taking into account factors such as gender 
(Wandell et al., 2010), spinal cord injury (Myers et al., 2010), previously 
unidentified clinical variables and individual differences in the exercise response 
(Morshedi-Meibodi et al., 2002, Singh et al., 2002, Myers et al., 2010). With regard 
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to MS, there is growing evidence that HRR measured at 3 minutes and 5 minutes 
post-exercise is significantly impaired in people suffering other chronic 
inflammatory disorders such as Sarcoidosis (Ardic et al., 2011), Buhçet’s disease 
(Kaya et al., 2009) and Systemic Lupus Erythematosus (Dogdu et al., 2010). 
Studies examining associations between brainstem lesion load and abnormal 
cardiovascular responses in PwMS have provided contradictory results (Anema et 
al., 1991, Acevedo et al., 2000, Vita et al., 1993). 
 
Evidence for cardiovascular autonomic dysfunction in PwMS is well established 
(Acevedo et al., 2000, Mahovic and Lakusic, 2007, Anema et al., 1991, Nasseri et 
al., 1999) however the inflammatory processes and  sympathetic and 
parasympathetic mechanisms, and their specific contributions to HR and HRR 
during exercise and recovery have yet to be determined. Whilst HRR is generally 
considered to be almost entirely regulated by parasympathetic activity of the 
autonomic nervous system (ANS) exerting its influence on the vagal nerve, 
Buchheit and colleagues have demonstrated that post-exercise parasympathetic 
activation can be significantly mediated by multiple factors, including the type and 
intensity of exercise performed (Buchheit et al., 2007), body posture during the 
recovery period (Buchheit et al., 2009a) and body temperature (Buchheit et al., 
2009b). Moreover, the delay in the speed at which the heart rate returns to 
baseline measures after exercise may reflect both deficits in parasympathetic 
mechanisms associated with an absence of vagal reactivation (Pierpont and Voth, 
2004), and the influence of long-lasting sympathetic excitatory mechanisms 
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reflected by increased concentrations of norepinephrine (NE) that can remain in 
circulation for several hours after intensive exercise (Schairer and Keteyian, 2007). 
Interestingly, we found a moderate inverse correlation between HRR and the 
Barthel Index (BI) at 3 mins (r=-.33, p<0.05) that further strengthened between 5 
mins (r=-.52 p<0.05) and 10 mins (r=-.53 p<0.05) suggesting a relationship 
between delayed recovery and physical impairment. The absence of statistically 
significant relationships between HRR values and other baseline measures of 
mobility (T2MW and TUG), leg strength and fatigue (FSS) would suggest that a 
delay in HRR may not correspond specifically to MS related disability, however the 
strength of association between HRR after intense physical activity and the BI as a 
measure of function, mobility and independence in activities of daily living warrants 
further investigation. 
 
To our knowledge this was the first study to measure differential values of 
perceived sensation during the active and recovery phases of a GXT in PwMS. 
Morrison et al (2008) reported RPE responses from a group (n=12) of mildly 
affected PwMS during a GXT however, a direct comparison between the two 
studies was prevented due to differences in the level of ambulatory disability, the 
wide disparity in group sizes and the method employed. Nevertheless, the 
significance in our results, especially in the resting values of RPE leg, and in the 
differences of sensations from breathing legs at peak work-rate support the use of 
differential RPE in this clinical group. That RPE leg values were the only resting 
measures differing significantly from those reported by the control group (p>0.05) 
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raises the important question as to whether the MS participants fully understood 
the verbal anchors and the numerical value of the RPE scale. We would argue that 
the compliance represented by the RPEbreathing values, in addition to the 
agreement of the RPEleg values at maximal effort with those of the control group, 
give a clear indication that the MS group fully understood and complied with the 
instructions for reporting sensations from both the upper and lower body. Indeed, 
the return of post-exercise values of RPEleg to the same pre-exercise values (p <= 
0.05) adds weight to our view that the pre-exercise RPE values were an accurate 
assessment of the sensations that the MS group were experiencing in the lower 
limb at rest.  
 
5.7 Limitations 
For the purpose of this study participants with a broad range of disease severity 
were tested, nevertheless the exclusion criteria meant that non-ambulatory PwMS 
and those with contraindications that precluded maximal exercise testing were not 
represented. The selection of a homogenous group of PwMS is a challenge in view 
of the heterogeneous, fluctuating symptomology and progressive nature of the 
disease. The unpredictability of the MS participants’ decision to terminate the GXT 
made it difficult to establish the precise mechanisms responsible. Cognitive 
impairment or anxiety may also have affected their motivation and compliance to 
the requirements of a GXT which in turn, influenced their time-course to post-
exercise recovery. Nevertheless, whilst the results will not extrapolate to all PwMS, 
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this study has investigated a substantially wider range of physical abilities and 
exercise capacities than previous reports.  
5.8 Conclusion 
 
The majority of participants with MS were unable to sustain a work-rate conforming 
to published physiological and perceptive markers of maximal exercise capacity, 
however their ability to perform exercise at high intensity was not limited by 
cardiovascular factors but more likely was the result of reduced central motor drive 
to the legs.  Performance and perceptive measures of exercise during the active 
and recovery phases are variable due to the heterogeneous nature of the MS 
symptoms.  Even though they performed at a substantially lower work rate, the 
HRR of PwMS was delayed when compared to the control group, and a high 
percentage of the MS group continued to experience lower limb exertion, even at 
rest. Further study is required to determine the central factors that affect 
performance and the post-exercise response to exercise intensity in PwMS.  
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Chapter 6 Responses to exercise intensity in MS 
 
 
This chapter examines physiological, perceptive and neurological response to 
exercise in MS to different exercise intensities, both during the active phase, and 
through the post-exercise time-course to recovery 
________________________________________________________________ 
6.1 Introduction 
 
Whilst a considerable body of scientific evidence exists to guide exercise 
prescription for apparently healthy adults, clinical groups and individuals with long-
term disabilities (Garber et al., 2011), there is a paucity of information relevant to 
the unique needs of PwMS. The physiological, neurological and perceptive 
response to exercise and post-exercise recovery in MS remains largely 
unexplored, and little or no scientific information is available upon which to to base 
safe, effective and appropriate exercise strategies, 
In Chapter 4 maximal exercise capacity in PwMS was shown to be lower than 
healthy controls. The results suggest that exercise performance is not limited by 
cardio-respiratory factors, but more by the inability to generate and maintain drive 
to the legs, perhaps reflecting central conduction abnormalities affecting the lower 
limbs (Shapiro, 2003). The characteristic neurological deficits of MS can be 
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mapped directly to demyelination and neuronal damage (Dutta and Trapp, 2011). 
Indeed, in MS the relationship between central conduction deficits, motor 
impairment and functional limitations affects health behaviours and adherence to 
exercise (Stuifbergen et al., 2006). In addition, there is an inverse association 
between neurological dysfunction and cardio-respiratory fitness (Motl and 
Goldman, 2011) that may further contribute to the inability of PwMS to maintain 
fatiguing exercise at higher intensity.  
 
MS presents a complex array of symptoms. Two specific problems associated with 
exercise are motor fatigue and thermosensitivity (Dawes, 2008b, Beer, 2010). 
Motor fatigue worsens with heat, prevents sustained physical activity, and 
interferes with physical functioning (Schapiro, 2007). In addition, a strong 
relationship has been observed between fatigue, core temperature and ratings of 
perceived exertion during dynamic exercise in PwMS (Mulcare et al., 2001, Humm 
et al., 2004). Fatiguing activity also contributes to changes in corticospinal 
excitability (Taylor and Gandevia, 2008). The inability to maintain drive to lower 
limbs during exercise is multifactorial, but in MS may be the result of transient, heat 
induced alterations to conduction properties In demyelinated fibres (Fromont et al., 
2010, van Diemen et al., 1992, Smith and Waxman, 2005, Humm et al., 2004),  
although the link between body temperature and temporary conduction 
abnormalities has yet to be proven (Humm et al., 2004). 
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Transcranial magnetic stimulation has been used extensively to investigate the 
central pathways following exercise (Brasil-Neto et al., 1994, Samii et al., 1996b, 
Ross et al., 2007, Meaney et al., 2007, Fernandez-Del-Olmo et al., 2011). Whilst 
TMS studies in MS have reported altered MEP characteristics between the 
fatigued and rested state (Sandroni et al., 1992), and post-exercise changes to 
MEPs have been observed  after fatiguing muscle contractions in the upper body 
(Sheean et al., 1997, Perretti et al., 2004, Liepert et al., 2005), there have been few 
studies exploring central responses in the lower limbs  following  dynamic exercise 
(Schubert et al., 1998, Thickbroom et al., 2008). Moreover, although TMS of 
resting muscle is considered a sensitive measure of deficits in corticospinal 
pathways (Davey et al., 1999, Roy et al., 2010) few investigations have examined 
MEPs elicited from non-activated muscle in MS. 
The purpose of this study was to compare responses to exercise intensity in PwMS 
to a group of healthy controls. We first monitored physiological and perceptive 
responses during single sessions of exercise training at different intensities, and 
then used TMS to compare neurological, physiological and perceptive responses 
through the post-exercise time-course to recovery.  
6.2.1 Methods and materials 
This is a single session comparator clinical trial of 2 single-session interventions 
with participants randomly allocated to the order of exercise intervention.  
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6.2.2 Setting 
The experiment was carried out at the Nuffield Orthopaedic Centre, or in the 
Human Performance Laboratory, Oxford Brookes University. The experimental 
procedures were carried out by the same investigators between 1200 and 1500hrs 
in a quiet room maintained at standard room temperature (~21°C). 
6.2.3 Participants 
Sixteen people with clinically definite MS confirmed MS (Poser et al., 1983) and 11 
age and gender matched controls were recruited to the study. The PwMS were 
referred through neurologists at the Nuffield Orthopaedic Centre and John 
Radcliffe National Health Service Trusts in Oxford, UK, or recruited through 
presentations at regional and local MS Society events and meetings. PwMS were 
required to provide written confirmation of their clinical status by their general 
practitioner or consultant neurologist. The TMS screening and exclusion criteria are 
detailed in Chapter 5. Each participant was required to sign an informed consent 
document in accordance with the Declaration of Helsinki (1983). The experimental 
protocols were approved by the Oxfordshire Research and Ethical Committee 
(08/H0604/3).  
Participants were asked to refrain from the consumption of tea, caffeine, alcohol or 
cigarettes for a period of at least 2 hours before attending each session. In addition 
they were requested not to participate in strenuous physical exercise during the 24 
hours prior to exercise sessions. On arrival at the test centre, personal details 
including MS classification, duration from disease onset, co-pathologies and 
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treatment history were documented. Participants completed a pre-participation 
physical activity questionnaire (PAR-Q), self-reported activity questionnaires, the 
Barthel Index (BI), the Subjective Vitality Scale (VS) and the Fatigue Severity Scale 
(FSS). Leg extension power (LEP) was measured in both legs with the Nottingham 
power rig (NUMAS, University of Nottingham Medical Faculty Workshops, 
Nottingham, UK) (Bassey and Short, 1990). The measurements were repeated 
until no further improvement was seen. The highest recorded power output was 
recorded in Watts (W). 
 
Each participant received a thorough description of the exercise test procedure and 
the methods that were to be used during subsequent exercise sessions. The 
participants were familiarised with Borg’s differential ratings of perceived exertion 
(RPE) CR10 scale for breathing (RPRbr) and legs (RPEleg) (Borg and Kaijser, 
2006). Declared medications were screened for precautions and contra-indications 
to exercise. Height, weight, baseline heart rate (BHR) and blood pressure (BP) 
were recorded.  
6.2.4 Exercise schedule 
Participants participated in a symptom limited, graded exercise test (GXT) 
performed on a cycle ergometer (Monark 874E, Monark AB, Vansbro, Sweden) to 
determine peak work rate measured in watts (Wpeak). The GXT has been 
described in detail in Chapter 4. Peak measures of the GXT are shown in Table 
7.1. Participants were then required to attend 2 exercise training (ET) sessions set 
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7 to 14 days apart. At each ET they performed 20 minutes of exercise on the cycle 
ergometer at intensity relative to the Wpeak determined during the GXT. The two 
ET intensities selected for the study were 45% (ET45) and 60% (ET60) relative to 
Wpeak. The sequence of ET45 and ET60 was randomly allocated at the first ET 
session 
 
Table 6.1 Peak measures attained during the graded exercise test 
Peak  MSG 
n=12 
CG 
n=9 
p 
Watts 132.7    ±40.0 180.0   ±43.0 .019 
HR (Bpm) 147.6    ±18.6 167.8    ±9.6 .036 
Temp°C 36.6      ±0.05 37.1    ±0.04 .018 
RPEbr 4.5       ±1.9 6.9    ±2.2 .025 
RPElegs 5.6       ±1.7 7.5    ±1.8 .218 
Note One-way ANOVA determined between-group difference 
6.2.5 Preparation and TMS data acquisition 
Participants were required to lie semi-supine on a two-section medical examination 
plinth positioned so that their upper bodies were angled to 30º of an up-right 
position. The target muscle from which MEPs were to be recorded was the tibialis 
anterior (TA) on the less affected side of the body. The skin lying under the 
electrodes was cleaned with an alcohol swab. Paired silver-chloride surface 
electrodes (T3404, Thought Technology Ltd, Montreal, Canada) were positioned 
with the inter-electrode distance set at 20mm over the middle of the belly of the 
muscle, parallel to, and just lateral to the medial shaft of the tibia, in line with its 
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longitudinal contour (Criswell, 2011). The locations of electrodes were carefully 
noted for precise replacement during the next visit. The reference electrode was 
attached at the olecranon process of the ulna.  
 
Single pulse TMS to the motor cortex was applied using two magnetic stimulators 
connected to a Bistim² module (Magstim Company, Dyfed. United Kingdom). The 
stimulators were set to fire simultaneously producing a single pulse from a double, 
cone shaped coil (110mm) specifically designed to elicit responses from relaxed 
muscles of the lower pelvic floor and lower limbs. Initial exploration determined the 
optimal stimulation point (hotspot) for the TA.  The hand-held coil was placed on 
the head parallel to, and ~ 0.5-1.5 cm lateral to the mid-line (nasion to innion), with 
its mid-point aligned antero-posteriorly (auricular point to auricular point) against 
the vertex (Devanne, et al. 1997; Cacchio et al, 2009). The stimulators were set at 
60% of the maximum combined output and the coil moved systematically around 
the location until the ‘hotspot’ was identified. The exact coil position was carefully 
maintained throughout the experiment by aligning it to marks on the scalp made 
with an indelible ink pen. 
 
The motor threshold (MT) of each subject (the lowest TMS intensity necessary to 
evoke MEPs in the target muscle) was determined by starting stimulation at 60% of 
maximal Bistim² output and reducing power in 5% increments until the stimulus 
artefact disappeared. The stimulator output was then increased in 1% increments 
until threshold was reached. MT was defined as the intensity that elicited 5 or more 
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MEPs with amplitudes of > 50µV in at least 5 of 10 successive stimuli from the 
relaxed target muscles (Rossini and Dal Forno, 2004). For the comfort of the 
participants an upper limit of 80% of maximal Bistim² output was used to elicit 
motor threshold. The experiment was conducted with the stimulator output set at 
120-130% of the motor threshold value. 
6.2.6 Peripheral stimulation 
 
For peripheral stimulation of the common peroneal nerve (MEPρeriph), correct 
positioning of the coil was determined by delivering a number of single stimuli at 
submaximal stimulation intensity. The optimal position was determined where the 
largest and clearest MEPperiph from the TA were produced (Ross et al., 2007). 
Peripheral stimulation was performed with the stimulator set at between 65%-70% 
of maximal stimulator intensity. EMG signals were recorded through a NL844 
(Neurolog 820) and relayed to a CED Micro1401 (Cambridge Electronic Design, 
Cambridge UK), amplified(x 1000) and filtered with a band-pass filter of 1000Hz to 
10Hz. A 55Hz notch filter was applied. The data was digitised at 2000 Hz and 
stored for further analysis on a computer. 
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Table 6.2 Pre-exercise MEP characteristics recorded from the tibialis anterior 
  
MS group 
         
    Control group 
 
      ET45     ET60    ET45    ET60 
Latency (ms) 34.0   ±7.8 35.7    ±7.6 29.7  ±2.5 29.7  ±1.7 
MEP (ms.mV) 4.3     ±1.3 4.6     ±1.0 4.6    ±1.0  4.1   ±0.6 
MEPρeriph (mV) 6.5     ±2.3 6.3     ±2.7 6.4    ±3.4  6.4   ±2.9 
Threshold 48.7  ±4.5 48.7  ±4.5 48.0  ±5.7 48.0  ±5.7 
 
 
 
6.2.7 Pre-exercise 
Test data was collected at three points prior to exercise.  TMS stimuli were 
delivered in blocks of 5 TMS trials (T1-T5) with a delay of 7-10 s between each 
trial, and 5 minute intervals between blocks. At each data-point, heart rate, blood 
pressure, tympanic temperature, and differential measures of RPE for breathing 
and legs were also recorded.  
 
6.2.8 Exercise training 
For the ET phase individuals were required to move to a friction-braked Monark 
Ergo-medic 824E cycle ergometer (Monark AG, Sweden) situated within 1 metre of 
the examination plinth. They were seated on the ergometer in an upright posture 
with their hands placed on the handlebars adjusted for personal comfort, saddle 
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heights adjusted to accommodate partial flexion of the knee between 170° to 175° 
with 180° denoting a straight leg position. Feet were firmly supported in the pedals 
by toe clips and straps. Additional taping was used when necessary to hold the 
heel of the foot away from the pedal crank shaft. Exercise started with unloaded 
cycling at the target cadence of 50 revolutions per minute (rpm) for approximately 1 
minute. A weight equating to 45%, or 60% of the Wpeak achieved during the GXT 
was then lowered onto the ergometer flywheel and timing of the ET commenced. 
Participants received verbal encouragement to maintain a pedal cadence of 50 rpm 
throughout ET lasting 20 minutes. At two minute intervals, measures of HR, 
RPEbreath RPElegs, and Temp°C were recorded. 
6.2.9 Post-exercise  
The participant alighted from the cycle-ergometer and returned to the supine 
position on the examination plinth where the EMG electrodes were re-attached. 
TMS, HR , BP, Tym°c and RPE were recorded at 30 seconds and at 2 minutes 
post-ET. Data-points then occurred every 2 minutes until 10 minutes post-ET, and 
then at 5 minute intervals until 35minutes post-ET. 
6.3 Analysis 
TMS data was analysed using Signal v.3.11 (Cambridge Electronic Design, 
Cambridge UK). MEPs were full wave- rectified (Halliday and Farmer, 2010) and 
calculated as the product of the mean amplitude (mV) multiplied by the duration 
(ms) taken as the area under the line delimited by vertical cursors (Ellaway et al, 
1998). The onset of rectified MEPs was defined as the deflection point of the 
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leading edge of stimulus artefact above the background EMG and marked by a 
vertical cursor with the second vertical cursor set at precisely 30ms from MEP 
onset. Areas were calculated for each trial (T1-T5). T1 was eliminated from further 
analysis and T2-T4 averaged into blocks of 4 trials. Post-exercise MEPs were 
normalised relative to pre-exercise values (Ellaway et al., 1998).  
 
TMS, HR, RPEbr,RPEleg and Temp°C data was imported into SPSS v 17.0 (SPSS 
inc, Chicago, USA) software for statistical analysis. Normal distribution of data was 
determined using a Kolmogorov-Smirnov test. Differences between the MS and 
control groups were calculated as continuous variables using one way analysis of 
variance (ANOVA) with the group as the single factor variable presented as the 
mean ± standard deviation (SD) (Bewick et al., 2004). Linear regression was used 
to test the strength of association between variables (Bewick et al., 2003). 
Appropriate parametric and non-parametric correlation coefficients determined the 
strength of association between baseline, performance and recovery measures. To 
investigate the relationship among several variables, multivariate regression 
models were fitted with various criterion measures as dependent or independent 
variables. All regression models were based on the mean values of participants 
when all measurement parameters were present. Performance and recovery 
profiles between groups were calculated measures using repeated measures 
ANOVA. Linear and quadratic equations were fitted to the ET and post-ET data 
and relationships determined by the strength of correlation coefficient together with 
the significance of slope coefficients. Significance was set at alpha (p< 0.05). 
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Cohen’s classification of correlation coefficients was used to determine strength of 
association. R higher than .50 is rated as strong,  r of .30  to .49 is considered 
moderate and r of .10 to .30 are considered weak when p=<0.05 (Weinburg and 
Abramowitz, 2008).  Significance was set at alpha (p< 0.05). Data is reported as 
means and standard deviations (SD). Recovery is defined as the post-exercise 
time-course  to pre-exercise mean values (±SD).   
6.4 Results 
Twenty nine people were recruited for the study (16MSG and 9 CG). One MS 
participant presented with severe hypotension and was referred back to their 
general practitioner, and one withdrew after failing to maintain pedalling cadence. 
Fourteen MSG and 9 CG completed the exercise test, 12 MSG and 9 CG 
completed the 2 exercise sessions. Two MSG participants failed to respond to 
TMS. The HR of one CG was affected by beta-blocker and consequently discarded 
however measures of other variables showed no effect and were therefore 
included. No adverse events or effects were reported. Pre-exercise baseline 
measures recorded before ET45 and ET60 are shown in Table 6.2. Participant 
descriptors can be found in Table 6.3. Repeated measures ANOVA revealed no 
significant differences in baseline measures of HR, Temp°C, RPEbr, RPEleg or 
TMS evoked MEPs between-groups or between-sessions.  In the next sections 
comparisons are made between the MSG and CG responses to exercise during 
ET45 and ET60 and their relative post- recovery periods. For the purpose of this 
thesis, only MSG results will be compared between the two sessions 
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Table 6.3 Participant details 
 
 
 
  
MS 
 
 
CG 
Age (years) 51.07 ±9.8 49.6  ±8.6 
Gender (male/female) 3male 11female 3male   6female 
Height (metres) 1.70.0 ±0.1 1.69±0.1 
Weight (Kgs) 65.0 ±23.3 74.0±9.4 
 
 
MS Categorisation 
 
RR  n=7 
 
SP n=7 
Disease duration Mean 12.8  ±9.6 yrs Range 2-36yrs 
Barthel Index Median 20 Range 14-20 
2 minute walk (metres) 116.7± 50.9 70-213 
TUG (seconds) 11.4±3.3 7.0 -18.3 
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Table 6.4 Pre-exercise resting measures 
 
 
6.4.1 MSG and CG ET 45 and ET 60 exercise phase 
During ET45 repeated measures ANOVA revealed no significant difference 
between MSG and CG for HR, Temp°C or RPEbr (p>0.05).  MSG RPEleg values 
were higher than CG from 14mins (p<0.05).  During ET60 there was no difference 
between MSG and CG for RPEbr, RPEleg or Temp°C. Repeated measures 
ANOVA revealed higher MSG values for HR at 14mins, the group difference 
diverging further at each successive data-point (p<0.05). Details of HR and RPEleg  
are shown in Fig.7.1. 
6.4.2 MSG and CG  ET 45 and ET 60 post-exercise recovery period 
During the ET45 recovery period, repeated measures ANOVA revealed no 
differences between groups for HR and Temp°C (p>0.05). MSG values of RPEbr 
              MSG                   CG  
 ET45 ET60 ET45 ET60 
HR (bpm) 63.9  ±1.4 63.6   ±0.9 62.0   ±0.1 63.6   ±1.5 
Temp°C 36.8  ±0.2 36.5   ±0.1 36.6   ±0.1 36.7   ±0.1 
RPEbr 0.4    ±0.6 0.6     ±0.5 0.5     ±0.1 0.6     ±0.1 
RPElegs 0.5    ±0.1 0.6     ±0.1 0.1     ±0.1 0.1     ±0.1 
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and RPEleg were higher than CG until 4 mins post-exercise (p<0.05).  During the 
post-60ET recovery period there were no significant differences between MSG and 
CG measures of HR, RPEbr and RPEleg measures (p>0.05).There were no 
between-group differences in TMS measures during either the post-ET45, or 
thepost-ET60 recovery periods (p>0.05). 
6.4.3 MSG comparisons for ET45 and ET60 
Repeated measures ANOVA of the exercise training phase revealed that mean HR 
was significantly higher during ET60 from the 6 minutes (p<0.05) with values 
diverging further at each successive data-point.  Measures of RPEbr, RPEleg and 
Temp°C during ET60 were consistently higher than ET45 (p>0.05) but not 
significantly so. During the 35 minute post-exercise phase, repeated measures 
Anova showed that there were no significant differences for measures of HR, 
RPEbr, RPEleg or Temp°C between sessions. Post-ET45 HR recovered to pre-
exercise values at 10 mins (p>0.05) while post-ET60 HR failed to recover before 
session-end (p<0.05). RPEbr recovered at 10 minutes post-ET45, and at 4mins 
post-ET60 (p>0.05), RPEleg recovered at 8mins post-ET45, and 15 mins post-
ET60 (p>0.05). Post-ET45 Temp°C did not change from pre-exercise measures 
(p>0.05), while post-ET60 Temp°C remained above resting measures for 25 mins 
(p<0.05).   
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Figure 6.1 Mean heart rate recorded during ET45 and ET60 sessions 
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Figure 6.2 Mean ratings of perceived exertion for breathing (RPEbr) recorded 
during ET45 and ET60 and post-exercise  
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Fig. 6.3 Mean ratings of perceived exertion for legs (RPEleg) recorded during 
ET45 and ET60 sessions 
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Post-exercise TMS measures 
TMS measures were significantly depressed after both training sessions (p<0.05). 
Mean MEP size were 71% ±38% of pre-exercise levels at 30 secs post-ET45 while 
post-ET60 MEPs reached their lowest point of 52% ±17.8% pre-exercise levels at 
the 2 minute data-point. Post-ET45 MEPs remained depressed until recovering to 
pre-exercise values at 10mins (p>0.05) while post-ET-60 MEPs recovered at 20 
mins (p>0.05). MEP latency and MEPρeriph were unchanged (p>0.05). Following 
ET60 we observed a strong negative relationship between Temp°C and MEPs (r=-
.65, p=0.023 (twin-tailed), with a linear regression equation of y=0.005x+37.3. 
 
Figure 6.4 Post-exercise corticospinal excitability 
 
Note. Mean motor evoked potentials (MEPs) at each post-exercise data-point are 
shown as %age of normalised pre-exercise values. 
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6.5 Discussion 
This study was designed to examine the neurophysiological and perceptive 
responses of PwMS to exercise intensity. We followed participants serially through 
the active and recovery phases of 2 exercise training sessions, performed at 45% 
and 60% of peak watts determined by a maximal exercise test.  During 20mins of 
exercise at lower intensity, PwMS reported significantly higher values of perceived 
exertion from the lower limb, and a substantial increase in breathing sensations 
when compared to healthy controls. At higher intensity, heart rate rate for PwMS 
was significantly higher than controls and failed to recover to pre-exercise values 
within the 35 minute post-exercise period. With regard to TMS, post-exercise 
MEPs elicited from the TA were significantly depressed after both exercise 
sessions with a clear intensity-dependent influence in the depth and duration of 
MEP depression. MEPperiph was unchanged meaning that the change to MEPs 
were due to neural processes above the neuromuscular junction. In addition, 
following exercise at higher intensity we found a strong negative relationship 
between evoked responses to TMS and body temperature.  
 
The study found no evidence of the altered HR response at the commencement of 
exercise previously reported in PwMS (Feltham et al., 2012). When directly 
comparing the effects of the two exercise intensities, the mean HR of PwMS 
reached 78% and 89.5% of GXT during ET45 and ET60 respectively. These 
results imply that current exercise recommendations of 60-85% HRpeak for PwMS  
(Jackson and Mulcare, 2009b) are achievable at relatively low exercise intensities. 
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Indeed, when taking into account the faster HR recovery times of ET45, the 
findings based on HR alone would support those of other studies suggesting that 
exercise at lower intensity to be better tolerated in PwMS (Collett et al., 2011b, 
Feltham et al., 2012). However, the differential measures of RPE show that PwMS 
experienced substantially higher levels of exertion than the control group in both 
the legs and breathing during exercise at light intensity. Indeed, during ET45 the 
MS group reported differential RPE values that were similar to their responses 
reported during ET60. The perception of exertion experienced in the lower limbs 
was higher than the control group even before exercise commenced, and returned 
to the same higher levels during the recovery period. This is an important finding. 
The RPE CR10 scale is purported to be a robust measure that reflects exercise 
intensity at least as well as heart rate (Borg et al., 1987, Noble and Robertson, 
1996, Cabanac, 2006),  however, our results suggest that this does not hold true 
for PwMS. Exercise intensity has been identified as an important determinant of 
adherence to exercise prescription (Perri et al., 2002) and continued participation 
in randomised controlled trials (Collett et al., 2011b). In this study PwMS reported 
substantially higher differential RPE values both at rest and during exercise at low 
intensity. Thus further investigation into perceptions of exertion in response to 
exercise intensity and duration is warranted for this clinical group. 
 
The post-exercise depression of TMS measures observed during the post-exercise 
phase were similar to those reported previously in healthy groups (Brasil-Neto et 
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al., 1993, Bonato et al., 1994, Verin et al., 2004, Meaney et al., 2007). Mean MEP 
size were 71% ±38% of pre-exercise levels at 30 secs post-ET45 while post-ET60 
MEPs reached their lowest point of 52% ±17.8%  pre-exercise levels at the 2 
minute data-point. An intensity-dependent magnitude of depression and significant 
delay in post-exercise recovery was clearly apparent between the two exercise 
sessions. In agreement with previous studies, peripherally evoked MEPs did not 
change in size, indicating that the cause of MEP depression originated at a point 
above the neuromuscular junction. While the physiological basis for post-exercise 
MEP depression is unresolved, the general consensus is that MEP size reflects the 
rapid modulation of cortical structures, a form of activity-dependent, plastic 
reorganisation high in the brain (Taylor and Gandevia, 2008, Teo et al., 2011). Few 
investigations have observed a post-exercise depression of MEP size in PwMS. In 
general, an increase or facilitation in MEP amplitudes is reported following maximal 
voluntary contractions (MVC) and fatiguing hand grips in PwMS  (Nielsen and 
Norgaard, 2002, Perretti et al., 2004, Thickbroom et al., 2006, Thickbroom et al., 
2008). To explain MEP facilitation previous Investigations have  generally 
concluded that MS related cortical dysfunction results in the down-grading, or 
failure of central inhibitory mechanisms leading to a facilitation of MEP amplitude 
rather than MEP depression following physical activity (Leocani et al., 2001, 
Perretti et al., 2004, Thickbroom et al., 2008, Thickbroom et al., 2006). However, 
we found MEPs to be significantly depressed in size. When considering the 
stability of pre-exercise MEPs, and that the duration of exercise was strictly 
controlled for, the results of this study suggest MEP amplitudes were profoundly 
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affected by the task, and the intensity at which the task was performed.  
Furthermore, in order to reduce both the variability of MEPs and increase their 
amplitude, previous studies have elicited MEPs from PwMS while they maintained 
a tonic muscular contraction. We observed MEP depression elicited from resting 
muscle, suggesting that the muscle activation used in previous studies has masked 
small, but critical alterations to MEP size. We observed no significant difference in 
post-exercise MEP measures between MSG and CG. Whether this was due to the 
intrinsic variability of MEPs or due to insufficient participant numbers is uncertain. 
Therefore in order for TMS to be a reliable and valid tool to evaluate central 
responses to exercise intensity in PwMS, further research involving larger numbers 
of participants is required. 
In PwMS MEP size is known to be further affected by multiple factors, such as 
temporal dispersion of the descending volley, partial or complete conduction block, 
frequency dependent conduction block or impedance mismatch (Smith and 
Waxman, 2005).  Conduction is also markedly affected by temperature (Smith and 
Waxman, 2005). Indeed an increase in body temperature is reported to 
detrimentally affect clinical signs and symptoms in up to 80% of PwMS (Guthrie 
and Nelson, 1995).  Previous studies utilising TMS to assess the effects of cooling 
suits (Capello et al., 1995, Kinnman et al., 2000) and hot baths (Humm et al., 2004) 
have failed to establish a link between MEPs and body temperature. We found a 
significant negative association between Temp°C and MEPs during the time 
course to recovery following 20 mins of moderate intensity exercise. However while 
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the result is both interesting and novel, it should be regarded with caution. 
Although tympanic temperature is assumed to reflect core temperature, this may 
not always hold true (Beenakker et al., 2001). Differences have been found in 
parallel tests of rectal and tympanic thermometers (Jensen et al., 2000). The 
accuracy of tympanic thermometers can be affected by unfamiliarity and an 
incorrect technique (Robinson et al., 2005). However, the Braun Thermoscan infra-
red tympanic thermometer used in this study has been shown to provide a reliable, 
accurate measure of temperature measurement when compared to bladder and 
rectal thermometry (Purssell et al., 2009, Nimah et al., 2006). Moreover, the 
researchers were highly practised in the use of the thermometer having recorded 
several thousand measures during almost 300 research sessions. Each measure 
was checked for consistency, and in the event of an anomaly or suspect reading, 
temperature was immediately re-taken. The strong negative association observed 
between temperature and MEPs only occurred after exercise at higher intensity. 
Although this is an important finding, further research is required before firm 
conclusions can be drawn 
 
There are several limitations to this study. Firstly, only those PwMS capable of 
cycling for 20 minutes were included meaning that not all PwMS are represented. 
The selection of an homogenous group of MS patients is a challenge when 
considering the heterogeneity of symptoms nevertheless, although only a small 
number of PwMS were studied they were representative of a broad range of 
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people at different stages in the disease. The unpredictable and changeable nature 
of MS can affect functionality and performance in a short space of time, making an 
accurate assessment of repeated exercise interventions particularly difficult.  Some 
PwMS were taking medications that may have affected heart rate. Great care was 
taken to ensure that daily habits and compliance to medication was adhered to 
between sessions hence, individual responses during each session should be an 
accurate reflection of the intensity at which exercise was performed. During the 
GXT, one individual with MS displayed a particularly high exercise capacity, in part 
due to their regular participation in cycling training, however their results were not 
atypical of the MS group, and were therefore included in the main study.  
 
In conclusion we have demonstrated that both at rest, and while exercising at the 
same intensity relative to peak work rate PwMS experience different perceptive 
measures of exertion when compared to matched healthy controls. The results 
suggest that exercise at lower intensity is better tolerated in PwMS. We also found 
an intensity-dependent influence of exercise on corticospinal excitability, the 
magnitude and duration related to exercise intensity and body temperature.  
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Chapter 7 General discussion 
__________________________________________________________________ 
This chapter is a synopsis of the thesis and discusses some of the specific issues 
arising from the study. The results have provided some interesting new 
perspectives and potential areas for further investigation 
__________________________________________________________________ 
The hallmarks of MS are variability and unpredictability, the only certainty being 
that over time, MS will cause moderate to severe disability in the majority of those 
affected by it (Thompson, 2008). Symptoms are generally observed differently by 
each individual, such that while for some, even minor symptoms can appear to be 
devastating (Shapiro, 2003), other individuals set themselves a challenge to 
overcome the drastic changes brought about by MS. Indeed, for them physical 
exercise not only offers hope for change,  but also provides an opportunity  to defy 
the course of the illness (Soundy et al., 2011). Hence, the need to provide safe, 
effective exercise recommendations and guidelines that are appropriate and 
adaptable to their changeable, complex needs. 
Understanding the heterogeneity of MS symptoms is fundamental to the planning 
of exercise strategies for PwMS. In Chapter 1, the thesis outlined the aetiology of 
MS, the acute and chronic effects of demyelination, and the functional deficits and 
irreversible disability that accompany progressive neuronal degeneration. In 
addition, it described the central repair mechanisms to inflammatory injury, allowing 
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the partial or complete restoration of neural function. Clearly an awareness of the 
changeable nature of MS is required to prevent a misinterpretation of the complex 
responses to physical activity, or disease progression. For instance, weakness and 
fatigue are both ubiquitous symptoms of MS that require constant monitoring and 
appropriate management to ensure continued participation in exercise 
programmes  
Although the effects of exercise in PwMS have been studied previously, the acute 
response to intensity, a key component of an exercise prescription, had not been 
reported. The aim of the thesis therefore, was to examine the acute physiological, 
central and perceptive responses of PwMS to exercise intensity, through both the 
active phase, and the post-exercise time-course to recovery. 
The studies conducted to serve the aim of the thesis addressed the following 
objectives 
 Compare responses to maximal exercise intensity in PwMS and controls 
 Examine and compare physiological and differential perceived responses to 
exercise  
 Examine central, physiological and perceived responses during the post-
exercise recovery period 
 Compare responses to different exercise intensities 
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The results of this thesis demonstrated the worth of an accurate assessment of 
peak exercise intensity in PwMS prior to setting an exercise prescription. The 
objective measurement of heart rate is central to the setting of exercise intensity in 
the clinical, community, and research environments. In the healthy population, HR 
varies linearly with 2OV
 max to the point of peak exertion, such that maximal HR is 
commonly estimated without the need to subject an individual to maximum levels 
of physical stress (ACSM, 2010). Hence, one of the most common methods of 
determining exercise intensity in the community health and fitness setting is to use 
the simple formula, 220-age (Londeree and Moeschberger, 1984). However, during 
maximal exercise we observed PwMS were unable to reach age-predicted HR 
max. Furthermore, we found that exercise at 60% of a maximal work-rate elicited a 
mean heart rate of 89.5% relative to HRpeak. Even at 45% peak work-rate, the 
mean heart rate of PwMS reached 78% relative to HR peak. Indeed, an exercise 
prescription set at the lower end of the current HR recommendation for MS 
(Jackson and Mulcare, 2009a, Ehrman et al., 2009) is at risk of substantially 
exceeding the exercise capacity of a large proportion of the individuals with MS 
tested in this thesis. Whilst our results imply that current exercise guidelines for MS 
are achievable at relatively low exercise intensities, given the well documented 
blunted heart rate response in PwMS, and the progressive impairments to heart 
rate control (Mahovic and Lakusic, 2007, Feltham et al., 2012) caution is required 
when basing exercise intensity for this clinical group on HR response alone. Our 
results further highlight the importance of individualised exercise prescription 
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based on accurate assessments of exercise capacity. Moreover, there is a strong 
inference that further research should be undertaken to determine the minimum 
levels of exercise intensity required to elicit a cardio-respiratory benefit. Until then, 
the results of this study suggest that current recommended intensities for exercise 
prescription in this group should be reviewed downwards.  
 
The RPE CR10 scale is a cost-effective, practical tool for assessing perceived 
effort during exercise, with or without disabling conditions (Noble and Robertson, 
1996), although small discrepancies have been reported occur in people with brain 
injury (Dawes et al., 2005). The results of this thesis show that PwMS consistently 
experience significantly higher levels of exertion in resting lower-limbs. During 
exercise at low intensity, differential measures of RPE were significantly higher 
than the control group. Indeed, during exercise at low intensity, their sensations of 
exertion were more similar to their values at high intensity. At maximal exertion, 
sensations of breathing were significantly higher than controls while sensations of 
leg exertion were similar to controls  When considering the inability of PwMS to 
maintain drive to the lower limbs, in addition to the persistent sensations of exertion 
from the legs during rest, and the different values given to sensations from legs 
and breathing, and the importance of the RPE scale for setting exercise intensity, 
the results indicate that perceptive measures of exertion in PwMS require further 
investigation..  
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The results support those of Feltham and colleagues who recently identified the 
RPE scale to be an insensitive marker of exertion in PwMS (Feltham et al., 2012). 
Negative responses to exercise are known to increase with perception of effort 
(Ekkekakis and Acevedo, 2006), and exercise intensity has been shown to 
adversely affect adherence to exercise prescription (Perri et al., 2002), provoke 
adverse events (Collett et al., 2011b) and lower attendance in controlled trials 
(Feltham et al., 2012). Hence this thesis identifies perception of effort in PwMS, 
especially in response to exercise at lower intensity, to be a critically important 
focus for further study. In summary, measures of perceived exertion prompted 
important considerations relating to the accurate assessment of exercise intensity 
in PwMS.  
 
The results of the maximal exercise study prompted further investigation into the 
central factors that limit exercise capacity of PwMS. The study not only confirmed a 
substantially reduced exercise capacity in PwMS when compared to healthy 
controls, but also observed that during maximal exertion, individuals with MS were 
neither limited by their heart rate, nor their breathing. Rather, in view of the 
physiological and perceptive measures, and the reasons PwMS gave for 
terminating the GXT, it appeared that leg fatigue, or lack of drive to the lower limbs 
was the limiting factor to achieving higher peak exercise values. We selected  
TMS, a reliable, non-invasive technique (Hallett, 2007) to explore the central 
pathways. Previous studies of single-pulse TMS have been frequently confounded 
by the considerable trial to trial variability in MEPs, within and between individuals 
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(Wassermann, 2002). Furthermore, previous investigators have experienced 
difficulty in eliciting responses from resting muscle in the lower limb of PwMS 
(Everaert et al., 2010). We therefore tested the reliability of dual magnetic 
stimulators configured to fire simultaneously through a single coil, a technique 
recently shown to be a reliable method to evoke responses in the general 
population (Rothkegel et al., 2010). Using a dual- stimulator configuration firing a 
single pulse through a focal coil designed specifically to elicit MEPs in the lower 
body, we produced consistent, repeatable TMS measures from the resting tibialis 
anterior of PwMS. The stability of the MEPs was comparable to that previously 
reported in healthy controls (Cacchio et al., 2009, Rothkegel et al., 2010). In 
addition, our results identified a previously known but little discussed phenomenon 
(Brasil-Neto et al., 1993, Schmidt et al., 2009). When analysing the demographics 
of blocks of MEPs, we observed the first MEP to be consistently larger than those 
following.  After discarding the first trial from each block, repeated measures Anova 
and strong intra-class correlation coefficients showed that blocks of trials elicited 
from the resting TA of PwMS were consistent and repeatable. 
 
Establishing the reliability of the TMS method was an original finding that enabled 
the measurement of central responses in the resting muscle of PwMS.  In fact, few 
TMS studies in MS have observed a post-exercise depression of MEPs. MS 
related conduction block, phase cancellation and impedance mismatch frequently 
lead to substantial changes in the size, latency and duration of MEPs. Thus in 
previous studies, subjects were generally required to maintain a tonic contraction 
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to increase MEP size. This may have obscured small changes to corticospinal 
activity after exercise in PwMs, and may explain the previously reported absence 
of post-exercise MEP depression typically observed in healthy groups. It may also 
account for the failure of previous studies to establish the link between body heat 
and corticospinal responses in MS (Capello et al., 1995, Kinnman et al., 2000, 
Humm et al., 2004). The experiment revealed that TMS is sensitive to intensity-
dependent changes to corticospinal excitability following exercise, and that 
exercise intensity influences both the depth of MEP depression, and its duration.   
While  TMS has been used to show use-dependent plasticity after cortical lesions 
in stroke (Conforto and Cohen, 2005), the use of TMS to study rehabilitative 
strategies in MS has been limited, perhaps due to difficulties eliciting MEPs in the 
lower limb (Everaert et al., 2010). Neuroplasticity is the basis for adaptive change, 
thus a better understanding of the acute and chronic reorganisation of central 
motor pathways may facilitate the further development of rehabilitative strategies 
(Kesselring et al., 2010b).  During fatiguing exercise, complex inhibitory and 
excitatory adaptations occur at multiple levels of the corticomotor system (Sacco et 
al., 2005), with increased physical activity acting as a potent trigger of cortical 
reorganisation, while disuse has the opposite effect (Sjostrom et al., 2008). 
Although functional magnetic resonance imaging (fMRI) has shown that 30 minutes 
of voluntary thumb movement in PwMS produces a training dependent cortical 
reorganisation, with a greater activation of cortical motor areas than in healthy 
controls (Morgen et al., 2004), the method is expensive and impractical for large 
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scale exercise studies. This study has shown that TMS provides an inexpensive, 
reliable and effective method to investigate excitatory changes in the corticospinal-
neuromuscular pathway in response to activities performed at different intensity. 
Our results suggest that the TMS technique employed in this thesis may provide 
the means to further evaluate the efficacy of rehabilitation strategies in MS. 
7.1 Final Remarks 
The main findings of the thesis support those of other recent studies reporting the 
effects of exercise intensity in PwMS (Collett et al., 2011b, Feltham et al., 2012). 
Exercise capacity of PwMS is substantially reduced when compared to age and 
gender matched healthy controls. However, for PwMS the ability to work at 
maximal intensity was limited neither by heart rate nor breathing, but by the lack of 
drive to the lower limbs. Further investigation revealed that significant, intensity-
dependent differences in HR and perception occurred during exercise and the 
time-course to recovery. A significant post-exercise depression in corticospinal 
excitability, with a clear intensity-dependent difference in the depth and duration of 
MEP depression was observed. In addition, we found an inverse relationship 
between internal body temperature and corticospinal excitability. Furthermore, an 
association exists between body temperature and differential ratings of perceived 
exertion. The results may provide further guidance to clinicians for the delivery of 
safe, appropriate and effective exercise prescription to PwMS, however further 
research is required in order to determine optimal exercise intensity for this clinical 
group. 
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8 APPENDICES 
 
 
 
8.1 RPE instructions given participants 
 
“_______________(name), during the exercise test we want you to pay close 
attention to how hard the exercise is. In particular we want to know how hard you 
are breathing, and the sensations that you are feeling in your legs. I’ll be asking 
you to select a number from this scale from 1 to 10. Each number represents the 
amount of effort that you can feel in your breathing or legs. The words are there to 
help you choose a number. Try not to underestimate or overestimate your feelings 
of exertion. Although there is no right or wrong answer, It is important that you are 
as accurate as possible. So, while you are resting, looking at the scale, how would 
you describe your breathing now? (Pause) And using the same scale, how would 
you describe the feelings in your legs?” 
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8.2 Instructions given to participants before a symptom-limited graded 
exercise test 
 
_____________(name) you are about to participate in a maximal exercise test. 
You will be pedalling at a constant 50rpm which you can see here (point to digital 
monitor). Every 2 minutes I’ll be placing a small weight on the weight plate (point) 
which increases the resistance on the flywheel (point) and the pedalling will 
become harder. As it does so, your breathing will get faster and harder, your heart 
beat will get faster and you may feel uncomfortable sensations in your legs. 
However, these are the sensations I need you to be particularly aware of. Pain 
anywhere in the jaw, any burning pain in the chest or between the shoulder blades, 
any pain that starts below the left ear and comes down the arm, or burning pain in 
the calves. All the other sensations are likely to be due to the exercise itself and 
shouldn’t be worried about, but if you have any concerns or doubts, then mention it 
to us.  
______________(name) as you are aware, maximal exercise testing can lead to 
heart attack, stroke or death. The likelihood of anything happening today is minimal 
and we will be monitoring you very closely. If we have any concerns, the test will 
be stopped immediately.In the unlikely event of anything untoward occurring, both 
___________ and I are fully trained to deal with the situation.  
When you start pedalling there will be no resistance on the flywheel so it may be 
difficult to keep to the set cadence but it will get easier when the weight plate is 
applied to the flywheel As the test proceeds you may start to watch the clock here 
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(point). We are keen that you finish the stage so we’ll be giving verbal 
encouragement to finish the stage. This is a maximal exercise test and we want to 
get the best result that we ca,  but you can stop this test at any time, for any reason 
Do you have any questions you want to ask us before we start? 
___________(name) can we proceed with the test?  
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8.3 Participant TMS Questionnaire  
 
1. Have you ever suffered from any neurological or psychiatric conditions?  YES/NO 
If YES please give details (nature of condition, duration, current medication, etc). 
…………………………………………………………………………………………………………………… 
2. Have you ever suffered from epilepsy, febrile convulsions in infancy or had recurrent fainting 
spells?           YES/NO 
3. Does anyone in your immediate or distant family suffer from epilepsy?   YES/NO 
If YES please state your relationship to the affected family member. 
…………………………………………………………………………………………………………………… 
4. Have you ever undergone a neurosurgical procedure (including eye surgery)?   YES/NO 
If YES please give details. 
……………………………………………………………………………………. 
5. Do you currently have any of the following fitted to your body?    YES/NO 
Heart pacemaker, Cochlear implant, Medication pump, Surgical clips 
6. Are you currently taking any un-prescribed or prescribed medication?   YES/NO 
If YESplease give details.…………………………………………………………………………………… 
7. In the last 3 days have you undergone anti - malarial treatment?   YES/NO  
8. Have you drunk more than 3 units of alcohol in the last 24 hours?   YES/NO  
9. Have you drunk alcohol already today?      YES/NO  
10. Have you had more than one cup of coffee, or other sources of caffeine, in the last hour? 
           YES/NO  
11. Have you used recreational drugs in the last 24 hours?    YES/NO  
12. Did you have very little sleep last night?      YES/NO 
13. Have you participated in a tDCS experiment in the last week?   YES/NO 
14. Are you left or right handed?        Left/Right 
15. Date of Birth          __/__/__ 
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 8.4 Physical Activity Readiness-Questionnaire (PAR-Q) 
 
Please read the following carefully and answer as accurately as possible by ticking 
the appropriate box for each question. 
         Yes  No 
1. Has a doctor ever said you have heart trouble?      
2. Do you ever suffer frequently from chest pains?      
3. Do you often feel faint or have spells of dizziness?     
4. Has a doctor ever said you have epilepsy?      
5. Has a doctor ever said you have high blood pressure?     
6. Has a doctor ever said you have diabetes?      
7. Has a doctor ever said you have asthma?      
8. Do you have a bone, joint or muscular problem which 
may be aggravated by exercise?        
9. Do you have any form of injury?        
10. Are you currently taking any prescription medications?      
11. Have you suffered from a viral illness in the last two  
         weeks?            
 Yes No 
Have you eaten anything within the last hour?   
Have you consumed alcohol within the last 24 hours?   
Have you performed exhaustive exercise within the last 48 hours?   
 
If you have answered YES to any of the above questions, or know of any possible reason 
(physical or psychological) that might affect the safety or accuracy of the tests - please 
inform a member of the research team. 
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8.5 Rating of Perceived Exertion (Category-Ratio10) Scale 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 Nothing at all 
0.5 Extremely light (Just noticeable) 
1 Very light 
2 Light 
3 Moderate 
4 Somewhat hard 
5 Hard 
6  
7 Very hard 
8  
9  
10 Extremely hard (almost maximal) 
. Maximal 
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8.6 Barthel Index 
 
Bowels 
0=incontinent or needs enema) 
1=occasional accident 
2=continent 
 
Bladder 
0=incontinent, or catheterised and unable to manage alone 
1=occasional accident 
2=continent 
 
Grooming 
0=needs help with personal care 
1=independent face/hair/teeth/shaving 
 
Toilet use 
0=dependent 
1=needs some help, but can do some things alone 
2=independent (on and off, wiping, dressing) 
 
Feeding 
0=unable 
1=needs help cutting, spreading butter etc 
2=independent 
 
Transfer (bed to chair and back) 
0=unable, no sitting balance 
1=major help (one or two people) can sit 
2=minor help (verbal or physical) 
3=independent 
 
Mobility 
0=immobile 
1=wheelchair independent, including corners 
2=walks with help of one person (verbal or physical) 
3=independent 
 
Dressing 
0=dependent 
1=needs help, but can do half unaided 
2 independent (including buttons, zips, laces, etc) 
 
Stairs 
0=unable 
1=needs help (physical or verbal) 
2=independent 
 
Bathing 
0=dependent 
1=independent (or in shower) 
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8.7 Classes of medication taken by participants with MS  
 
Drug No. of participants 
No medication 7 
Analgesic 11 
Antibiotic 2 
Anti-convulsant 8 
Anti-depressant 13 
Anti-diabetic 2 
Anti-fatigue 4 
Anti-histamine 1 
Anti-hypertensive 10 
Anti-inflammatory  steroid 5 
Anti-osteoporosis 2 
Anti-spasticity 12 
Bladder dysfunction 10 
Bowl dysfunction 1 
Cannabis 2 
Contraceptive pill 2 
Immunomodulator 13 
Ihhaler-respiratory 2 
Non steroidal anti-inflammatory 3 
Pneumococcal vaccine 1 
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